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Abstract 
Despite recent advances in stem cell biology, immunotherapy and 
transplantation, substantial barriers still exist in the large-scale specific 
separation of a discrete population of human therapeutic cells from a cell 
suspension. The ideal purification technique should combine high cell purity, 
yield and function, with fast processing and affordability. Currently, 
fluorescence-activated cell sorting with flow cytometry (FACS) and magnetic 
activated cell sorting (MACS®) are the most used methods for cell separation 
and purification and have been employed extensively in molecular biology, 
diagnostic and cell sorting applications, because they are considered to be 
gentle, fast and scalable. However, these methods have several key 
disadvantages; they are invariably expensive, yield low log cell reduction 
(LCR) rates, and suffer from drawbacks when applied to niche cell 
populations, such as those requiring multiple tandem separation steps and/or 
involving combined positive and negative cell selection steps. To address this 
challenge, a new cell affinity selection system was developed. The selectivity 
is based on the reversible monomeric avidin – biotin interaction and it is 
primary designed for positive selection. The initial studies were performed on 
flat, nonporous, glass coverslips and the technology was then successfully 
transferred on high grade smooth non-porous glass beads (with a diameter of 
79.12 to 118.59 μm). The multi-step ‘layer-by-layer’ deposition procedure 
culminating in dextran-coated supports bearing monomeric avidin was 
rigorously characterized and subsequently employed in packed bed 
chromatography experiments with human erythrocytes isolated from cord 
blood and B lymphocytes from cell lines. The developed affinity selection 
platform was highly selective, efficient and, most importantly, resulted in high 
yields, cell purity and viability comparable with MACS® technology. 
Additionally scale up is possible and could be easily transferred to another 
chromatographic matrix with the appropriate structure. 
Key words: Affinity separation, human therapeutic cells, red blood cells, B 
lymphocytes, T lymphocytes, dextran, monomeric avidin, D- biotin, 
competitive displacement, glass coverslips, non-porous glass beads, MACS® 
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1. INTRODUCTION 
1.1 CELL THERAPHY 
Cell therapy, a subtype of regenerative or reparative medicine, has the potential 
for treating diseases of tissue malformation, degeneration, trauma, and genetic 
deficiency (Daley, 2010). Every year millions of people suffer and die from 
serious and largely incurable degenerative diseases of the nervous system, for 
example Parkinson’s disease, multiple sclerosis and strokes, the heart (e.g. 
myocardial infarction), the liver (e.g. hepatitis), the pancreas (e.g. diabetes) and 
other organs (McLaren, 2001). The aim of cell therapy is to replace, repair or 
enhance the biological function of damaged tissue or organs (Gage, 1998) 
using isolated and characterized stem or mature functional cells from different 
sources with or without the addition of gene therapy.  
For cell therapies two different techniques may be used: i) includes the use of a 
scaffold and ii) a scaffold free approach. In scaffold-based cell therapies, 
scaffolds, made from different natural and synthetic materials, act as the 
extracellular matrix of native tissues and are designed to degrade and to be 
eventually replaced by regenerated tissues. On the other hand, the scaffold free 
approach does not require any support material. Scaffold free cell therapies can 
be implemented using three different methods: i) single cells injection therapy; 
ii) implantation of cell sheets; or iii) microtissues, cell aggregated gain structure 
and functionality of the native tissue (Demirbag et al., 2011).  
The first evidence, that a specific, ‘master’, cell type might be responsible for 
reconstituting the bone marrow of people who had been exposed to lethal 
doses of radiation, was published in 1945 by (Hipp and Atala, 2008). Eleven 
years later, in 1956, bone marrow transplantation, the first cell-based therapy, 
was conducted (Thomas et al., 1957). Most types of tissue damage or disease 
that disrupt cell function override the capacity of the mature body to self-repair. 
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In such cases, cell therapy could be employed, using cells that can provide the 
function that is required once they are transplanted back into the body (Gage, 
1998). 
The choice of the cell source depends on many factors, such as access to cells, 
their potency, cultivation parameters, and ability to multiply and manipulate 
cells. The number of cells needed for successful cell therapy is usually a limiting 
factor, at the same time, some cell types cannot self-renew under in vitro 
conditions (Table 1.1).  
Table 1.1: Cell source considerations (adapted from Gage, 1998) 
Cell source Advantages Disadvantages Solution 
Autologous  
(same organism) 
Immunologically 
privileged 
 
No ethical issues 
Limited supply 
 
Time constraints 
for donor and host 
Cryopreservation 
 
Multiplication in vitro  
Allogeneic  
(same species) 
Greater supply 
 
Fewer time 
constraints on 
donor (rapidly 
gained) 
Cellular immunity 
 
Ethical issues 
Immunosuppress 
 
Encapsulation 
Xenograft 
(different species) 
Greater supply 
 
No time 
constraints on 
donor 
Cellular and 
humoral immunity 
 
Possible transfer of 
new viruses across 
species 
Immunosuppression 
 
Encapsulation 
 
Genetically masked 
immunity 
Cell line 
(immortalized or 
tumorigenic) 
Infinite supply 
 
No time 
constraints for 
donor or host 
 
Safety test and 
standardization 
simplified 
Cellular and 
humoral immunity 
 
Tumorigenicity and 
neoplasia 
Immunosuppression 
 
Encapsulation 
 
Genetically masked 
immunity 
 
The quantity of cells necessary to achieve an optimal effect depends on 
application and cell source. For example, in clinical trials of transplantation of 
autologous mononuclear bone marrow cells, doses between 1 and 4*107 cells 
were used for efficient treatment (Perin et al., 2003). In one of the more recent 
studies three doses of 2*106 bone marrow mesenchymal stromal cells have 
been used to treat tissue damage caused after allogenic haematopoietic stem 
cell transplantation (Yin et al., 2014). 
Chapter 1: Introduction  
 
3 
 
From immunogenic prospective, autologous cells (i.e. those that are collected 
directly from the patient) are the preferred option for cell therapy. But due to the 
ability to collect the cells in a time period that meets the needs of the patients, 
allogenic cells (i.e. those that are collected from the same species), are 
preferred. The first cells, which were employed successfully in the clinic for cell 
therapy, were autologous keratinocytes (Gallico et al., 1984) and since then 
huge advances have been made.  
According to the World Health Organisation (WHO) International Clinical Trials 
Registry Platform, more than 150 cell-based autologous and allogenic therapies 
are now in different phases of clinical trials. 
1.1.1 CELL SOURCES FOR CELL THERAPIES 
1.1.1.1 Stem cells 
Stem cells are undifferentiated cells, with the ability to divide indefinitely in 
organism and with the potential to give rise to different cell types. When a stem 
cell divides asymmetrically, the daughter cells can either enter a path leading to 
the formation of differentiated specialized cells or self-renew to remain stem 
cells (Bongso and Richards, 2004). Stem cells are distinguished from other cell 
types by the following four characteristics:  
• Self-renewal: stem cells are particularly immortal because of telomerase 
expression, which allows them to divide repeatedly; 
• Clonality: a single cell has a capacity to create more stem cells because 
of asymmetrical cell division; 
• Potency: capability to differentiate into at least one, and sometimes 
many, specialized cell types (Table 1.2); 
• Plasticity: stem cells have the ability to differentiate into cell types from 
different germ layers (Melton and Cowan, 2004). 
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Table 1.2: Potency of stem cells (adapted from Stem cell basics, 2009) 
Potency Property 
Totipotency Having the unlimited ability to give rise to all the cell types of the 
body plus the entire cell types that make up extra-embryonic tissues, 
such as the placenta. Totipotent cells are found only in an embryo 
after the first few cell divisions. Once gastrulation begins, the cells 
are considered pluripotent. 
Pluripotency Having the ability to give rise to several types of all three embryonic 
germ layers (endoderm, mesoderm and ectoderm), but cannot make 
extra-embryonic tissues, such as the amnion, chorion, and other 
components of the placenta.  
Multipotency Having the ability to develop into more than one cell type of the 
body. 
 
There are four classes of pluripotent stem cells: embryonic stem cells, 
embryonic germ cells, embryonic carcinoma cells and induced pluripotent stem 
cells (iPS) (Smith, 2001). The ability of pluripotent stem cells to give rise to a 
wide array of differentiated derivatives is the reason why they may prove to be 
extremely useful for cell-based therapy (Donovan and Gearhart, 2001). The 
discovery that bone marrow and purified haematopoietic stem cells can give 
rise to non-haematopoietic tissues, suggests that these cells may have greater 
differentiation potential than was previously assumed (Reya et al., 2001). 
Stem cells are present not only in embryos but also in many tissues of adult 
animals and are important in tissue repair and homeostasis (Donovan and 
Gearhart, 2001). 
Mammalian stem cells are usually classified according to their tissue of origin 
(Bongso and Richards, 2004). The microenvironment, i.e. the region from which 
stem cells originate, is called a ‘niche’. This is a subset of tissue cells and 
extracellular substrates that can indefinitely house one or more stem cells and 
control their self-renewal and progeny production in vivo (Spradling et al., 
2001). 
Some types of stem cells, such as bone marrow and skin, have already been 
used in cell therapies, and others are being effectively employed in trials for 
cardiac repair, neurological and immunological application and for a treatment 
of genetic blood disease (Trounson et al., 2011). Combining stem cell therapy 
Chapter 1: Introduction  
 
5 
 
with pharmacological, surgical, and interventional treatment may increase 
therapeutic options in future (Perin et al., 2003). 
Embryonic stem cells are derived from the pluripotent inner cell mass of the 
pre-implantation, blastocyst-stage embryo (Evans and Kaufman, 1981; Martin, 
1981). Outgrowth cultures of blastocysts give rise to different types of colonies 
of cells, some of which have undifferentiated phenotype (Donovan and 
Gearhart, 2001). The cells of the inner cell mass are destined to differentiate 
into tissues of the three primordial germ layers (ectoderm, mesoderm and 
endoderm) and finally form the complete soma of adult organism. In nature 
embryonic stem cells are ephemeral, i.e. present only at the earliest stages of 
development, and could be found only in the inner cell mass. However, the 
continuous in vitro subculture and expansion of an isolated inner cell mass on 
an embryonic human or murine fibroblast feeder layer leads to the development 
of an embryonic stem cell line (Bongso and Richards, 2004) that appears to be 
immortal (Donovan and Gearhart, 2001). 
Cell types that eventually could develop into the various organs of the body can 
also be found in the foetus. Research with pluripotent fetal stem cells has been 
limited to only a few cell types (neural crest stem cells, fetal haematopoietic 
stem cells, fetal mesenchymal stem cells and pancreatic progenitors). Fetal 
blood, placenta and umbilical cord are rich sources of fetal haematopoietic stem 
cells (Bongso and Richards, 2004). 
Embryonic stem cells could be the ideal resource for tissue engineering 
purposes because of their fundamental properties. However, their clinical 
application is limited because they represent an allogeneic resource and thus 
have the potential to evoke an immune response. New stem cell technologies, 
such as somatic cell nuclear transfer and reprogramming, promise to overcome 
this limitation (Hipp and Atala, 2008). Another disadvantage is pluripotency of 
undifferentiated embryonic stem cells, demonstrated by spontaneous formation 
of teratoma-like masses. Although these are classified as benign, the 
appearance in an anatomically sensitive (such as central nervous system and 
joint capsules) location could pose a considerable safety concern (Fink Jr., 
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2009). One study has shown that both, human embryonic stem cell and induced 
pluripotent stem cells, can induce the formation of teratomas. After 
subcutaneous or intratesticular injection of 1*106 fully characterized 
undifferentiated cells in mice, at least 81 % of population developed teratoma 
within 2 months (Gutierrez-Aranda et al., 2010). Earlier Lee et al. (2009) 
reported that minimal number of human embryonic stem cells needed to form 
teratomas in intramyocardical area is 1*105 cells and 1*104 cells, when cells are 
injected in the skeletal muscles. A study before reported that even less cells 
(between 0.5 and 1*103 cells) were sufficient enough to induce teratoma 
formation in subcutaneous dorsal regions (Cap et al., 2007)  
Embryonic stem cells themselves cannot be used in cell therapy due to their 
characteristics, so are expanded ex-vivo in the culture, which could lead to 
spontaneous malignant transformation. Other concerns involve the ability of the 
embryonic stem cell to migrate from the implantation site and the biologic 
impact of non-target cellular impurities within the differentiated cell product (Fink 
Jr., 2009).    
Although biological material can be donated, human embryonic stem cell 
research is ethically and politically controversial because it involves the 
destruction of embryos, which have the potential to grow into human beings if 
implanted in women’s uterus (Lo and Parham, 2009). 
Adult stem cells, also known as somatic stem cells, can be found in diverse 
tissues and organs (Bongso and Richards, 2004). They are derived from so-
called somatic cells that are no longer capable of making germ cells (Donovan 
and Gearhart, 2001). The fact that stem cells are also still present in postnatal 
vertebrates is evident from the observed continuation of tissue growth and 
differentiation, which is essentially an extension of the latter part of prenatal 
gestation in mammals (Marshak et al., 2001). Currently, we do not have a 
sufficient understanding of the developmental events that lead to organogenesis 
from the inner cell mass, to program the production of tissue- and organ-specific 
stem cells (Weissman, 2000).  
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Adult stem cells tend to be multipotent, tissue-specific, self-renewing 
populations of cells which can differentiate into cell types associated with the 
organ system in which they reside (Spradling et al., 2001). Their isolation has 
proven quite problematic as they are rare, in the order of 1 in 10,000 cells, 
within the tissue of interest. Currently, it is known that niche of stem cells exist 
in many tissues, such as the bone marrow, the brain, the liver, the skin, the 
skeletal muscle, the gastrointestinal tract, the pancreas, the eye, the blood, and 
the dental pulp (Hipp and Atala, 2008). Furthermore, experimental results 
suggest that those adult stem cells are extremely resilient to changes in 
temperature, pH values, and exposure to toxic substances (Presnell et al., 
2002). 
The most studied adult stem cells are the haematopoietic stem cells, which 
have been used widely in clinical settings for over 40 years and form the basis 
of bone marrow transplantation success (Bongso and Richards, 2004). 
Haematopoietic stem cells are present in the bone marrow and umbilical cord 
blood and also in smaller numbers in the blood stream (Gage, 1998). 
Mesenchymal stem cells are another well-characterized population of adult 
stem cells. It is thought that they respond to local injury by dividing to produce 
daughter cells that differentiate into multiple mesodermal tissue types and a 
variety of other connective tissues (Short et al., 2003).   
Adult stem cells were thought originally to have a limited potential for production 
of differentiated derivates, however later studies have questioned that view (e.g. 
neural stem cells can form blood-forming and muscle tissue (Bjornson et al., 
1999)). Such findings have had a significant impact on the debate over the 
derivation and use of pluripotent stem cells from embryos (Donovan and 
Gearhart, 2001).  
In contrast to embryonic stem cells, isolated adult stem cells can be used for 
purposes of cell therapy and, at the same time further differentiated in ex-vivo 
culture. 
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The major differences between human adult and embryonic stem cells are 
summarised in Table 1.3. 
Table 1.3: Differences between human adult and embryonic stem cells (adapted from 
Bongso and Richards, 2004) 
Human adult stem cells Human embryonic stem cells 
Stem cells from organs are scarce and 
hard to access and purify 
Once derived and propagated, stem cells 
exhibit prolific cell growth and are 
abundant 
Multipotent; low plasticity Pluripotent; versatile; high plasticity 
Maintenance of normal genetic make-up 
in vitro conditions not known 
Normal karyotype in late passages in ‘cut 
and paste’ protocol; changes in 
karyotype in late passage in high density 
bulk culture protocol 
Telomerase levels low Telomerase levels high and consistent; 
unlimited self-renewal 
Shortening of chromosome length with 
ageing 
No shortening of chromosome length 
with serial passaging 
Early apoptosis Late apoptosis 
Customizing stem cells / differentiated 
tissues not possible 
Possible via somatic cell nuclear transfer 
No risk of teratoma induction after 
accidental transplantation 
Risk of teratoma induction after 
transplantation if not purified 
Epigenetic genomic changes difficult to 
reverse 
Reversible 
No ethical issues Ethical issues limited to some countries 
and institutions 
Applications: transplantation therapy  Applications: (1) transplantation therapy; 
(2) pharmaceutical screening; (3) gamete 
and embryo production; (4) studies on 
human development, congenital 
anomalies and infant cancers 
 
1.1.1.2 Progenitor cells 
Progenitor cells are the link between adult stem cells and differentiated cells. 
They have a tendency to differentiate into specific types, but, unlike stem cells, 
are usually unipotent, and sometimes oligopotent. Their capability to self-renew 
in vitro and in vivo is limited, and their growth is slow, probably because of their 
function in tissues and organs, which is to replace normal cell loss. Similar to 
stem cells, they have their niches and they can be mobile (Weissman et al., 
2001), and they are commonly equated with stem cells. 
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1.1.1.3 Blood products 
The term ‘blood product’ refers to any therapeutic substance that is prepared 
from human blood. Blood can be separated into a variety of blood components 
for different clinical applications (McClelland, 2001). Blood cells are 
continuously produced throughout the human lifespan from rare pluripotent 
bone marrow stem cells, called haematopoietic stem cells, which are, like other 
stem cells, endowed with two characteristics: they give rise to additional stem 
cells during self-renewal and also undergo differentiation (through a process 
called haematopoiesis) to progenitor cells that become variously committed to 
different haematopoietic lineages (Orkin, 2001; see Figure 1.1). 
 
Figure 1.1: Schematic view of haematopoiesis (redrawn from Reya et al., 2001). 
Haematopoietic stem cells can be subdivided into long-term self-renewing stem cells, 
short term stem cells or multipotent progenitors. They give rise to common lymphoid 
progenitors (CLP), which are precursors of all lymphoid cells (B cells, T cells and 
natural killer (NK) cells); and common myeloid progenitors (CMP), which are 
precursors of granulocyte macrophage precursors (GMP) and megakaryocyte 
erythrocyte precursors (MEP). Dendritic cells, granulocytes and macrophages are 
derived from GMP and MEP give rise to platelets and red blood cells. Besides GMP, 
CLP as well give are precursors of dendritic cells. 
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Red blood cells (erythrocytes) are the most abundant cells in the blood. They 
are biconcave discs and their major component is haemoglobin, a globular 
protein, which transports oxygen. Red cells are produced in the bone marrow 
and usually lose their nuclei when they are released into the blood stream. 
Consequently, mature human red cells do not have a nucleus (Bain, 1996). Red 
blood cells transfusions are widely used for the treatment of anaemia, for 
around 40 % of patients’ red blood cells transfusions are the only possible 
treatment (Malcovati, 2009). 
White cells are made up of a nucleus and a cytoplasm. They are divided into 
granulocytes, also known as polymorphonuclear leucocytes, and mononuclear 
cells. There are three types of granulocytes (neutrophils, eosinophils and 
basophils) and two types of mononuclear cells (lymphocytes and monocytes). 
Neutrophils have a nucleus which is divided into two to five fragments or lobes. 
They are produced in the bone marrow and their major function is tissue 
phagocytosis. They move to the sites of infection or inflammation where they 
ingest, kill and break down bacteria. Eosinophils have a nucleus, which is 
usually bilobed, and in their cytoplasm they contain granules which take up the 
acidic dye eosin. Eosinophils are also produced in the bone marrow and are 
important for the body’s defence against tissue parasites, being able to 
discharge their granule contents extracellularly. Eosinophils are also involved in 
allergic reactions. Basophils have a lobulated nucleus, often obscured by large 
granules. They are produced in the bone marrow, and play a major role in 
allergic and inflammatory responses in tissues. Lymphocytes are produced in 
the bone marrow and probably in the thymus. They are divided into three 
functional types: B cells, T cells and natural killer (NK) cells. B cells differentiate 
in tissues into plasma cells, which secrete antibodies, thereby providing 
humoral immunity. T cells function in cell-mediated immunity, as do NK cells. T 
cells also modulate B cell function. Monocytes have lobulated nuclei and 
voluminous cytoplasm, which may be vacuolated or contain granules. They 
differentiate in tissues into macrophages and are phagocytic. They also present 
antigen to lymphocytes. Monocytes differentiate also into Kupffer cells of the 
liver and microglial cells of the brain (Bain, 1996).  
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Lymphocytes, especially T cells, have been employed for the purposes of 
adoptive cell therapies, where cells are isolated, activated and expanded or 
genetically engineered in order to express chimeric antigen receptors or 
conventional alpha/beta cell receptors. After sufficient expansion, cells are 
injected into patients with cancer in an attempt to give their immune system the 
ability to overwhelm remaining tumour via T cells which can attack and kill 
cancer cells. Various adoptive cell therapies are currently in I/II stage of clinical 
trials (Wang and Rivière, 2015). 
Platelets (thrombocytes) are cell fragments, produced in the bone marrow by 
fragmentation of megakaryocytes, large bone marrow cells. Platelets are 
smaller than red and white cells. They are a natural source of growth factors. 
They circulate in the blood and are involved in haemostasis, leading to the 
formation of blood clots. They are also involved in inflammation, phagocytosis 
and cytokine signalling (Bain, 1996). 
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1.2 DOWNSTREAM PROCESSING OF CELLS FOR CELL 
THERAPY 
The number of cellular therapies for the treatment of a wide variety of diseases 
in the development and in the clinical trials is increasing intensively. One of the 
major challenges facing the translation of whole cell products into not only 
licensed therapies but further research, drug screening and pharmacological 
testing, is the development of efficient and scalable purification system. Current 
devices are expensive, with limited scale-up and they struggle to provide high 
resolution separations whilst ensuring sufficient cellular recovery (Weil and 
Veraitch, 2014). At the present, most regenerative treatments based on cell 
separation are restricted to tissues such as blood and bone marrow, but there is 
a potential for cell therapies based on cells derived from a variety of tissues, 
such as adipose tissue and intestine (Tomlinson et al., 2012).  
The history of cell separation is long, dating back to the 1960s when first 
physical and biochemical differences between different cell types were 
identified, such as density and availability of selectable enzymes (Esser, 1998). 
In 1967, Plotz and Talal reported fractionation of splenic antibody-forming rat 
cells on glass bead columns. A year after, in 1968, first purification of human 
blood cells was published (Böyum, 1968). Separation is based on Ficoll – 
density gradient media. Later on, a tremendous number of methods were 
developed. Most of them are simple and reliable routine procedures; many have 
as well the advantage of requiring little equipment (Esser, 1998), therefore are 
still recognized and widely used as a pre-enrichment step in purification not only 
on laboratory scale, but as well on preparative scale. 
For the purposes of cell therapy it is expected that a single dose for a treatment 
of a patient will consist of between 107 and 109 cells of high purity. Current 
requirement is less than 10-1 impurity cells per dose (Schriebl et al., 2010). 
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1.2.1 CELL SEPARATION TECHNIQUES 
Nowadays, a large variety of cell separation techniques are commercially 
available and are predominately based of three methodologies: adherence, 
density and antibody binding. New procedures that utilise more than one 
cellular property are being developed and are mostly based on microfluidic 
technologies but are only available on an experimental scale (Tomlinson et al. 
2012).  
In general, cell separation techniques can be divided in four groups, namely 
methods based on (i) physicochemical properties; (ii) affinity; (iii) biophysical 
properties (label-free methods); or (iv) combination of at least two cellular 
properties. 
1.2.1.1 Physicochemical-based methods 
Physicochemical-based methods are in generally based on traditional methods 
such as centrifugation and membrane filtration. These label-free techniques are 
known by low resolution capacity and are therefore used as pre-enrichment 
step of very distinct cell types and/or for cell concentration (Diogo et al., 2014). 
Apheresis is a medical procedure in which patient’s or donor’s whole blood is 
passed through a medical device and separated by centrifugation. Depending 
on the application, various processes are employed. For example, device can 
contain an additional column or filter to selectively remove plasma, plasma 
components, immuglobulins and/or certain type of cells. To isolate the buffy 
coat, the blood fraction containing white blood cells and platelets, additional 
saline washing steps are integrated in the device. At the end, final product is put 
back in the patient or collected and injected intravenously as a treatment 
(Schwartz et al., 2013). 
Density gradient centrifugation is a single batch process. Two immiscible 
solutions with different densities, usually sucrose and a polymer, are combined. 
Cells are added on the top and then centrifuged to allow their distribution within 
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the gradient. After centrifugation, cells with lower density will settle down at the 
interface (Diogo et al., 2012). Different polymer solutions are commercially 
available for this technique, such as Percoll, Ficoll, Lymphoprep and Dextran 
(Gonzáles-Gonzáles et al., 2011).  
Density gradient centrifugation is an effective method for the enrichment of 
haematopoietic stem cells, usually resulting in a two- to five-fold increase. This 
enrichment is the result of the removal of denser and more mature cell types, 
such as red blood cells and granulocytes (Wognum et al., 2003). 
Although it is believed that specify of this method is not large enough, this 
problem can be overcome by repeated centrifugation steps using different 
concentrations of working solutions combined with different velocities 
(Tomlinson et al., 2012). However, repeat centrifugation step can be a problem 
in itself with expected losses of 20-30 % in cell population with each 
centrifugation step (Lemarie et al., 2005). 
Membrane filtration is an alternative physiochemical method for cell 
separation based on cell size and membrane pore size (Diogo et al., 2014). It is 
used for isolation of single cells from mechanically and often enzymatically 
treated tissues (Tomlinson et al., 2012). This technique is label-free, simple to 
use at relatively low cost, can be run continuously and with a possible scale-up. 
The biggest disadvantage is clumping (Diogo et al., 2014), causing cell loses. 
Polyurethane foaming membranes modified with carboxyl functional groups and 
coated with Pluronic F127 or hyaluronic acid have been used for the isolation of 
CD34+ cells from whole peripheral blood (Higuchi et al., 2006; Higuchi et al., 
2008) and human adipose-derived stem cells (Wu et al., 2012).  
Cell adhesion is a technique that utilises cellular adherence and is routinely 
used for the isolation of single cells from digested or explanted primary tissue. It 
is very simple and relatively cheap method, but is often time consuming and not 
specific, therefore, nowadays it is only used for applications where cell purity is 
not a concern and isolation of various cell populations is not required 
(Tomlinson et al., 2012). After cells of interest are bound, contaminant cells, 
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which are usually present in suspension, are simply removed by medium 
exchange (Lennon and Caplan, 2006). Cell adhesion is usually the first step in 
the isolation of mesenchymal stem cells from bone marrow, umbilical cord blood 
or adipose tissue (Kern et al., 2006). 
1.2.1.2 Affinity-based methods 
Affinity-based cell separations relay on the interaction of cell surface-bound 
molecules and their complementary ligands (e.g. monoclonal antibodies, 
aptamers and lectins). The specificity and diversity of monoclonal antibodies 
offer enormous possibilities for immunoaffinity-based isolation of cells. 
Antibodies have been coupled to toxins to obtain selective cell killing, 
fluorochromes to allow fluorescent activated sorting, and various solid supports 
such as flasks, beads and magnetic particles to achieve selective cell 
adherence.  
There are two types of cell selection, namely positive and negative. The former 
is isolation of a target cell population which is labelled with antibodies and then 
removed from the remaining unlabelled cells. In the latter, the unwanted cells 
are labelled with antibodies and then removed (Thomas et al., 1999).  
Fluorescent activated cell sorting (FACS) allows physical separation of 
fluorescent labelled sub-populations of target cells from a heterogeneous 
population and is one of the most widely used high-resolution techniques for 
purification of cells.  
FACS was invented in the late 1960s with a purpose of flow cytometry and cell 
sorting of viable cells. After the discovery of hybridomas in 1975 and 
consequently continuous production of monoclonal antibodies, the pool of 
possible FACS applications has expanded (Herzenberg et al., 2002; Battula et 
al., 2009; Jiang et al., 2010).  
Prior to the separation, cells are labelled with fluorescently-labelled monoclonal 
antibodies against specific surface antigen markers. When surface markers are 
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absent, reporter construct can be inserted using vectors inside the cells to make 
fluorescent labels. The downside of this approach is regulatory concerns when 
genetically modified cells are used in clinical application (Diogo et al., 2014).  
Sorter has three major components: fluidics, optics and electronics. After 
analysis and identification of the target population, cells in the liquid stream are 
separated into small droplets through the use of mechanical vibrations (Brown 
and Wittwer, 2000), followed by one of the existing sorting mechanism:  
• Mechanical sorting with a mechanical device referred to as ‘catcher 
tube’: If the cell is identified as a cell of interest, it is captured by the 
catcher tube and collected into a tube or into a concentration module; 
otherwise it is dispatched to the waste tank. 
• Electrostatic sorting: The droplets containing a cell of interest are 
charged electrically. When a charged droplet passes through a high 
voltage electrostatic field between deflection plates, it is deflected and 
collected into the corresponding collection tube (Gasol, 2005). 
FACS is a powerful, high-resolution, tool in biomedical research, but with very 
limited scale-up. However, the equipment is large, very expensive and requires 
skilled personnel to operate it (Diogo et al., 2012).  
Magnetic activated cell sorting (MACS®) is a trademark name (Miltenyi 
Biotec, Bergisch Gladbach, Germany) for magnetic-based cell separation 
method. Prior to sorting, the cells are labelled with a monoclonal antibody, 
which is specific to a surface antigen. The antibodies are directly covalently 
labelled with magnetic particles. The cell suspension is then passed through a 
column containing a ferromagnetic matrix placed in a strong external magnetic 
field. The matrix creates a strong magnetic field gradient, which acts as a 
specific cell filter: magnetically labelled cells are retained on the column, while 
unlabelled cells flow through (Miltenyi et al., 1990). After washing, the matrix 
and bound microbeads are demagnetized by removing the column from the 
magnetic field, and the retained cells are easily eluted without chemical or 
physical treatment. Both, the enriched and depleted fractions, are suitable for 
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further use (Kantor et al., 1998; Kastrinaki et al., 2008). For highly purified cells, 
the MACS® procedure needs to be repeated and combined with other methods, 
usually with flow cytometry (Miltenyi and Schmitz, 2000). 
Due to the biological and optical inertness, colloidal super-paramagnetic 
particles ranging from 20 to 100 nm have become the gold standard for 
magnetic separations. Microbeads are always in suspension, therefore binding 
kinetics is fast. Due to their size, these particles do not saturate cell epitopes 
and therefore there is no need to be removed after completed separation 
(Grützkau and Radbruch, 2010). Microbeads are since recently available as 
well in column free form (EasySepTM, Stem cell technologies, Vancouver, British 
Columbia, Canada).  
Positive selection by EasySepTM is done by labelling with dextran-coated 
magnetic nanoparticles using bispecific anti-surface antigen-anti-dextran 
tetrameric complex. Tube containing cell suspension is then placed inside the 
magnet and unlabelled cells are removed by pouring out the supernatant. Tube 
is then removed from the magnet and cells of interest are ready to use after 
several washes with buffer (Wognum et al., 2003) 
Miltenyi Biotec has launched autoMACSTM in recent years, a multimagnetic 
device that allows and parallel processing of samples and for clinical 
applications, and CliniMACSTM, closed and sterile system for automated 
purifications on large scale (1.2*1012 cells in total). Both systems are being 
widely used for enrichment of stem and progenitor cells from bone marrow, 
umbilical cord blood and mobilized peripheral blood (Diogo et al., 2014). 
To achieve high purities using MACS® technology, separation step is often 
repeated and/or combined with other cell separation methods, such as density 
gradient centrifugation, FACS and selective killing with a specific antibody, 
conjugated with cytotoxic molecule (Diogo et al, 2014).  
When compared to other separation methods, MACS® may present undesirable 
biological effects, due to the use of magnetic particles, which can interfere with 
cellular properties and further analysis, since cell’s optical properties can 
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change. Overall, MACS® is easy to use, it is faster than FACS and provides with 
comparable purities and efficacies (Grützkau and Radbruch, 2010). 
Since FDA approval of MACS® for clinical purposes, in particular the enrichment 
of CD34+ cells in neuroblastoma ex-vivo therapy, MACS® has been considered 
as the gold standard for stem cell isolation (Handgretinger et al., 2002). 
Affinity chromatography is an example of strong and specific binding, which is 
based on so called lock and key mechanism (Miller, 2005) and offers a huge 
potential in cell separation.  
Chromatography is one of the most important separation methods and a part of 
a thermal separation procedure. According to IUPAC definition, chromatography 
is “a physical method of separation in which the components to be separated 
are distributed between two phases, one of which is stationary (stationary 
phase) while the other (the mobile phase) moves in a definite direction” (Ettre, 
1993). Chromatographic-like separations are used in industry and research 
from the industrial revolution in the nineteenth century, but the real 
breakthrough occurred in 1931, when Lederer and co-workers separated lutein 
and zeaxanthine in carbon disulphide and the xanthophylls from egg yolk on a 
column of calcium carbonate powder (Braithwaite and Smith, 1996). Nowadays, 
chromatography is still the unit operation of choice for the majority of high value 
biotherapeutics, because it can achieve high purity, combined with flexibility of 
operation. 
Affinity chromatography is “the particular variant of chromatography in which the 
unique biological specificity of the analyte and ligand interaction is utilized for 
the separation” (Ettre, 1993) and it is also known by the names biospecific 
interaction chromatography (BIC) and bioselective adsorption chromatography 
(BAC). It is used primary with biomolecules (antigens, enzymes, proteins, 
viruses and hormones) for two reasons: (i) establishment of strong and stable 
complexes between biomolecules and ligands; and (ii) highly complex media in 
case biomolecules are present (Miller, 2005). It provides an elegant method for 
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the high yield purification in a single step under mild conditions of pH and ionic 
strength (Braithwaite and Smith, 1996). 
For purposes of affinity chromatography, a ligand with a specific binding affinity 
is covalently bound to the support, usually a column. Components with a 
specific affinity for the ligand are bound and non-bound material goes straight 
through the support (Braithwaite and Smith, 1996).   
Ligands can be classified into two types: (i) monospecific, which recognize only 
one species (e.g. monoclonal antibodies); and (ii) group-specific, which would 
bind a group of analytes (e.g. protein A) (Miller, 2005). Some ligands are listed 
below in the Table 1.4.  
Table 1.4: Some group-specific ligands and their specifies (adapted from Miller, 2005) 
Ligand Specificity 
Natural ligands 
Antigen Antibody 
Antibody Antigen 
Concanavalin A, lentil lectin, wheat germ 
lectin 
Polysaccharides, glycoproteins, 
glycolipids 
Soybean trypsin inhibitor, methyl esters 
of various amino acids, D-amino acids 
Various proteases 
Glutathione Glutathione-binding proteins 
Protein A and protein G Many immunoglobulin classes and 
subclasses 
DNA, RNA, nucleosides, nucleotides Nucleases, polymerases, nucleic acids 
Synthetic ligands 
Phenylboronic acid Glycosylated haemoglobins, sugars, 
nucleic acids, and other cis-diol 
containing substances  
Cibacron Blue F3G-A dye, derivatives of 
AMP, NADH, and NADPH 
Certain dehydrogenases via binding at 
the nucleotide binding site 
Amino acids: lysine, arginine Proteases 
Ni(II) (IMAC) Histidine containing proteins / peptides 
Fe(III), Ga(III) (IMAC) Phosphorylated peptides 
Molecular imprinted polymers Non-biological analytes 
 
The majority of affinity based separations are run in a batch elution or step-
gradient mode, where a change in eluent composition causes the release of the 
bound compounds, which are washed off the column as a band and separated 
from the others. 
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Cell affinity chromatography relies on the interaction of cell surface-bound 
molecules and their complementary ligands (usually monoclonal antibodies). If 
a ligand is directly or indirectly covalently (Figure 1.2) bound to a 
chromatographic support and is accessible to the cells passing it, then cell 
surface molecules will bind to it and will be removed from the solution (Kumar et 
al., 2003).  
 
Figure 1.2: Direct and indirect immunoadsorption techniques (redrawn from Thomas et 
al., 1999). With the direct technique the antibody is bound on the separation matrix, 
whilst in the indirect technique, the cells are labelled with antibodies which bind to a 
reagent on the matrix surface. 
 
Historically, various chromatographic supports have been employed for cell 
separation. First attempts of packed bed chromatography for cell separation are 
dated back to the 1970s, when Plotz and Talal (1967) separated splenic 
antibody-forming cells from rats on glass bead columns. The glass beads were 
modified with agarose and then functionalized with polyclonal γ-globulin. 
Between 20 and 50 % of bound cells were eluted from the column in the viable 
form by buffer containing divalent cations and elution buffer enriched with 
EDTA.  
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In 1977, Kondorosi et al. published a comprehensive study of positive 
separation of rat T lymphocytes on columns packed with glass beads, 
polymethylmetaacrylic plastic beads and nylon wool. All materials were after 
surface activation functionalized with rat immunoglobulins or various proteins 
(bovine serum albumin, ribonuclease and lysozyme), followed by binding of 
rabbit anti-rat immunoglobulin and finally cells. Bound cells were then eluted in 
a batch by Eagle’s MEM/Hepes medium supplemented with foetal bovine 
serum. Cells in eluted fractions were very pure (93 - 94 % purity) and with 
recovery between 86 and 89 %.  
Besides on glass and polymethylmetaacrylic beads, packed bed 
chromatography of cells was demonstrated on large polyacrylamide beads 
(Truffa-Bachi and Wofsy, 1970) and Sephadex G-10 beads (Ly and Mishell, 
1974). Although selectively of the last support can be questionable (Kanski et 
al., 1981). In the majority demonstrated methods represent positive selection of 
cells. Alongside gradient elution by change in mobile phase, mechanical 
agitation (Berenson et al., 1986; Thomas and Lansdorp, 1988), increased 
velocity (Thomas and Lansdorp, 1988), cleavage of antibody complexes 
(Thomas et al., 1989; Schlossman and Hudson, 1973) and just recently 
thermally mediated cell fractionation (Nagase et al., 2012) were reported. Avidin 
coated Sephadex beads were even used for enrichment of CD34+ cells 
(Johnsen et al., 1999). In spite of this, packed bed chromatography is not widely 
used for cell separation due to high shear stress, long processing times, slow 
transport, based on diffusion, and high cost (Diogo et al., 2014), although there 
is a potential in beads as a separation matrix.  
As an alternative to packed bed columns, expanded bed chromatography was 
proposed, since this technique is characterized by a high interparticular 
porosity, surface area and consequently lower shear forces. This makes it 
potentially an efficient and gentle affinity chromatography-based cell separation 
technique (Diogo et al., 2014). In the past this method was applied for negative 
and positive selection of monocytes from human peripheral blood on 
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perfluorocarbon supports modified with avidin and functionalized with 
biotinylated monoclonal antibodies (Ujam et al., 2003). 
Another alternative are monolithic connective chromatography supports, widely 
used for the purification of macromolecules, such as viruses, virus-like particles, 
plasmid DNA and cells. The transport of the target molecule through these 
supports is based on convection, which allows quick separation of molecules of 
large sizes rather than diffusion, which favours separation of small molecules. 
The result is high productivity and eradication of one of the basic problems 
connected with traditional chromatography, based on beaded porous particles, 
that of low diffusion rates and consequently high processing times (Jungbauer 
and Hahn, 2004). 
Cryogels are macroporous and supermacroporous monoliths with highly 
interconnected pores made by polymerization in a partially frozen state where 
the ice crystals act as porogens (Lozinsky et al., 2003). Cryogels were first 
reported in the late 70s, but the real breakthrough occurred in the late 90s, 
when their biotechnological and biological potential was recognized (Lozinsky, 
2008). 
For the cryogel preparation, a polymer reaction mixture, which contains gel-
forming reagents, is frozen at temperatures a few degrees below the solvent 
crystallization point. Although the frozen system looks like a single solid block, it 
remains heterogeneous, because it contains so-called, unfrozen liquid 
microphase (UFLMP), where gel-forming reagents are concentrated. As UFLMP 
presents only a small portion of total initial reaction mixture, the concentration of 
gel precursors increases dramatically promoting the formation of gel. When 
crystals of frozen solvent are melted, macropores filled with solvent are left. The 
shape and pore diameter depends on the concentration of precursors and the 
regimes of cryogenic treatment (Lozinsky et al., 2003). Cryogels have low 
resistance to flow due its large interconnected pores. Another disadvantage is 
low binding capacity for proteins and small nanoparticles (Jungbauer and Hahn, 
2004). 
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The primary application of supermacroporous cryogels was direct capture of 
proteins from crude feedstocks. Direct capture of recombinant lactate 
dehydrogenase expressed in E. coli was obtained by immobilized metal affinity 
chromatography (IMAC) of the His-tagged enzyme. Lactate dehydrogenase was 
then purified with drying at 70 °C, followed by rehydration (Jungbauer and 
Hahn, 2004). 
Separation of cells started with bacteria and yeast separation using anion-
exchange chromatography. The support allowed selective separation of yeast 
and E. coli cells using linear salt gradient (Jungbauer and Hahn, 2004). 
Poly(vinyl alcohol) cryogels have been frequently used for cell immobilization, 
but in most cases the cryogel is the shape of beads and packed into the column 
housing. From the tissue engineering prospective, cryogels prepared from 
xanthan are used as scaffolds for fabrication of artificial organs. Xanthan 
cryogels are used as well in cell entrapment and food technology (Jungbauer 
and Hahn, 2004). 
Amongst other applications, they have been employed in the separation of 
particular mammalian cell populations (B lymphocytes) using specific antibodies 
against differentially expressed cell surface targets (Dainiak et al., 2007). 
Antibodies are immobilized through Protein A and cells have been recovered by 
two different approaches: treatment with a solution of secondary antibody with a 
higher affinity for the target cell or mechanical deformation of the cryogel matrix 
by compressing it to 50 % its original height. However, purification yields have 
been relatively low, only around 40 %, as 81 % of applied B lymphocytes were 
retained on the column, of which 70 % were eluted (70 % of cells in the elution 
fraction were B lymphocytes, 20 % were T lymphocytes and 10 % of unknown 
origin. Additionally, the capacity of the column was approximately 1.6*106 cells 
which is below the desired cell number for the single therapeutic dose (Kumar 
and Srivastava, 2010).  
As mentioned above, cryogels have been employed as well as scaffolds in 
tissue engineering. Cryogel scaffolds are reported to promote cellular adhesion 
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and proliferation, which can be a downside when using cryogels as a matrix for 
affinity chromatography (Henderson et al., 2013). 
Hollow fibres are another alternative to packed bed columns. They are often 
used when it is necessary to remove low molecular weight impurities from 
nanoparticles and cells. Hollow fibre modules consist of numerous 
semipermeable membrane tubes packed in a tailor-made housing.  
Hollow fibre modules are routinely used for haemodialysis and can be a very 
attractive option for cell separation due to their low price, biocompatibility, 
production under cGMP conditions and large surface area for cell adsorption. A 
problem with this approach is the high level of non-specific cell attachment, 
which demands an additional round of enrichment (Nordon and Craig, 2007). 
Dissociation mechanisms for the disruption of bonds between antigen and 
antibody include reduction of disulphide bridges (Grimsley et al., 1993), 
enzymatic proteolysis targeting specific peptide sequences (Nordon et al., 1996; 
Nordon et al., 1998; Civin, 1992; Sutherland et al., 1992), and competitive 
binding using peptides (Tseng-Law et al., 1995) or polyclonal antibodies 
(Rasmussen et al., 1992).  
The idea of using fibres for affinity fractionation of cells is not new. In the past 
cell fraction on nylon fibres was reported (Edelman et al., 1971; Rutishauser 
and Edelman, 1972). 
Aqueous two phased affinity systems is an alternative affinity separation 
method with possible scale-up under cGMP conditions. It is a liquid-liquid 
fractionation method used primary for the purification of biological products 
(Diogo et al., 2014).  
The affinity partitioning is usually performed by incubation of cell suspension 
with affinity ligand, usually monoclonal antibody. Afterwards it is mixed with 
polyethylene glycol (PEG) or its derivate and dextran. This solution can be 
additionally supplemented with salts to balance the electrostatic differences 
between phases and making the environment cell friendly. Cells of interest are 
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partitioned in the top PEG phase, which can be easily collected and cells 
recovered by centrifugation and further analysed with flow cytometry (Sousa et 
al., 2011). 
Successful isolation of CD34+ cells from whole umbilical cord blood has been 
reported. Erythrocytes are partitioned in bottom phase, which consist of 
hydrophilic dextran. The purity and recovery of cells of interest in the top phase 
is dependent on initial antibody concentration. In total it is possible to achieve 
42 % purity with more than 95 % yield (Sousa et al., 2011). 
1.2.1.3 Label-free methods 
To reduce the cost of downstream processing of cells, tag-less methods have 
been introduced, where the separation is based on biophysical properties of 
cells. 
Field flow fractionation can be used for gentle cell isolation on a laboratory 
scale. Separation is done in a capillary and it is based on laminar flow and field 
that it is applied to it. Based on physical characteristics, cells are distributed 
within the flow profile and therefore different fractions can be collected 
separately (González-González et al., 2011).  
The simplest variant of field flow fractionation is use of gravity field. Roda et al. 
(2009a; 2009b) have demonstrated isolation of mesenchymal stem cells from 
various sources and haematopoietic stem and progenitor cells from peripheral 
blood. Undifferentiated stem and progenitor cells have “more primitively” 
structure than differentiated cells and therefore separation can be done based 
on shape and cytoplasm-to-nucleus ratio (Diogo et al., 2012). 
Dielectrophoresis devices can be employed for the purposes of cell 
separation. Microchannels of the device are filled with buffer solution into which 
cell suspension is injected. When an electric field is generated, cells can be 
separated, moved or trapped. The cellular response is based on polarization 
between the suspending medium and intrinsic dielectrical properties of the cells, 
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which depend on the cell density, size, physiology and differentiation state. 
Several cell enrichments have been reported so far, including enrichment of 
CD34+ cells and neural stem cells from various sources (Diogo et al., 2014). 
1.2.1.4 Combined methods 
Cell-rolling columns represent a novel system for continuous separation of 
stem cells with different surface marker expression levels by using the dynamic 
interaction of the cell surface and a solid surface. Cells are weakly adhering to a 
solid surface via multiple specific interactions between the cell surface maker 
molecules and the corresponding immobilized antibody. Separation depends on 
the hydrodynamic force and cells are slowly rolled on the solid surface of 
column (Yamaoka and Mahara, 2011). 
Because the rolling speed is determined by the number of interactions between 
the cells and the ligands, the system works as a continuous-type cell separation 
column (Yamaoka and Mahara, 2011), and the rolling velocity is controlled by 
the ligand or cell surface receptor density (Eniolla et al., 2003; Greenberg and 
Hammer, 2001; Greenberg et al., 2000; Hammer and Apte, 1992; Hammer and 
Lauffenburger, 1987).  
In nature, cell rolling is mainly observed in blood vessels as an inflammatory 
response of leukocytes (von Andrian et al., 1991), and its mechanism is derived 
from the temporary interaction between the cell surface and the ligands. This 
principle would enable a labelling-free separation (Yamaoka and Mahara, 
2011). Recently microfluidic device for cell sorting by deterministic cell rolling 
was presented, where the separation is based on the cell rolling and the 
expression of the surface markers. The separation was demonstrated with P-
selectin as a specific ligand and two leukemic cell lines – one positive and 
another negative for the selected ligand (Choi et al., 2012). 
Lab-on-chip methods operate on microfluidic scale using disposable closed 
devices and utilise a multitude of cellular characteristics for isolation of cells, 
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predominantly are label-free. These techniques are mostly still in the 
experimental stage, but offer a great potential to improve cell separation not 
only for purposes of research, as well as for clinical applications, although at the 
moment, the biggest challenge is to improve sensibility – i.e. physicochemical 
and biophysical differences between cell types can often be minimal (Tomlinson 
et al., 2012). It was reported that integration with existing devices can improve 
the sensitivity (Weil and Veraitch, 2014), another options are affinity ligands 
(Diogo et al., 2014). 
Lab-on-chip methods have several features important for smooth and stress-
free separations of delicate cells, such as laminar flow and possible integration 
with existing systems (Diogo et al., 2014). 
This approach for cell separation is relatively novel, but there have been already 
several studies of cell separation published, for example isolation of human 
embryonic stem cells (Diogo et al., 2014). 
Panning is an immunoadsorption technique that utilises covalently bound 
affinity ligands to polystyrene cell culture flasks. Cells positive for the ligand are 
bound to the surface, while other cells can be easily removed by gentle 
washing. This technique has limited scale-up and usually purity and yield 
achieved are low, although it has been applied for isolation of CD34+ cells from 
bone marrow (Diogo et al., 2014).  
PluriBeads have been recently put on the market as a separation technique 
based on size and affinity. At first, beads (standard diameter 100 µm) with 
immobilized antibodies are added to the cells. After completed incubation, 
suspension is sieved through a mesh. To increase purity, sieves are gently 
rinsed with buffer. After washing, sieve is transferred to a new centrifuge tube 
and flow is stopped with a Luer-lock adapter. Cells are then shortly incubated in 
detachment buffer. After an adapter is removed, cells are collected in the tube 
and beads maintain on the sieve. It is possible to isolate two or more cell types 
at the same time using a cascade of beads and complementary sieves 
(Heinrich and Heinrich, 2012; Pierzchalski et al., 2013).  
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This technique is still on the experimental scale and has been so far used for 
the isolation of CD4+ and CD8+ cells from human blood and offers yields and 
purities similar to MACS® (Pierzchalski et al., 2013). 
1.2.1.5 Cell separation methods – current status and future 
trends 
At the moment, apheresis is still the gold standard for blood derived therapies, 
but separation of stem, progenitor and tissue specific cells is in the majority 
based on the expression of membrane antigens (Weil and Veraitch, 2014).  
Currently the two technologies routinely used for cell separation and purification 
are FACS and MACS®. As mentioned above, both are based on expression of 
one or two cell surface antigens, but there is a number of potential 
disadvantages associated with their scale-up: (i) they require multiple 
separation steps, (ii) they involve combined positive and negative cell 
separation, (iii) cells may be sensitive to components used, and (iv) cells may 
suffer from undesirable biological effects from the cross-linking of the selection 
marker. Besides FACS and MACS® there are few cell separation alternatives, 
the most promising being methods based on chromatography, such as hollow 
fibre membranes and cryogels.  
Chromatography is still the unit operation of choice for the majority of high value 
biotherapeutics, because it can achieve high purity, combined with flexibility of 
operation. Therefore it offers a huge potential in cell purification and separation. 
Preparative chromatographic cell separation can provide a highly purified 
population of a specific cell type suitable for diagnostic, biotechnological and 
biomedical applications (Kumar and Srivastava, 2010). 
The current methods used for applied cell separation are summarized in Table 
1.5.  
Chapter 1: Introduction  
 
29 
 
Table 1.4: Cell separation techniques 
 Cell separation technique Principle Example Advantages Limitations 
Ph
ys
ic
oc
he
m
ic
al
-b
as
ed
 m
et
ho
ds
 
Apheresis 
 
Size, density Continuous 
isolation of buffy 
coat (white blood 
cells, platelets) 
from whole blood 
(Schwartz et al., 
2013) 
Labelling not 
required 
 
Easy and technically 
feasible 
 
Continuous process 
 
Short process time 
 
Cheap 
 
Closed system 
Low resolution and 
purity 
 
Crude separation 
 
Density gradient centrifugation 
 
Density Enrichment of 
mononuclear cells 
from human cord 
blood with Ficoll-
Paque solution 
(Jaatinen and 
Laine, 2007) 
Labelling not 
required 
 
Easy and technically 
feasible 
 
Short process time 
 
Low resolution and 
purity 
 
Limited scale-up 
 
Membrane filtration 
 
Size   Single cell 
isolation from 
dissociated 
primary tissue 
(Tomlinson et al., 
2012) 
Fast and simple 
 
Labelling not 
required 
 
Continuous process 
 
Closed, disposable 
systems 
 
Possible scale-up 
 
Low selectivity 
 
Clumping 
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Cell adhesion 
 
Adhesion 
properties 
Isolation of human 
mesenchymal 
stem cells from 
bone marrow 
(Lennon and 
Caplan, 2006)  
Simple and relatively 
cheap 
 
Labelling not 
required 
 
Possible scale-up 
 
Low resolution and 
purity 
 
Limited scale-up 
 
Time consuming 
 
Im
m
un
oa
ffi
ni
ty
-b
as
ed
 m
et
ho
ds
 
Fluorescence activated cell sorting (FACS) 
 
Expression of 
surface 
markers, 
size 
Isolation of CD34+ 
cells from cord 
blood (Brown and 
Wittwer, 2000) 
High resolution 
 
High purity  
 
Fast  
 
Multiparametric  
 
Cost 
 
Limited scale-up 
 
Requires trained 
personnel  
 
Labelling required, 
antibody stays on 
cell after sorting 
 
Low yields 
 
Shear stress 
 
Magnetic activated cell sorting (MACS®) 
 
Expression of 
surface 
markers 
Isolation and 
transplantation of 
CD34+ peripheral 
autologous 
progenitor cells 
(Handgretinger et 
al., 2002) 
Fast 
 
High purity when 
separation step 
repeated / combined 
with other methods 
 
Automated 
 
Closed system 
 
Cost 
 
Labelling required, 
antibody stays on 
cell after sorting 
 
Lower selectivity 
than FACS 
 
Shear stress 
 
Low yields 
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Affinity chromatography 
 
Expression of 
surface 
markers 
Isolation of CD34+ 
cells from cord 
blood using 
cryogels (Kumar 
and Srivastava, 
2010) 
Fast 
 
Scale-up 
 
Highly selective 
 
 
Cost 
 
Labelling required, 
antibody can stay 
on cell after sorting 
 
Shear stress 
 
 
Aqueous two-phase systems  
 
Expression of 
surface 
markers 
Isolation of CD34+ 
cells from 
umbilical cord 
blood (Sousa et 
al., 2011) 
Scale-up Low selectivity 
 
Labelling required, 
antibody can stay 
on cell after sorting 
La
be
l-f
re
e 
m
et
ho
ds
 
Field flow fractionation 
 
Cellular 
biophysical 
properties  
Isolation of 
haematopoietic 
stem and 
progenitor cells 
from peripheral 
blood (Roda et al., 
2009b) 
Label-free 
 
Cost 
Low throughput 
 
Low selectivity 
Dielectrophoresis 
 
Cellular 
biophysical 
properties 
Isolation of CD34+ 
cells from 
peripheral blood 
and bone marrow 
(Talary et al., 
1995) 
Label-free 
 
Cost  
Low throughput 
 
Low selectivity 
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C
om
bi
ne
d 
m
et
ho
ds
 
Cell-rolling columns 
 
Cell rolling, 
hydrophoresis 
Isolation of CD34+ 
cells from bone 
marrow (Yamaoka 
and Mahara, 
2011) 
Fast 
 
Scale-up 
 
Highly selective 
 
Labelling required, 
antibody can stay 
on cell after sorting 
 
Lab-on-chip devices 
 
Various Isolation of 
circulating tumour 
cells from whole 
blood (Nagrath et 
al., 2007) 
Laminar flow 
 
Automation and 
integration in existing 
systems 
 
 
 
Low throughput 
 
Scale-up 
 
 
Panning 
 
Adhesion 
properties, 
expression of 
surface 
markers 
Isolation of CD34+ 
cells from bone 
marrow (Cardoso 
et al., 1995) 
Simple 
 
 
Time consuming 
 
Scale-up 
 
Low resolution and 
purity 
pluriBeads 
 
Size, 
expression of 
surface 
markers 
Isolation of CD4+ 
and CD8+ cells 
from human blood 
(Pierzchalski et 
al., 2013) 
 
Simple 
 
Fast 
 
High resolution and 
purity 
 
Cells do not maintain 
labelled 
Scale-up 
 
Labelling required 
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Despite very few problems encountered during lab scale cell isolation, 
substantial barriers still exist to the efficient commercial scale preparation of 
large amounts of highly purified target cell populations. Commercially 
available cell separation devices at the moment are not generic – usually are 
dependent on the method of separation and cell type isolated (Weil and 
Veraitch, 2014). Table 1.5 summarizes the characteristics of separation 
devices currently being applied for purposes of cell therapies.  
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Table 1.5: Commercially available devices for separation of human therapeutic cells (adapted from Weil and Veraitch, 2014). 
Device Manufacturer Method of 
separation 
Targeted cell type Processing 
time 
Purity 
(%) 
Viability 
(%) 
Process 
yield (%) 
Isolex® 300(i) Baxter Magnetic activated 
cell sorting 
CD34+ cells 2-3 hours 90 At least 
92 
25-51 
CliniMACS® Miltenyi Biotec Magnetic activated 
cell sorting 
Haematopoietic 
progenitors; 
mesenchymal 
stromal cells; T-
cells; dendritic cells 
2.5-3 hours 78-99 78-99 15.7-43.4 
CEPRATE® SC CellPro Continuous flow 
immunoadsorption 
Autologous CD34+ 
cells 
Less than 1 
hour 
72 36.6 41.4 
Sepax® Biosafe Density gradient base 
separation 
Mononuclear cells 
from bone marrow 
35 minutes N/D 80.5 83 
CELLectorTM flask Applied Immune 
Science 
Antibody panning 
selection 
Various cell types 2-3 hours 32.5 15.1 17 
SmartPReP 2 
BMACTM 
Harvest 
Technologies 
Corporation 
Centrifugation Autologous stem 
cells from bone 
marrow 
Less than 15 
minutes 
N/D N/D 74.6 
COBE® 2991 Cell 
processor 
CaridianBTC Centrifugation Autologous stem 
cells from bone 
marrow 
14-28 
minutes 
85-90 98 47 
Elutra® Cell 
separation system 
CaridianBTC Counter-flow 
elutriation 
Monocyte 
enrichment of 
apheresis products 
1 hour 13.6-79.5 93.8 79-100 
Celution® 800/CRS Cytori Real-time cell 
processing 
Adipose-derived 
cells 
1-3 hours 60 89.2 N/D 
FACSCaliburTM flow 
cytometer 
Becton Dickinson 
Biosciences 
Fluorescence 
activated cell sorting 
Various cell types 2-4 hours 73.6 15.5 39.2 
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1.3 CELL SEPARATION PROCESS DESIGN 
CONSIDERATIONS 
Cell separation involves the physical removal or selective killing of target cells 
from a mixed cell population and it is a multistep procedure. For example, 
gradient density centrifugation is often employed as a pre-enrichment step 
followed by an antibody-mediated technique (Thomas et al., 1999).  
Several criteria should be taken into account during set-up of separation 
process. The most important are the final application of the cellular product, 
the cellular properties, the resolution capabilities required and the scalability 
of the process (Diogo et al., 2012). 
No matter which approach is used for cell separation there is a need to 
evaluate efficiency by calculating cell purity, recovery and viability. Purity 
relates to the enrichment of population of interest based on known factors, 
such as cell surface phenotype, which are associated with target cell 
population. Cells are complex and therefore it is usually necessary to assess 
the expression of more than one marker to confirm their purity. Recovery is 
the percentage of cells, target and/or total cell population, obtained post 
enrichment and compared to the number of cells in origin population. In 
conjunction with purity, gives the information on the efficiency of the cell 
separation. Viability is one of the indicators of cell quality after separation. 
This parameter determinates if the depleted cell population of interest is fit for 
the further use (Tomlinson et al., 2012). 
Initial planning and design is the most important step in process set-up with 
detailed understanding of cells of interest, their origin and function. Due to the 
complexity of the separation process, current methods generally offer a 
balance between purity and recovery (Tomlinson et al., 2012).  
Challenges associated with the cell purification can be divided into three 
parts, namely (i) biological challenges; (ii) processing challenges; and (iii) 
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CHALLENGES 
ASSOCIATED 
WITH CELL 
PURIFICATION 
Biological 
challenges 
Cell recovery  
Target cell population 
Sufficient cell numbers 
Removal of contaminants 
Cross-contamination prevention 
 (autologous samples) 
Marker selection 
Processing 
challenges 
Physical stress upon cells 
Target cell population 
Cell clumping and sticking 
Removal of contaminants 
Regulatory requirements 
Adherent vs. suspension cells 
Engineering 
challenges 
High throughput 
Scale-up 
Sufficient log enrichment 
Sterile and clossed process 
Process monitoring 
Quality control 
engineering challenges (Weil and Veraitch, 2014) and are summarized in a 
schematic below (Figure 1.3). 
Figure 1.3: Challenges associated with cell separation of cellular therapies (adapted 
from Weil and Veraitch, 2014).    
 
Cells are living material which requires separation process to be handled in a 
sterile and closed environment to maintain sterility and prevent contamination, 
while operating in a cell-friendly environment to maintain their viability and 
function (Tomlinson et al., 2012). When cells are exposed to a new material 
they undergo common conformational changes, e.g. changes in membrane 
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structure, and clustering. Interactions between cell and surface can lead to 
changes in carbon-based molecules, so those molecules are chemically and 
morphologically altered and the result is conformational changes of 
membrane proteins. At the same time biological systems are extremely 
complex and usually can only function normally in aqueous media, and many 
important biological processes occur at relatively deeply buried interfaces, 
between different layers (Castner and Ratner, 2002). 
“Cell-friendly” materials are so called biomaterials. They may be defined as 
materials which are designed to be in contact and interact with tissue, blood, 
cells, proteins and any other living component (Xue-Jun, 2005). Whilst in 
contact with cells, biomaterials should be chemically and mechanically stable, 
biocompatible and not induce non-specific cell attachment. The latter is 
currently considered as one of the biggest problems in cell separation using 
chromatography approach (Kumar and Srivastava, 2010). Non-specific cell 
surface interactions may be avoided or decreased with the use of soft 
materials and studies have shown that softness and elasticity of the surface 
are important parameters for cell-surface interactions (Dainiak et al., 2006). 
Alternatively, decreasing the temperature has been proven to decrease non-
specific binding. 
Purity and process efficiency are vital due to usually low cell target numbers 
and cost. Cell clumping and sticking is often caused by incomplete 
dissociation of tissue, coagulation when blood is used and/or dead cells 
present in the population (Tomlinson et al., 2012). 
Successful results obtained in clinical trials requiring stem cells have opened 
a niche for methods with possible scale-up to overcome the bottleneck in 
demand for purified stem cells (Gonzáles-Gonzáles et al., 2011). Scale-up is 
not always possible; therefore it is important to initially choose the design 
which will allow high throughput separations not only on laboratory scale, but 
as well on the preparative scale. 
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One of the major biological challenges represents contaminants removal. 
Besides removal of unwanted cell population and cell debris, processing 
contaminants (growth factors, cryopreservatives, enzymes and serum) and 
external risks (endotoxins, bacterial, viral, fungal or parasitic infection) must 
be removed and assessed (Weil and Veraitch, 2014).  
When separation is affinity-based, ligand selection is important step in method 
set-up. Monoclonal antibodies or antibody fragments are the most appropriate 
and commonly used ligands for effective affinity fractionation of cells.  
Each antibody consists of four protein subunits, two light chains and two 
heavy chains, arranged in Y-shape. Disulphide bridges between cysteine 
amino acid residues hold the chains together. Each of the light and heavy 
chain consists of a constant and a variable region, which binds to the target 
molecule, the antigen. Breaking an antibody at the ‘hinge’ yields three 
segments, two identical Fab fragments and one Fc fragment. Each Fab 
fragment consists of one light chain and half of a heavy chain. The Fc 
fragment contains the lower halves of both heavy chains (Figure 1.4; Clark 
and Pazdernik, 2010).  
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Figure 1.4: Antibody structure and antibody fragments made by antibody 
engineering (redrawn from Clark and Pazdernik, 2010). Antibody consist of four 
protein subunits, two light chains (constant light (CL) and variable light (VL)) and two 
heavy chains (constant heavy (CH) and variable heavy (VH)). Fab fragments are 
produced by protease digestion of the ‘hinge’ region. A disulphide bond holds the 
heavy and the light chains together. To make an antibody fragment without any 
constant region, the genes for VH and variable light VL domain are expressed on a 
bacterial plasmid. Because of the lack of disulphide bonds, the structure is unstable. 
Therefore, disulphide bonds are engineered into the two halves (dsFv fragment), or a 
linker is added to hold the VH and VL domains together (scFv fragment). 
 
For efficient and specific separation it is not necessary to use the whole 
antibody. With antibody engineering it is possible to manipulate the antigen 
binding regions of the antibodies and then attach them to other molecular 
fragments (see Figure 1.4). The antibody fragments used include Fab, Fv, 
and a single chain Fv (scFv) regions. For further stabilization of the single 
chain Fv, a linker is added which holds both domains together. A variety of 
engineered antibody constructs are being investigated, such as a diabody, 
which consists of two scFv fragments assembled together (Clark and 
Pazdernik, 2010). 
Antibodies used for cell separation do not need to be absolutely specific to the 
target cell, as long as other cells in cell suspension are not expressing the 
same antigen. A surprising finding has been that cell separation can also be 
achieved by high expression of the target antigen. In a breast cancer model 
system, it was demonstrated that cells expressing high levels of a target 
antigen were not efficiently removed by antibodies labelled on magnetic 
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beads (Gee, 1997a). Reducing the antigen-antibody interactions by restricting 
the amount of monoclonal antibodies coupled to the beads, resulted in 
improved separation efficiency. The most likely explanation for the negative 
effect of high antigen density is that overcrowding of the monoclonal antibody 
molecules on the cell surface can cause steric hindrance and reduce binding 
to the secondary antibody. The criteria taken into account for the selection of 
the target antigen should not be focussed only on the distribution and density 
of the antigen, but also on its biological function. For example, highly mobile 
antigens that undergo rapid internalization upon cross-linking or binding are 
generally unsuitable (Gee, 1997b).  
Affinity-based separations are very expensive mainly due to the monoclonal 
antibody cost. To reduce cost on large-scale production, novel immunoaffinity 
ligands have been proposed – aptamers (Diogo et al., 2014). Aptamers are 
synthetic peptides or highly-specific single strain nucleic acids generated by 
combinatorial chemistry in vitro. They can be developed in automated 
processes and then easily modified with fluorochromes, biotin or any other 
nanoparticle (Nery et al., 2009). Aptamers are already used for stem cell 
isolation, e.g. isolation of human adult mesenchymal stem cells from bone 
marrow, was reported (Guo et al., 2006). 
Aptamers can be used as an alternative when surface markers are not known 
or monoclonal antibodies are not commercially available. They can be 
employed as well when the cell type of interest does not have unique 
markers, which makes the isolation of a homogeneous population difficult 
(Tomlinson et al., 2012). 
In the final product should be present only individual cell types in a viable form 
and with intact cellular function. It is important to know that product can 
contain more than one cell type and be still classified as pure (Halme and 
Kessler, 2006). To confirm retained biological cellular function, in vitro testing 
and animal models can be used (Halme and Kessler, 2006).  
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1.4 RESEARCH AIMS AND SCOPE 
The aims for the work presented here were to advance new single-use cell 
affinity selection format.  
The project had the following four main objectives:  
I. Define an appropriate biocompatible coating for glass material; 
II. Identify suitable ligands for effective attachment and detachment of 
cells from the support material in viable form;  
III. Following preparation and characterisation of functionalised affinity 
glass beads, to carry out a comprehensive study using human 
therapeutic cells (red blood cells) and B and T lymphocytes from 
various cell lines to evaluate the efficiency, productivity and selectivity 
of cell adsorption and desorption from the supports, and the impact of 
the developed method on the cell viability and the expression of cell 
surface markers; 
IV. Evaluate developed separation process and compare its performance 
and cost with MACS®, the gold standard in cell separation, using 
various cell line mixtures. 
  
Chapter 1: Introduction  
 
42 
 
1.5 STRUCTURE OF THESIS 
Thesis has been structured in the following way:  
 
Chapter 1: Introduction: In this chapter the aims and objectives of the 
research are presented and the thesis structure is introduced. This chapter 
covers as well the literature review of downstream processing of cells in order 
to provide background and context to the research.   
In next three chapters results of experimental work are presented. Each 
chapter consist of short abstract, introduction, materials and methods, results 
and conclusions section. 
Chapter 2: Tailored surfaces for affinity selection of human therapeutic 
cells: In this chapter various approaches undertaken for surface modification 
and functionalization of glass coverslips and hollow capillary tubes are 
explained in order to establish “cell-friendly” environment for cell attachment 
and detachment. 
Chapter 3: Preparation, characterization and application of non-porous 
glass beads for the positive selection of human red blood cells: 
Preparation and characterization of glass beads is presented in this chapter, 
as well as the development of the separation method for red blood cells.  
Chapter 4: Application of glass bead chromatography for the positive 
selection of human white blood cells: The development of an affinity 
chromatography method for the positive selection of human white blood cells 
is explained in this chapter.  
Chapter 5: Glass bead chromatography versus MACS® Microbeads: A 
first principle comparison: In this chapter a comparative study between 
developed affinity chromatography method and MACS® affinity based 
magnetic beads separation using various human cell suspensions is 
presented, together with economic comparison. 
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Chapter 6: Conclusions and future work: This chapter presents all the 
main conclusions arising from all the work presented within the thesis. It also 
outlines proposals for future work. 
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2. TAILORED SURFACES FOR AFFINITY 
SELECTION OF HUMAN THERAPEUTIC CELLS 
Abstract 
Chromatography offers huge potential in cell purification and separation; 
however in most studies performed so far the adsorbent materials are 
unsuitable for the selection of human therapeutic cells. In this chapter are 
presented approaches used in the development of generic, scalable and 
transferrable selection system for human therapeutic cells, with an emphasis 
on the engineering of clinically approved materials for the highly selective 
affinity-based adsorption and gentle efficient detachment of human cells in a 
viable form are detailed. A reliable system was developed on glass coverslips 
and successfully transferred to small case studies, where tailored surfaces 
were tested under flow-conditions using glass hollow capillary tubes. The 
affinity separation system developed in this work can be easily applied to any 
chromatographic support already present on the market. 
2.1 INTRODUCTION 
At present there are no truly affordable, scalable, cell enrichment devices on 
the market capable of selecting therapeutic cells. The clinical benchmark 
remains magnetic affinity cell sorting (commercially known as MACS®), a 
method developed more than 30 years ago for the purification of human red 
blood cells (Molday et al., 1977). Alternatively, fluorescence-activated cell 
sorting (FACS) may be used. Both methods are deemed too expensive and 
inappropriate for large scale separation (Kumar and Srivastava, 2010). 
To many bioprocessors, who see chromatography as the solution to all high-
resolution separation problems, trust in magnetic-based methods is 
misplaced. However, most chromatographic studies to date have employed 
unsuitable adsorbent materials, such as porous Sephadex beads, and have 
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therefore yielded very poor results in comparison to magnetic bead separation 
(Johnsen et al., 1999; Diogo et al., 2012).  
The critical design goal for a chromatographic support for affinity selection of 
human therapeutic cells would be a biocompatible surface with minimal 
adsorption of biological fluid-borne proteins. Furthermore, to achieve high 
selectivity and yields, non-specific cell binding should be impeded to prevent 
inflammatory responses. With this in mind, specific cell interactions could be 
achieved by chemically grafting the appropriate density and types of cell 
affinity ligands on the biocompatible surface (Massia et al., 2000).  
Various potential cell-compatible materials have been investigated in the past, 
with many materials and coatings being successfully applied for purposes of 
regenerative medicine. The most popular materials are polyethylene glycol 
(PEG), PEG-based hydrogels, polyacrylamide, polyvinyl alcohol and 
compositions of polyacrylate and PEG. Another routinely used material is 
cross-linked dextran, which is used not only as a cell culture microcarrier, a 
drug delivery vehicle, a macroporous scaffold, but it is also popular as a low 
protein-binding support for chromatography separations (Massia et al., 2000; 
Massia et al., 2003; Lévesque and Shoichet, 2006) due to the nature of 
dextran, as it has more peptide-grafting sites than PEG (Massia et al., 2000). 
Additionally Österberg et al. (1993; 1995) simultaneously reported on the 
capability of cross-linked dextran to further reduce non-specific protein 
adsorption in comparison to PEG; consequently, the level of non-specific cell 
attachment is reduced (Lévesque and Shoichet, 2006). As a coating, oxidized 
dextran forms a uniform ultrathin film on grafted surfaces (Kühner and 
Sackmann, 1996).  
The most popular affinity chromatographic techniques are based on 
interactions between antibodies and antigens, lectins and sugar, and avidin 
and biotin (Sproβ and Sinz, 2012). Specific binding of biotin to the egg white 
protein avidin or the bacterial analogue streptavidin is one of the most useful 
interactions in immunochemistry due to its high affinity, with a dissociation 
constant of approximately 10-15 M (Green and Toms, 1973). Bound avidin is 
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stable at extreme conditions including high and low pH’s, high buffer salt 
concentration and even when exposed to chaotropic agents (Wilchek and 
Bayer, 1988).  
Biotin, also known as vitamin H, vitamin B7 and coenzyme R, is a small 
water-soluble molecule with a molecular weight of 244.3 Da. It is present in all 
living cells and serves as a coenzyme in the citric acid cycle and takes a part 
in cell growth, affecting chromatin structure and mediating gene regulation 
(Zempleni, 2005). Mammals cannot synthesize biotin, so they depend on the 
dietary intake from microbial, plant or animal sources (Zempleni et al., 2009). 
In the most cases, biotin does not have any negative impact on the biological 
systems and their activity (Zempleni, 2005). It can be used as a cell surface 
label and it allows highly sensitive detection of labelled molecules using 
streptavidin-peroxidase conjugates (Cole et al., 1987), even in vivo (Cronan 
and Reed, 2000). Additionally, using biotin as a derivatization reagent does 
not have impact on the activity of the biotinylated molecule (Diamandis and 
Christopoulos, 1991), therefore it is not a surprise that it is targeting of 
immobilized avidin or streptavidin with biotinylated molecules a powerful tool 
not only for separation and purification, but also for immunoassays, receptor 
studies, and immunocytochemical staining (Hermanson et al., 1997).   
When applying avidin-biotin approach for the purpose of affinity 
chromatography, the biggest disadvantage is the severe conditions necessary 
to release the bound biotin or biotinylated molecule, such as reduced pH to 
2.8 (Hermanson et al., 1997) or mechanical disruption of the bond (Kuo and 
Lauffenburger, 1993). To reduce the dissociation constant between avidin and 
biotin, several strategies have been developed, such as monomerization of 
tetrameric avidin, chemical modification of biotin binding site on the avidin, 
site-directed mutagenesis of avidin, and development of biotin analogues 
(Sproβ and Sinz, 2012). 
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Table 2.1: Dissociation constants for the interactions between various forms of avidin 
and biotin 
System Dissociation constant  Reference 
tetrameric (strept)avidin – 
biotin 
KD=10-15 M Livnah et al., 1993  
KD=4*10-14 M Green, 1990  
monomeric avidin (activated 
with cyanogen bromide) – 
biotin 
Three classes of subunits: 
1/4 subunits KD=5*10-8 M 
1/3 subunits KD=1*10-10 M 
the remaining subunits 
KD=1*10-15 M 
Green and Toms, 
1973 
monomeric avidin (activated 
with sodium borohydride) - 
biotin  
more than 90 % of 
subunits KD=10-7 M 
Green, 1970; Sproβ 
and Sinz, 2012 
(strept)avidin - desthiobiotin KD=2*10-9 M Green, 1970 
pH dependant  Hirsch et al., 2002 
 
Table 2.1 summarizes the dissociation constants for the most common avidin-
biotin interactions. It shows that the dissociation constant of biotin and avidin 
is significantly lower when native, tetrameric avidin is monomerized. To 
prevent spontaneous re-association, tetrameric avidin is at first immobilized 
and then its subunits are dissociated under denaturing conditions (Hermanson 
et al., 1997). When avidin is activated with sodium borohydride, more than 90 
% of subunits are in the monomeric form with a dissociation constant for biotin 
of 10-7 M (Green and Toms, 1973). Thus, it is possible to elute bound biotin 
and biotinylated molecules by competitive displacement using excess free 
biotin (Hermanson et al., 1997).  
In this work, approaches undertaken for the modification and functionalization 
of glass coverslips and glass hollow capillary tubes in order to establish 
environment for gentle positive cell selection are detailed. 
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2.2 MATERIALS AND METHODS 
2.2.1 MATERIALS 
Borosilicate glass coverslips (10 mm in diameter; 0.13-0.16 mm thick) were 
supplied by Fischer Scientific UK Ltd. (Loughborough, UK) and rectangular 
borosilicate glass hollow capillary tubes (inner dimensions: 3.0 mm x 0.3 mm 
x 100 mm) for the flow-based assay were purchased from CM Scientific Ltd. 
(Silsden, UK).  
Liquinox® detergent, (3-aminopropyl)triethoxysilane (3-APTES; ≥98 % purity), 
biotin p-nitrophenyl ester (98 % purity), dextran from Leuconostoc spp. (Mr ≈ 
70000), sodium borohydride (NaBH4, 98 % purity), sodium tetraborate 
(Na2B4O7, Borax; anhydrous, ≥98.0 %), picrylsulfonic acid (2,4,6-
trinitrobenzenesulfonic acid, TNBS; 1 M water solution) and picric acid 
((O2N)3C6H2OH; ≥98 % pure, moistened with water) were obtained from 
Sigma-Aldrich Company Ltd. (Gillingham, UK). PD-10 desalting column and 
HiTrap Protein G HP 1 mL column were purchased from GE Healthcare Life 
Sciences (Little Chalfont, UK). Quant*Tag™ Biotin kit was supplied by Vector 
Laboratories Ltd. (Peterborough, UK). Desiccated avidin, egg white 
(Molecular Probes®, Invitrogen; Mr ≈ 66000; biotin binding of 13.6 units/mg of 
protein), D(+)-biotin (Acros Organics; 98 % purity), 7-aminoactinomycin D 
(Molecular Probes®, Invitrogen; 7-AAD), streptavidin R-Phycoerythrin 
conjugate (Molecular Probes®, Invitrogen; SAPE; 1 mg/mL solution), Trypan 
blue (Molecular Probes®, Invitrogen; 0.4 % solution), RPMI-1640 liquid 
medium with 2.05 mM L-glutamine (Thermo Scientific HyClone; RPMI), foetal 
bovine serum (Thermo Scientific HyClone; FBS; standard filtered through 
three sequential 100 nm (0.1 μm) pore size rated filter), DSB-X biotin 
(Molecular Probes®, Invitrogen), Ficoll-Paque™ Plus (GE Healthcare Life 
Sciences) and BCA Protein assay kit (Thermo Scientific Pierce) were 
purchased through Fischer Scientific UK Ltd. (Loughborough, UK). All other 
materials and reagents were supplied by Fischer Scientific UK Ltd. 
(Loughborough, UK). Acetone, toluene and ethanol were HPLC grade (Fisher 
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Chemical brand). Sodium azide (NaN3) was supplied as 99 % pure and 
suitable for cell culture. Guanidine hydrochloride (Gdm HCl) was purchased 
as an 8 M water solution. Ammonium bicarbonate (NH4HCO3), 
Ethylenediaminetetraacetic acid (EDTA; disodium salt dehydrate suitable for 
electrophoresis), glycine (C2H5NO2; Gly), hydrogen chloride (HCl), potassium 
chloride (KCl), sodium acetate (C2H3NaO2), sodium chloride (NaCl) sodium 
hydrogen carbonate (NaHCO3), sodium hydroxide (NaOH), sodium 
metaperiodate (NaIO4), sodium phosphate (Na3PO4) and 
tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), salts used for 
preparation of buffer solutions, were analytical grade (99+ % purity) and 
suitable for use in cell culture. Phosphate buffered saline (PBS buffer) was 
supplied in a form of tablets. Each tablet prepares 100 mL of PBS buffer. 
Dimethyl sulfoxide (DMSO) was 99 % pure and molecular biology grade.  
All solutions were prepared using water purified by a Millipore Elix Gulfstream 
Clinical 100 (Merck Millipore UK Ltd, Watford, UK) water purification system. 
Buffer solutions were prepared by dissolving a known mass of buffering 
species into ca. 80 % of the desired final volume of deionized water, titrating 
with 1 M solution of HCl or NaOH and adding water to yield the final volume. 
Sterilization of solutions and suitable materials was performed either by 
autoclaving at 121 °C and 1.03 bar for 30 min using an ASB 300T autoclave 
(Astell Scientific, Sidcup, UK) or by sterile filtration through a 0.22 µm filter 
(Merck Millipore UK Ltd, Watford, UK). 
Rituximab (anti-CD20 monoclonal antibody) was purchased from Roche 
(Basel, Switzerland), BB7.2 (anti-HLA-A2 monoclonal antibody) and anti-
glycophorin A (Gly A) monoclonal antibody in cell culture supernatant were 
kindly provided by Dr Oliver Goodyear (School of Immunity and Infection, 
College of Medicine, University of Birmingham, UK).  
Continuous human cell lines Jurkat E6.1, Bristol-8 and CCRF-HSB-2 were 
purchased from the Health Protection Agency, Culture Collection (Salisbury, 
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UK), Toledo continuous human cell line was purchased from LGC Standards 
(Teddington, UK). 
Red blood cells were isolated from umbilical cord blood, which was obtained 
from anonymous donors through NHS Blood and Transplant (NHSBT). Table 
2.2 below summarizes the cells and antibodies used in this study. 
Table 2.2: Cells and antibodies used in experiments 
Cells Targeted antigen Monoclonal antibody 
Red blood cells CD235a 
(glycophorin A) 
Anti-CD235a (anti-glycophorin A; 
Gly A) 
Toledo cell line  
(B lymphocytes) 
CD20 Anti-CD20 (Rituximab) 
CCRF-HSB-2 cell line  
(T lymphoblasts) 
HLA-A2 Anti-HLA-A2 (BB7.2) 
Bristol-8 cell line 
(B lymphocytes) 
   
2.2.2 METHODS 
2.2.2.1 Surface modification 
Preparation of aminated glass material 
Glass coverslips and hollow capillary tubes were cleaned by a method 
developed by Rowland et al. (1995). In short, the material was immersed in 
acetone in an ultrasonic bath (Fisherbrand S15, Fisher Scientific Ltd, 
Loughborough, UK) for 2 min, rinsed with 95 % ethanol, immersed in 95 % 
ethanol in ultrasonic bath for 20 min, rinsed with water, immersed in 2 % 
Liquinox® brand detergent in ultrasonic bath for 20 min, followed by an 
extensive rinsing with water. The glass surfaces were finally dried overnight at 
40 ˚C in a drying cabinet (Belling, Unfield, UK).  
Amination of glass surfaces was carried out as described by Massia and Stark 
(2001). Briefly, the cleaned surfaces were immersed in 7 % solution (v/v) of 3-
APTES in toluene for 1 h, rinsed with toluene, followed by 10 min alternating 
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cleaning in toluene and water in ultrasonic bath until there was no visible 
evidence of silane multilayer build on the surface. This procedure was 
completed by drying at room temperature overnight in a fume cupboard. 
Application of aldehyde groups on the animated glass surfaces 
The immobilisation of aldehyde groups on the glass surfaces is a three step 
procedure (see Figure 2.1) and was performed according to the protocol 
described by Massia and Stark (2001).    
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Figure 2.1: Reaction scheme for the surface modification of aminosilane derived 
glass surfaces. Dextran was oxidized by sodium metaperiodate (NaIO4), and then 
covalently coupled to the aminosilane derived glass surface. Sodium borohydride 
(NaBH4) was used to reduce unstable Schiff’s bases. Reactivation of the surfaces 
was done by NaIO4 oxidation. 
 
The first step in the glass surface modification with aldehyde groups was the 
oxidation of dextran using NaIO4. Freshly prepared 0.1 M NaIO4 solution was 
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added to dextran solution (1 g of dextran dissolved in 30 mL of water) to make 
50 % molar ratio. Because of the photosensitivity of the oxidized dextran, all 
following steps were performed in containers wrapped in aluminium foil to 
protect the material from the light. The solution was stirred at 4 °C overnight, 
purified by dialysis in water and subsequently freeze dried using a Pirani 10 
freeze dryer (Edwards, Crawley, UK). The lyophilized dextran was dissolved 
in 0.2 M NaHCO3 buffer, pH 10, (final dextran concentration of 0.02 g/mL) and 
2 mL of the above solution was added to the aminated glass surfaces. The 
materials were left to incubate on a 3-D rocking platform STR 9 (Stuart 
Scientific, Stone, UK) with shaking at 70 revs/min for 30 min at room 
temperature. The dextran solution was subsequently decanted and replaced 
by 0.1 M NaBH4 in water to reduce the free Schiff’s bases and to quench any 
free unreacted aldehyde groups. After 2 h of incubation at room temperature 
on a 3-D rocking platform at 70 revs/min, the NaBH4 was decanted, the 
surfaces were rinsed three times with water, and left to dry at 40 °C overnight 
in a drying cabinet. The dextran derived surfaces were oxidized by adding 2 
mL of fresh 0.1 M NaIO4 solution and left to incubate overnight in an OLS200 
linear shaking water bath (Grant Instruments, Cambridge, UK) at 4 °C. The 
NaIO4 solution was then decanted and the modified coverslips and hollow 
capillary tubes were rinsed three times with water to remove any residual 
chemicals. The surface modification was completed by air-drying at room 
temperature inside a fume cupboard.  
Immobilization of monomeric avidin 
The aldehyde derived glass coverslips and hollow capillary tubes were 
functionalized with monomeric avidin, following the modified procedure, 
described by Sproβ and Sinz (2012). The materials were first incubated 
overnight at room temperature in the presence of tetrameric avidin solution (2 
mL with final concentration of avidin 2.5 mg/mL in 100 mM Na3PO4, pH 7.0). 
The materials were incubated for a further 6 h in 2 mL of 80 mM NaBH4 
solution at room temperature, to reduce Schiff’s bases and unreacted 
aldehyde groups. The tetrameric avidin was then cleaved to its individual 
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subunits by the addition of 2 mL 6 M Gdm HCl in 0.2 M KCl buffer, pH 1.5. 
Following incubation for 66 h at room temperature, non-bound and weakly 
bound avidin was eluted with 0.1 M NH4HCO3 buffer and any irreversible 
biotin binding sites on the immobilized avidin were blocked with 2 mL of 0.4 
mM D-biotin solution in 50 mM Tris-HCl buffer, pH 7.5. In order to release the 
reversible or low affinity monomeric biotin binding sites, the glass surfaces 
were rinsed three times with 0.1 M Gly, 0.15 M NaCl buffer, pH 2.8, and then 
re-equilibrated with PBS buffer, pH 7.2, as described by Hermanson et al. 
(1997). 
2.2.2.2 Purification of anti-glycophorin A monoclonal 
antibody from cell culture supernatant 
Gly A antibody, produced by HB-8162™ hybridoma cells, was purified from 
frozen cell culture supernatant using a 5 mL HiTrap Protein G HP column (GE 
Healthcare, Uppsala, Sweden) connected to an ÄKTA Explorer 100 Air 
chromatographic system (GE Healthcare, Uppsala, Sweden). 
Following equilibration with 20 mM Na3PO4, pH 7, for 10 column volumes 
(CVs), the column was loaded with the 1 mL of defrosted supernatant 
containing the Gly A antibody at a flow rate of 1 mL/min (75 cm/h). The 
column was then washed with 5 CVs of the equilibration buffer, and the bound 
antibody was eluted with a linear gradient (0-100 %) of 0.1 M Gly-HCl buffer, 
pH 2.7 for 10 CVs. Drop by drop neutralization of the eluted antibody fraction 
was done by adding 1 M Tris-HCl buffer, pH 8, until a pH of 7 was achieved. 
The final antibody concentration was determined by absorbance reading at 
280 nm using UV-VIS spectrophotometer (UV mini 1240, Shimadzu, Milton 
Keynes, UK). The antibody concentration was calculated using equation 2.1: 
𝑐𝐴𝐴 = 𝐴280𝑥                 (2.1) 
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were: cAb represents the concentration of antibody in the solution (mg/mL); 
and, x is the expected absorbance of 1 mg/mL antibody solution in a 1 cm 
light path cuvette (mg/mL; usually 1.36 mg/mL (Pace et al., 1995)).  
NaN3 up to a final concentration of 0.1 % (v/v) was added to the antibody and 
the solution was stored at 4 °C until further use. 
2.2.2.3 Biotinylation of antibodies 
The biotinylation of the monoclonal antibodies used in this study was 
performed using a modified protocol, first devised by Kantor and Roederer in 
1997. First, a buffer exchange of the antibody solution to PBS buffer was 
performed using a disposable PD-10 desalting column. Subsequently, D-
biotin was covalently coupled to the primary amines to the constant region of 
the heavy chain of the antibody using the procedure described below. A fresh 
solution of 10 mg of D-biotin dissolved in 1 mL of anhydrous DMSO was 
prepared and added to the antibody solution under manual mixing (6.06 mL of 
D-biotin solution for each mg of antibody in the buffered solution). The mixture 
was then placed in a laboratory shaker (IKA-VIBRAX-VXR, JK electronic, 
Staufen, Germany) at a motor speed 600 for 1 h at room temperature. The 
reaction was stopped by adding 10 % (v/v) of 1 M Tris-HCl buffer, pH 8, any 
remaining D-biotin was removed and the buffer was exchanged to PBS using 
a PD-10 column. The amount of biotinylated antibody was determined by 
absorbance reading at 280 nm, using a UV-VIS spectrophotometer as 
described in Section 2.2.2.2. The biotinylated antibodies were subsequently 
stored at 4 ºC until further use. 
2.2.2.4 Surface functionalization 
The avidin modified glass coverslips and hollow capillary tubes were 
functionalized with the biotinylated antibodies as follows. The light sensitive 
material was first rinsed with PBS buffer, pH 7.2, and then incubated in 10 
µg/mL antibody solution in PBS buffer for 1 h at room temperature on a 3-D 
Chapter 2: Tailored surfaces for affinity selection of human therapeutic cells 
 
69 
 
rocking platform at 70 revs/min. The remaining antibody solution was then 
removed and the surfaces were rinsed once with PBS buffer. The glass 
surface functionalization is presented in the Figure 2.2.  
 
Figure 2.2: Two schematic representations of antibody coupling to glass surfaces. 
(A) Coupling of biotinylated antibody to mono-avidin modified supports, followed by 
cell binding. (B) Binding of biotinylated antibody labelled cells to mono-avidin 
modified supports. 
 
The mass of bound antibody was determined using equation 2.2: 
𝑚𝐴𝐴 = �𝑐𝐴𝐴,𝑠𝑠𝑠𝑠𝑠 − 𝐴280,𝑎𝑎𝑎𝑎𝑎𝑥 � ∗ 𝑉𝑠𝑠𝑠𝑠𝑠 − �𝐴280,𝑎𝑟𝑟𝑟𝑟𝑟𝑟𝑥 ∗ 𝑉𝑟𝑟𝑟𝑠𝑟𝑟𝑟�   (2.2) 
were: mAb is the mass of the bound antibody (mg); cAb,stock and Vstock are the 
concentration (mg/mL; usually 0.05 mg/mL) and volume (mL) of the starting 
antibody solution respectively; A280,after is the absorbance at 280 nm of the 
antibody solution at the end of the incubation time; x is the expected 
absorbance of 1 mg/mL antibody solution in a 1 cm light path cuvette (mg/mL; 
usually 1.36 mg/mL); A280,rinsing and Vrinsing are the absorbance at 280 nm and 
the volume (mL) of the rinsing fraction respectively. 
2.2.2.5 Cell culture 
All cell lines were cultured in static cell culture using RPMI medium, 
supplemented with 10 % (v/v) FBS. The complete growth medium was stored 
at 4 °C and used within one month. 
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Cryovials containing frozen cells were rapidly thawed in a 37 °C water bath 
and then transferred to a biological safety cabinet (Advanced Bio Safety 
Cabinet Class II, Astec Microflow, Andover, UK). The contents of each 
cryovial were then promptly transferred into a 15 mL centrifuge tube 
containing 10 mL of pre-warmed growth medium. Cell suspension was 
centrifuged in a Heraeus Labofuge 400R centrifuge (Thermo Scientific, Fisher 
Scientific, Loughborough, UK) at 200 gav for 5 min at room temperature. The 
supernatant was decanted and the cell pellet was gently resuspended in 5 mL 
of growth medium. Cell viability was checked with Trypan blue exclusion 
assay and cells were counted using a Neubauer Improved Bright-Line 
haemocytometer (Sigma Aldrich, Gillingham, UK). Cells were subsequently 
seeded at a density of 3*105 cells/mL in cell culture flasks and incubated in a 
Heracell 150i CO2 incubator (Thermo Scientific, Fisher Scientific, 
Loughborough, UK) in controlled environment (5 % CO2; 37 ºC). A complete 
growth medium exchange was performed every 48 h, with an aim not to 
exceed cell density of 1*106 cells/mL. Viable cells were counted and 1*105 
cells/mL were seeded into fresh tissue culture flasks, filled with pre-warmed 
growth medium. If necessary were cell suspensions split between two or more 
flasks.  
2.2.2.6 Isolation of red blood cells from umbilical cord blood 
Red blood cells were isolated from umbilical cord blood by density gradient 
centrifugation. Routinely, fresh umbilical cord blood was diluted four times in 
PBS buffer supplemented with 2mM EDTA, The blood/buffer suspension (35 
mL) was carefully layered over 15 mL of Ficoll-Paque Premium™ in a 50 mL 
centrifuge tube and centrifuged at 400 gav for 30 min at room temperature in a 
swinging-bucket rotor Heraeus Labofuge 400R centrifuge (Thermo Scientific, 
Fisher Scientific, Loughborough, UK). The bottom layer containing the red 
blood cells was then transferred to a new 50 mL centrifuge tube and topped to 
the 45 mL with PBS and 2 mM EDTA buffer. The suspension was gently 
mixed by inversion and centrifuged once again at room temperature at 300 gav 
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for 10 min. The supernatant was discarded and the pellet was diluted with 
PBS. The cells were stored at 4 °C and used within 2 weeks. 
2.2.2.7 Cell labelling with antibody 
Following centrifugation of cell culture or red blood cell suspension at 200 gav 
for 5 min at room temperature, the supernatant was discarded and the cell 
pellet was resuspended in PBS buffer to a final concentration of 1*106 
cells/mL. The biotinylated antibody was added to the cells at a final 
concentration of 10 µg/mL and the mixture was left to incubate in the CO2 
incubator for 30 min, protected from the light. The cell suspension was 
centrifuged once again and the pellet was resuspeneded in PBS to a final 
concentration of 3.5*106 cells/mL. The mass of antibody bound to the cells 
was calculated using equation 2.2 as described in Section 2.2.2.4. 
2.2.2.8 Static binding studies 
All static binding studies of the photosensitive materials were performed in 24 
well non-treated cell culture plates at room temperature with shaking at 70 
revs/min using a 3-D rocking platform. 
The impact of the D-biotin on the viability of selected cells and their 
identity/functionality, cells were incubated in the presence of 0 to 3 mmol/L of 
D-biotin in PBS buffer for 2 h at room temperature, protected from the light. In 
addition, the impact of DSB-X biotin, a commercially available derivate of 
desthiobiotin with a seven-atom spacer, was evaluated at the concentration of 
3 mmol/L.  
Cell suspensions were centrifuged at 200 gav for 5 min and 2.5*106 cells in the 
pellet were resuspended in D-biotin or DSB-X biotin solution for 2 h. Cells 
were then collected and transferred into PBS buffer. Their viability and identify 
were assessed by flow cytometry (Guava easyCyte 8HT Flow Cytometer, 
Merck Millipore UK Ltd, Watford, UK).  
Chapter 2: Tailored surfaces for affinity selection of human therapeutic cells 
 
72 
 
The amount of the biotinylated BB7.2 antibody bound to the tetrameric or 
monomeric avidin immobilized on glass coverslips was determined as follows. 
The coverslips were first rinsed with PBS buffer and subsequently 400 µL of 
antibody solution of various concentrations (0–2 mg/mL) was added. After 2 h 
incubation at room temperature, the supernatants were collected and the 
coverslips were washed with 400 µL of PBS buffer. The absorbance of the 
supernatants and the washes was measured at 280 nm and the mass of 
bound antibody was calculated as described in Section 2.2.2.4 . 
Cell binding capacities were evaluated for bound biotinylated CD20 antibody 
to coverslips and labelled cells with antibodies. In the first case, coverslips 
were incubated overnight at 4 °C in 20 µg/mL biotinylated antibody solution 
and then the next morning were coverslips gently rinsed by PBS buffer. In the 
second case, 5 mL of cell suspension (2.5*106 cells/mL) were incubated at 
room temperature on a 3-D rocking platform (70 revs/min) in the 50 µg/mL 
antibody solution in PBS buffer. After 1 h suspension was centrifuged at 200 
gav for 5 min, supernatant was decanted and pellet gently resuspended in 5 
mL of fresh PBS buffer. For the cell binding studies, a set of coverslips in 24-
well plates was prepared and gently rinsed by PBS buffer. To each well 400 
µL of cell suspension was added with the concentrations from 2.5*104 to 
2.25*106 cells/mL. The plates were gently agitated on a 3-D rocking platform 
(40 revs/min) for 30 min at room temperature, protected from the light. After 
completed incubation, suspensions were collected and coverslips gently 
rinsed by 1 mL of PBS buffer. Cells in the suspensions were evaluated and 
counted by Trypan blue exclusion assay (see Section 2.2.2.10, Equations 2.3 
and 2.4). 
The kinetics of cell attachment was determined using the two approaches 
presented in Figure 2.2, i.e. (A) coupling of biotinylated BB7.2 antibody (10 
µg/mL) to tetrameric or monomeric avidin derived glass coverslips, followed 
by CCRF-HSB-2 cell binding; and, (B) binding of biotinylated BB7.2 antibody 
labelled CCRF-HSB-2 cells to tetrameric or monomeric avidin derived glass 
coverslips.  
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In both cases, the avidin derived or the BB7.2 functionalised glass coverslips 
were placed in 24 well plates and rinsed with PBS buffer. Cell suspension 
(400 µL of 3.5*106 cells/mL) was added to each well and left to incubate on a 
3-D rocking platform for the in between 0 and 8 h. At the end of the 
incubation, the supernatants were collected and the coverslips were washed 
with 400 µL of PBS. The residual cells in the supernatants and the washes 
were counted using a haemocytometer and their viability was checked with 
Trypan blue exclusion assay. The bound cells were then calculated by 
difference. 
The kinetics of cell elution was tested using a 2 mM solution of D-biotin in 
PBS buffer. CCRF-HSB-2 cells (2*106 cells in PBS) were incubated with the 
avidin derived or the BB7.2 functionalised glass coverslips for 30 min. At the 
end of the incubation, the supernatants were collected, the coverslips were 
washed with 400 µL of PBS, and D-biotin solution (500 µL) was added to 
each well and left to incubate for various times (0 to 180 min). At the end of 
the incubation, the supernatants were collected and the coverslips were 
washed with 500 µL of PBS. The cells in all the supernatants and washes 
were counted using a haemocytometer and their viability was checked with 
Trypan blue exclusion assay.  
Experimental data from static binding studies was fitted with One Site 
Saturation model with SigmaPlot 12.0 software (Systat Software Inc., 
Chicago, Illinois, USA). Determined were maximum number of adsorbed 
antibodies/cells (Bmax), needed time to reach a half of maximal binding (kt), 
binding rate (kA) and dissociation constant (kD).  
2.2.2.9 Flow-based assay 
A flow based assay is a simplified technique, developed for purposes of cell 
growth, adhesion, and attachment observation under controlled shear flow 
conditions, using glass hollow capillary tubes with a well-defined rectangular 
cross section and good optical quality. As shown in Figure 2.3, the system 
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consists of a hollow capillary tube, which is glued to a microscope slide and 
mounted on microscope stage, a Harvard syringe pump and two flasks with 
cell suspension and cell-free buffer. Valves on the both flasks are connected 
with electronic valve (Cooke et al., 1993).  
 
Figure 2.3: Schematic representation of the flow based assay set up. The system 
consists of: a hollow capillary tube mounted to a microscope stage; a Harvard 
syringe pump; two flasks with cell suspension and cell-free buffer; and, an electronic 
microvalve (redrawn from Cooke et al., 1993). 
 
The Olympus microscope (model IX70; Tokio, Japan) is connected to a video 
digitizer (Archimedes 310 microcomputer, Watford Electronics video digitizer; 
Watford Electronics, Watford, UK) thereby allowing for the on-line observation 
of cell attachment, rinsing of unbound cells, cell rolling and cell detachment. 
Consequently, the uniformity of the functionalised surface under observation 
as well as the ligand accessibility to the cells can be observed. 
The glass hollow capillary tubes were cleaned, modified with aldehyde groups 
and functionalized with anti CD20 or Gly A antibody, biotinylated with D-biotin, 
as described in the Section 2.2.2.3. B lymphocytes or red blood cells from 
cord blood (1*106 cells/mL) were passed through the glass hollow capillary 
tubes at a flow rate of 30 cm/h (0.3 mL/min) until all cell suspension passed 
the capillary tube. The glass hollow capillary tubes were then rinsed with PBS 
buffer at 600 cm/h for 5 min and bound cells were eluted with 2 mM solution 
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of D-biotin in PBS buffer at a flow rate of 30 cm/h until no more cells could be 
detected in the outlet. 
2.2.2.10 Analytical methods 
The surface area of the glass coverslips was measured by an ASAP 2020 
accelerated surface area and porosimetry system (Micromeritics U.K. Ltd, 
Hexton, UK). The coverslips were degassed by means of a two-stage 
temperature ramping under a vacuum of ˂10 mmHg, followed by sample 
analysis at -169 °C using nitrogen gas. The surface area was determined from 
adsorption isotherms by the Brunauer, Emmett and Teller (BET) theory 
(Lowell et al., 2006). 
The reactive amino groups on the supports were assessed with the TNBS 
assay. Existing amino groups would react with TNBS to form a highly 
coloured complex (Halling and Dunnill, 1979). The assay was performed 
according to Hermanson et al. (1997). For this an aqueous mixture of 1 M 
TNBS (10 µL) and 0.05 M solution of Borax (1.5 mL) was added to an 
aminated support and heated up to 70 °C in water bath, before being cooled 
to room temperature. Both coverslips and hollow capillary tubes were then 
consecutively washed with water, 50 % acetone in water (v/v), 100 % acetone 
and finally twice with water. To each sample, 5 mL of 1 M solution of NaOH 
was added, in order to release picric acid (2,4,6-trinitrophenol). Finally the 
samples were heated up to 70 °C and left to cool to room temperature. For 
the determination of TNBS, the absorbance of the suspensions was read at 
410 nm using a UV-VIS spectrophotometer. Samples were compared with 
standards (Appendix A) prepared by various dilutions of picric acid in 1 M 
NaOH. 
The presence of the amino reactive groups together with the aldehyde groups 
introduced by coupling the oxidized dextran to the amino-activated surfaces, 
was assessed using K-Alpha X-ray Photoelectron Spectrometer (XPS) 
System (Thermo Fisher Scientific, Waltham, Massachusetts, USA). A detailed 
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analysis of carbon (C), nitrogen (N), sodium (Na), oxygen (O), silicon (Si), 
boron (B) and iodine (I) was carried out on the 0.16 mm2 sample area at room 
temperature with the ion gun operated in the range of 50-1500 eV. 
The mass of immobilized avidin was determined by the Pierce™ Bicinchoninic 
acid (BCA) Protein assay. For the assay, to the samples 50 µL of water and 
950 µL of BCA reagent, prepared according to the manufacture’s manual, 
were added. Samples were incubated for 1 h on a 3-D rocking platform (70 
revs/min) at room temperature. Optical density of slurries was measured at a 
wavelength of 562 nm. Samples were calibrated against albumin in water 
(Appendix B). 
Determination of the functional biotin binding sites of the immobilized avidin, 
which is usually lowered by active side blocking, denaturation, and steric 
hindrance, which was assessed calorimetrically. At first biotin p-nitrophenyl 
ester was dissolved in 100 µL of DMSO and then diluted in 0.5 M C2H3NaO2 
buffer, pH 5, to the final concentration of 0.2 mg/mL. Solution was 
immediately filtered and optical density was measured at 210 nm. Meanwhile 
supports were equilibrated in 0.5 M C2H3NaO2 buffer, pH 5. Then 2 mL of 
prepared biotin p-nitrophenyl solution was added. In the next step, supports 
were rinsed several times with water. Yellow p-nitrophenol was eluted using 
400 µL of 0.1 M NaOH solution. Optical density of eluted fractions was 
measured at a wavelength of 410 nm. Number of biotin binding sites 
calculated using equation 2.3: 
𝑁 = 𝐴410𝑟𝑛 ∗ 𝑉 ∗ 𝑥 ∗ 𝑀𝐴𝑟𝑠𝑠𝑟𝑟                  (2.3) 
were: N represents number of biotin binding sites (µg biotin bound per mL of 
support), A410nm absorbance at 410 nm, V fraction size (mL), x number of 
collected fractions and Mbiotin molecular weight of biotin (244.3 g/mol). 
The content of free soluble biotin in the fractions collected during the 
monomeric avidin immobilization were analysed by label-free Quant*Tag™ 
Biotin Kit. Working solution and standards were prepared according to the 
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manufacturer. To the 20 µL of the sample or standard, 1 mL of working 
solution was added and incubated for 30 min at room temperature on a 3-D 
rocking platform. The absorbance of the slurries was measured at 535 nm 
and biotin was determined from the standard curve (Appendix C). 
The surface of fully functionalized coverslips was visualized with 1530 VP 
scanning electron microscope (SEM; Carl Zeiss Microscopy Ltd, Cambridge 
UK). The analysis was carried out at room temperature and accelerating 
voltages of 1-30 kV were used. Coverslips were dried in advance at room 
temperature and immobilized on the aluminium stubs with double sided 
adhesive carbon conductive dots. Silver paint was placed on the side of the 
supports to act as a conductor and the samples were derived with gold in an 
argon atmosphere before imaging. 
Cells were counted and their viability checked with Trypan blue exclusion 
assay using a haemocytometer. Cell suspensions were gently mixed with 0.4 
% solution of Trypan blue with a 1:1 ratio (v/v). To a chamber, 10 µL of the 
prepared suspension was pipetted. All cells (non-viable cells were stained 
blue, viable cells remained opaque) were counted in at least one square 
under 40x magnification using Nikon Eclipse E200 microscope (Nikon 
Corporation, Tokyo, Japan). The total number of cells in a sample was 
calculated using equations 2.4 and 2.5. 
  𝑁𝑁𝑠𝑠𝑠𝑡𝑡 = 𝐴𝑝𝑝𝑟 𝑠𝑠𝑠𝑡𝑟𝑝 ∗ 𝑥 ∗ 104 ∗ 𝑉𝑠𝑡𝑛𝑝𝑡𝑝             (2.4) 
Nrtotal is the total number of cells in the suspension, Aper square is the average 
cell count per square, x is the dilution factor and Vsample is the initial volume of 
the cell suspension. The calculation of the percentage of viable cells in the 
suspension was done by the following equation  
𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 = 𝐴𝑣𝑟𝑎𝑣𝑣𝑎
𝐴𝑎𝑜𝑎𝑎𝑣
∗ 100              (2.5) 
were Aviable is the number of viable cells counted and Atotal represents the total 
number of counted cells. 
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Immunophenotypic analysis of cells was determined by flow cytometry using 
Guava easyCyte 8HT flow cytometer (Merck Millipore UK Ltd, Watford, UK) 
with excitation at 488 and 640 nm. Cells for the analysis were centrifuged at 
300 g for 5 min, then the supernatant was removed and the pellet 
resuspended in PBS buffer. Biotinylated antibodies remained on the surface 
of the cells were targeted with SAPE. Cells were incubated at room 
temperature for 30 min in the darkness. Just before the analysis 5 µL of 7-
AAD viability dye was added. A minimum of 5,000 events per sample were 
recorded. Data was analysed with InCyte software (Merck Millipore UK Ltd, 
Watford, UK). 
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2.3 RESULTS AND DISCUSSION 
2.3.1 PREPARATION AND CHARACTERIZATION OF GLASS 
SUPPORTS 
Surface area of a single glass coverslips was determined to be 0.798392 cm2, 
which is similar to the theoretical value of 0.785398 cm2. 
Preparation of glass supports for reversible cell separation can be divided into 
three distinct phases: (i) reductive surface amination; (ii) preparation of 
dextran-derived glass coverslips; and (iii) immobilization of monomeric avidin. 
In the first stage, reductive amination of the surface was performed with 3-
APTES, followed by immobilization of oxidized dextran. Both techniques were 
adopted from Massia and Stark (2001). In the third phase, tetrameric egg 
white avidin was at first immobilized on the dextran-derived glass coverslips, 
and then its subunits were dissociated under denaturing conditions (Sproβ 
and Sinz, 2012; Hermanson et al., 1997). 
Reactive amino groups on the glass coverslips were determined using an 
assay originally described by Halling and Dunnill (1979) employing TNBS. A 
high degree of the reproducibility between batches was achieved during the 
deposition of amino groups onto support. On the average (result is based on 
the 4 batches of aminated glass coverslips produced), 11.65 ± 0.05 mmol of 
picric acid was released per cm2 of the support. 
XPS analysis was performed on amino- and aldehyde-derived coverslips and 
results were compared to non-modified coverslips. Table 2.3 summarizes the 
atomic percentages (%) of the detected elements in the overall scan of the 
support. 
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Table 2.3: X-ray photoelectron spectroscopy survey of non-modified, amino- and 
aldehyde-derived glass coverslips. Data presented is an average based on three 
analyses across the coverslip.   
Element  Non-modified glass coverslips 
Amino-derived 
glass coverslips 
Aldehyde-derived 
glass coverslips 
C (atomic %) 18.82 6.00 ▼ 8.18 ▲ 
N (atomic %) N/D* 1.18 ▲ 1.09 ▼ 
Na (atomic %) 3.09 0.94 ▼ 1.35 ▲ 
O (atomic %) 47.49 58.32 ▲ 56.59 ▼ 
Si (atomic %) 22.93 27.78 ▲ 28.01 ▲ 
B (atomic %) 3.26 3.08 ▼ 2.65 ▼ 
Ti (atomic %) 0.63 0.69 ▲ 0.59 ▼ 
Zn (atomic %) 1.06 0.48 ▼ 0.33 ▼ 
K (atomic %) 2.72 1.53 ▼ 1.22 ▼ 
*N/D not detected, ▼decrease, ▲increase 
 
The deposition of 3-APTES on the surface of glass coverslips results in the 
decrease of atomic percentage of carbon (C), sodium (Na), boron (B), zinc 
(Zn) and potassium (K), the major components of glass coverslips. An 
increase in nitrogen (N), oxygen (O), silicon (Si) and slightly titan (TI) was 
observed. This correlates with the elemental composition of 3-APTES. The 
increase of titan is most likely due to the surface sensitivity of the XPS and is 
therefore not relevant for this study. The detailed scan of Si has relieved the 
decrease in silicon dioxide (SiO2), also known as silica, one of the major 
components in glass. An increase of silane (SiH4) is also noted, which is part 
of 3-APTES. The results achieved by XPS-analyses indicates that the 
deposition of amino groups was successful.  
In comparison to the analysis of amino-derived coverslips, covalent coupling 
of oxidized dextran (deposition of aldehyde groups) to the amino-derived 
supports leads to the increase of the atomic percentage of C, Na and slightly 
Si. The atomic percentage of all other elements has decreased, as expected, 
due to the elemental composition of oxidized dextran (Figure 2.1). High-
resolution scan of C1s has shown the presence carbon connected to other 
elements in three different ways, namely (i) C in the ring; (ii) C-O-C or C-OH; 
and (iii) O-C-O. All three relations are present in the structure after completed 
deposition of aldehyde groups. Increase of Na is most likely due to the 
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surface modification method, i.e. coupled oxidized dextran is furthermore 
oxidized by NaIO4. 
The biotin binding capacities of samples of immobilized tetrameric and 
monomeric form of avidin after completed dissociation were evaluated using a 
BCA-protein determination kit, following the modified procedure first described 
by Sorensen and Brodbeck (1986). Figure 2.4 shows that after dissociation of 
tetrameric avidin, the mass of bound protein is significantly reduced from 
tetrameric (black bar) to monomeric (light grey bar) avidin. After blocking the 
non-reversible biotin binding sites, the mass of accessible immobilized protein 
is further reduced (dark grey bar). 
 
Figure 2.4: Immobilized forms of avidin on the surface of aldehyde-derived 
coverslips analysed by BCA assay. Mass of accessible tetrameric (black bar), 
monomeric avidin (light grey bar) and immobilized avidin after blocking of non-
reversible biotin binding sites (dark grey bar). Immobilized aldehyde groups on glass 
coverslip (white bar) react with BCA assay reagent. Presented data is based on 10 
analysed batches of coverslips. Bars represent an average, while error bars standard 
deviation.  
 
After dissociation, native tetrameric, avidin is cleaved into four identical 
subunits - monomers (Figure 2.5). Each monomer has one biotin binding site, 
which remain intact after dissociation. The number of biotin binding sites is 
expressed as a mass of biotin bound per area. 
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Figure 2.5: Avidin egg white structure (Livnah et al., 1993; structures obtained 
through RCSB Protein Data Bank). (A) 3D structure of avidin. Avidin is a symmetrical 
tetrameric glycoprotein, which consists of four identical subunits (red, white, ochre 
and green). Each subunit has one biotin binding site (yellow atoms). (B) Biotin 
molecule bound to monomeric avidin. 
 
As bicinchoninic acid acts as a detection reagent for the formation of copper I 
from copper II in the presence of proteins (Hermanson et al., 1997), BCA 
assay was introduced for the evaluation of the covalently bound avidin on the 
surface. Based on the structure of avidin and its subunits it would be expected 
that the difference in the mass of the immobilized monomeric avidin would be 
four times lower than the mass of tetrameric avidin, but this is not the case. 
Additionally, it was observed that oxidized dextran immobilized on the support 
reacts as well with BCA assay reagents and gives a signal. Furthermore, the 
quantity of covalently bound protein per support is usually in the nanomolar 
range, but the statistical analysis has shown that the mass of the immobilized 
protein on the support from the same batch and even between batches 
produced on different occasions differs for less than 5 %. After completed 
dissociation of tetrameric avidin, the mass of immobilized protein assessed 
with BCA assay was reduced for 25.8 % and for further 16.4 % after 
irreversible biotin binding sites were blocked (Figure 2.4), which correlates 
with the data reported so far (Table 2.1; Hermanson et al., 1997). Based on 
this, complete dissociation of the tetrameric avidin into its subunits was not 
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expected, either achieved. On the support are left most likely immobilized all 
four forms of avidin – monomers, dimers, trimers and tetramers. To avoid 
confusion, the phrase “monomeric avidin” is from this point onwards used for 
the avidin after completed dissociation.  
It is not necessary that only monomers have reduced dissociation constant for 
biotin (Green and Toms, 1973), therefore to assess the actual functional 
capacity of immobilized avidin on the support the determination of the number 
of biotin binding sites was employed.  
As previously mentioned, when the protein is coupled to solid supports, the 
maximum binding potential is typically lowered by the blocking of the active 
site, denaturation and steric hindrance. Coupling of biotin p-nitrophenyl ester 
to the functionalized support with avidin allows for the measurement of the 
number of biotin binding sites. Cleavage of p-nitrophenol results in only biotin 
being bound to the avidin. Theoretically, avidin has a maximum activity of 14.4 
units per milligram of protein (Hermanson et al., 1997). The mass of 
remaining biotin on the support after cleavage was determined to be 0.27 ± 
0.1 µg/cm2, but the distinction in the number of biotin binding sites between 
different conditions was less than 5 %. Due to the nature of the assay, the 
difference represents experimental mistake and not actual variation between 
accessible biotin binding sites. It is believed that the surface area of 0.798 
cm2 of each glass coverslip is too small for definitive conclusions. 
Free biotin remained in the buffer after blocking of non-reversible binding sites 
was assessed. From 0.4 mM of biotin initially present in the blocking solution, 
0.03 mM (less than 10 %) remained bound to the supports. The results 
correlates with reports from Green and Toms (1973) and Sproβ and Sinz 
(2012), who suggest that after activation of immobilized tetrameric avidin with 
NaBH4, 90 % of the subunits remained on the surface allow reversible binding 
of biotin.  
SEM image of non-modified and fully functionalized glass coverslip are shown 
in Figure 2.6. 
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Figure 2.6: SEM analysis of non-modified and fully functionalized glass coverslip. (A) 
Surface of non-modified glass coverslip (600x magnification). (B) Surface of fully 
functionalized glass coverslips (450x magnification). The corner of the support was 
deliberately snapped off, so that the grafted layer (yellow arrow) can be observed. 
The visual appearance of all 3 analysed coverslips from various surface 
functionalization batches was similar. 
 
From the SEM images a good dispersion of grafted layers is observed. The 
coating was so uniform that under 600x magnification it was impossible to 
detect the grafted film, therefore the corner of fully functionalized coverslips 
with biotinylated antibody was deliberately snapped off.  
2.3.2 STATIC BINDING KINETIC TESTS 
2.3.2.1 The impact of free biotin on cells 
Prior to experiment to competitive elution of cells with biotin, the impact of 
various concentrations of D-biotin and DSB-X biotin on the viability of Toledo 
cell line and their identity/functionality was investigated. After 2 h incubation, 
no differences in the cell viability were detectable by Trypan blue exclusion 
assay. In all cases the calculated viability (Equation 2.4) was above 99 %. 
The starting cultures and the cells obtained after the experiment were 
analysed by flow cytometry to determine the expression of CD20 membrane 
antigen and viability was proven with 7-AAD (Table 2.4). 
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Table 2.4: Expression of CD20 cell surface marker and cell viability of a Toledo cell 
line after 2 h exposure to D-biotin and DSB-X biotin. The experiment was performed 
in 3 parallels using glass coverslips from different surface modification batches; the 
presented data is an average. 
 Biotin 
concentration 
(mM) 
CD20 positive 
and viable cells 
(%) 
CD20 positive 
and dead cells 
(%) 
CD20 negative 
cells (%) 
D-biotin 0 98.58 0.00 1.42 
0.5 97.67 0.22 3.11 
1 97.26 0.00 2.74 
1.5 97.13 1.22 1.65 
2 97.16 0.17 2.67 
2.5 97.08 1.84 1.08 
3 96.55 1.38 2.07 
DSB-X 
biotin 
0 98.44 0.01 1.55 
2 97.25 1.64 1.10 
  
Before and after the assay, more than 96 % of cell population was viable and 
positive for CD20. This suggests that neither D-biotin nor DSB-X biotin have 
impact on their immunophenotype and viability. In comparison to the control 
populations, the viability has decreased by time, but not significantly. Based 
on the experimental results, D-biotin solubility in PBS buffer is poor above 3 
mM, additionally there was no significant difference observed between the 
elution efficiency with 2 mM or 3 mM D-biotin solution.  Therefore it has been 
decided to use both biotins for further studies (see Section 2.3.2.4) at the 
previously recommended concentration of 2 mM (Hermanson et al., 1997).  
Besides D-biotin and DSB-X biotin a wide selection of commercially available 
biotins were considered as potential biotinylation reagents and/or compounds 
of the elution buffer to even further reduce the dissociation constant between 
immobilized monomeric avidin and biotin. Due to the narrow window of cell-
friendly conditions, they were all disproved. For example, 2-iminobiotin, 
popular guanidine analogue of D-biotin in protein separations, is not 
appropriate due to its poor solubility at physiological pH. Furthermore, the 
dissociation constant of avidin-biotin complex is pH sensitive and will bind 
even tightly at natural and acidic pH, with the strongest bond at pH between 
9.5 and 11 (Hofmann et al., 1980). Other popular and commercially available 
biotins (e.g. iodoacetyl-LC-biotin) were rejected due to their insolubility in 
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water and therefore they must be at first dissolved in dimethylformamide 
(DMF) or DMSO before diluting in water containing buffers (Elia, 2008). Both, 
DMF and DMSO, are cytotoxic, which leads to loss of cell functionality and 
can produce side effects in patients (Jeffers et al., 1995; Katkov et al., 2006). 
2.3.2.2 Kinetics of binding of biotinylated antibody to 
immobilized avidin 
The adsorption kinetics of the biotinylated BB7.2 antibody on glass coverslips 
functionalized with either monomeric or tetrameric avidin is presented in 
Figure 2.7. Until 60 min of incubation, there are no significant differences in 
the binding of biotinylated antibody to the monomeric and tetrameric avidin. 
After 1 h (nearly 40 % of antibody was bound to the modified support), binding 
of antibody to the monomeric avidin was occurring faster in comparison to the 
tetrameric avidin. This is most likely due to the steric hindrance present in 
case of tetrameric avidin, therefore the antibody bound faster to the easier 
accessible monomer. After 8 h of incubation more than 80 % of antibody was 
bound to the immobilized monomeric and tetrameric avidin. 
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Figure 2.7: Adsorption of biotinylated BB7.2 antibody on glass coverslips, 
functionalized with tetrameric (white circles) and monomeric (black circles) avidin, 
respectively. The experiment was performed in 3 parallels, dots represent an 
average value. Maximum antibody adsorption is 0.5410 mg/m2 for monomeric avidin 
and 0.5009 mg/m2 for immobilized tetrameric avidin. Half of the maximum antibody 
adsorption is achieved within 106.5 min (monomeric avidin) and 136.3 min 
(tetrameric avidin). In both cases is rate of adsorbed antibody determined as 0.004 
mg/m2*min.  
 
2.3.2.3 Binding capacities of functionalized glass surfaces 
The binding capacity of prepared glass coverslips was evaluated by targeting 
immobilized antibody with B lymphocytes (Toledo cell line) and by application 
of antibody-labelled cells to the glass support (Figure 2.8).  
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Figure 2.8: Binding capacity for the binding of B lymphocytes to the glass coverslips 
for the biotinylated antibody bound to the cells (black circles) and bound to the 
coverslips (white circles) 
 
The comparison of specific binding of B lymphocytes to the avidin modified 
glass coverslips revealed slight differences in the biding of antibody labelled 
cells and cells binding to the immobilized biotinylated antibody. Binding up to 
the 2.5*105 cells/mL no significant differences were observed, as well as 
above 2.0*106 cells/mL. The binding efficiency between stated concentrations 
was improved when antibody was conjugated to cells in advance. The reason 
for this might be the differences in the kinetics of cell binding, as well as due 
to the multivalent cell attachment and consequently steric hindrance 
(Magdelin and Moser, 2012) – on the each cell is more than one surface 
antigen and each can bind to the antibody, additionally one antibody can bind 
to two antigens (Ginaldi et al., 1998). As the goal of the cell binding to the 
glass coverslips was to maximize the binding efficiency (with the 2.25*106 
cells/mL nearly 80 % breakthrough was achieved) and simultaneously to use 
enough cells to be able to count them with haemocytometer and check their 
viability with Trypan blue exclusion assay, it was decided to proceed with cell 
concentrations above 2.0*106 cells/mL.  
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2.3.2.4 Kinetics of cell binding to functionalized glass 
surfaces 
For a better understanding of cell attachment on immobilized monomeric and 
tetrameric avidin through biotinylated complementary antibodies, a set of 
static kinetic tests was performed on non-porous glass coverslips. For this 
purpose Bristol-8 cell line and biotinylated BB7.2 antibody were used. As seen 
in Figure 2.9, cell attachment depends on the type of immobilized avidin as 
well as on the location of biotinylated antibody. When cells were pre-labelled 
with complementary biotinylated antibodies and contacted with monomeric 
avidin derived glass coverslips, the kinetics of cell binding were markedly 
improved when cells in comparison to non-labelled cells attaching to antibody 
linked supports. It is believed that this is due to the fact, that when antibodies 
are bound to the surface antigens of cells are orientated in the most optimal 
way, so consequently a tail of antibody, where biotin is bound, is directly 
exposed to the immobilized form of avidin (Magdelin and Moser, 2012). When 
biotinylated antibodies are at first bound to the avidin, they might not be 
orientated in the optimal way. From the Figure 2.9 below can be as well seen 
that there are no significant differences between binding cells on the 
monomeric or tetrameric immobilized avidin through biotinylated antibody. 
The reason for this might be the avidin immobilization procedure. At first is 
tetrameric avidin bound to the support and then cleaved to achieve the 
monomeric form. According to the previous reports this results in the most 
optimal organization and orientation of protein with minimal steric hindrance 
(Massia and Stark, 2001). 
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Figure 2.9: Kinetic static test of cell attachment. Comparison of binding kinetics of 
unlabelled target cells on biotinylated “antibody labelled” glass coverslips (monomeric 
avidin, white circles; native avidin, black circles) and of biotinylated “antibody labelled 
cells” to complementary native (white squares) and monomeric (black squares) 
avidin. There were no differences observed between tetrameric and monomeric 
avidin in terms of maximum binding capacity (3.4*1010 cells/m2 when antibody is 
immobilized on the surface vs. 1.9*1010 cells/m2 when cells are incubated in advance 
in antibody solution) as well as half of all adsorbed cells is adsorbed within 16.5 min 
when antibody is on the surface vs. 67 min when antibody in on cells.  
 
Interestingly, the adsorption capacity of prepared supports is nearly 1.8 times 
greater when antibody is in advance immobilized on the avidin-derived glass 
support. Additionally, when comparing adsorption rates, the difference is even 
greater – adsorption is 20 times greater when antibody is immobilized on the 
surface (1.5*109 cells/m2*min vs. 7.5*107 cells/m2*min). This suggest that 
kinetics of binding is dependent more on the how is affinity ligand immobilized 
on the surface, rather than the form of immobilized avidin. By binding 
antibodies to the cells the impact of site hindrance is greater, therefore it takes 
more time to specifically bind biotinylated antibody to the avidin matrix. This 
might have impact on the chromatography-based separations and it might 
require decrease of loading flow rates in order to optimize binding efficiency.  
At this stage non-specific cell binding to amino- and aldehyde-derived glass 
coverslips was evaluated. After completed incubation and gentle rinsing, no 
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cells remained bound to the support, which confirms previous reports by 
Österberg et al. (1993; 1995), who state that grating oxidized dextran to the 
surface reduces non-specific binding. 
2.3.2.5 Kinetics of cell elution from functionalized glass 
surfaces 
As suggested by Hermanson et al. (1997), cell elution was performed using 2 
mM solution of biotin. At first, Brisol-8 cell line was bound to the fully 
functionalized support through biotinylated BB7.2 antibody, followed by an 
elution up to a 3 hr. Bristol cell line and CCRF-HSB-2 cell line (T lymphocytes) 
were chosen as an alternative to Toledo cell line. The choice of the cell line 
was made based on the expression of the surface markers, i.e. number of 
HLA-A2 antigens on the surface of B lymphocytes is similar to the expression 
of CD20 surface antigens of Toledo cell line. As shown in Figure 2.9, cell 
elution experiments were conducted with two different antibody biotinylation 
reagents, D-biotin and DSB-X biotin.  
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Figure 2.10: Cell detachment studies of Bristol-8 cell line (T-lymphocytes) bound to 
the glass coverslips through biotinylated BB7.2 antibody. In the study the elution 
kinetics between D-biotin (black triangles) and DSB-X biotin (white triangles) as 
antibody biotinylation reagent was compared. Experiment was performed in 3 
parallels with triangles representing the average value. The dissociation rate, kD, was 
determined to be in both cases 5*104 cells/min. Half of cells were eluted within 19 
min (D-biotin) and 22 min (DSB-X biotin). 
  
DSB-X was introduced because its seven-atom spacer could potentially 
improve and hasten competitive elution of cells. However, this couldn’t be 
observed in the static test conducted on non-porous glass coverslips. Also no 
significant differences in comparison to D-biotin as biotinylation reagent was 
detectable, but it is believed that DSB-X biotin would improve cell elution in 
online experiments using various chromatographic supports, due to its 8 atom 
spacer. After 1 hr of incubation in 2 mM D-biotin or DSB-X solution in 1x PBS, 
approximately 80 % of cells were eluted with a viability of at least 98 % 
(Trypan blue exclusion assay). The immunophenotypic analysis of cells after 
elution has relieved the presence of HLA-A2 marker on the surface of eluted 
cells. In both cases more than 98 % of cell population was positive for HLA-A2 
and at the same time in a viable form after 7-AAD staining. In contrast, the 
number of eluted cells bound on the immobilized tetrameric avidin was below 
the limit of detection.  
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The elution experiments were repeated with Toledo cell line and red blood 
cells. In both cases, approximately 80 % of cells were eluted within 30 min of 
elution on static test, as shown in Figure 2.11.  
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Figure 2.11: Photographs of bound B lymphocytes (Toledo cell line) and red blood 
cells on glass coverslips during elution under 4x magnification (Toledo cell line, A-H) 
and 10x magnification (red blood cells; i-viii). Photos of cells after completed 
incubation (A; i), after rinsing with 1x PBS (B; ii), after 1 min (C; iii), 5 min (D; iv), 10 
min (E; v), 15 min (F; vi), 20 min (G; vii) and 30 min of elution (H; viii). 
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2.3.3 FLOW-BASED ASSAY 
Following the successful elution of bound cells, the technology was tested 
under flow conditions in small scale using glass hollow capillary tubes. The 
monomeric avidin coated glass tubes were functionalized with the biotinylated 
antibody as described in Section 2.2.2.3. This method was adopted only for 
the initial qualitative analysis of functionalized surfaces; as the surface area of 
the single tube was too small to reliably assess modification and 
functionalization steps of material preparation. Additionally the number of cells 
used for the single experiment was below the limit of detection for Trypan blue 
exclusion assay and consequently cell count with haemocytometer. 
Following the binding of B lymphocytes (Toledo cell line) to the support 
through the biotinylated anti-CD20 antibody, cell binding and elution under 
flow conditions were observed. Both, cell attachment and elution with 2 mM 
solution of D-biotin in PBS buffer were performed at a linear flow rate of 30 
cm/h. In  Figure 2.12 photographs of the inside of glass hollow capillary tube 
under 4x magnification taken during binding, rinsing of not bound and even 
weakly bound cells and elution are presented. After 30 min of elution 
significantly fewer cells remain bound in comparison to the beginning of 
elution.  
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Figure 2.12: Video frame sequences of B lymphocytes (Toledo cell line) flowing 
through mono-avidin coated glass hollow capillary tubes functionalised with the 
biotinylated anti-CD20 antibody. During cell attachment (1st row) bound cells (frame 
A; marked with arrow) and cells passing through the hollow capillary tube (frames A-
C, yellow circles) can be observed. During washing (2nd row; frames D-F), unbound 
and weakly-bound cells (pink circles) are passing through. Elution was performed for 
30 minutes (3rd and 4th row). After 5 min cells are already eluted (frames G-I; blue 
circles), after 30 min significantly less cells remains bound and eluted cells are still 
passing through (frames J-L; turquoise circles). 
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Although flow-based assay was used only for the visual assessment of the 
developed affinity based system for the separation of human cells under flow 
conditions, it did confirm adequacy of the technology for the further application 
in the chromatography-based positive selection. As the elution took 
approximately 30 minutes, it was clear there is a need for the optimization of 
separation conditions, e.g. number of applied cells, flow rates and number of 
immobilized ligands, in order to be able to separate cells relatively fast, 
efficiently and in a viable form.  
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2.4 CONCLUDING REMARKS 
In order to develop a new gentle and efficient affinity based separation 
technique for the purification and fractionalization of human cells a new 
system using, cell-friendly adsorbent materials was developed. Dextran has 
proven to be an appropriate choice for the base grafted layer, as it is not 
cytotoxic and the non-specific cell binding is minimal. In combination with 
monomerized avidin and biotinylated antibodies it allows an efficient binding 
of cells with a high affinity. At the same time it is possible to elute cells in a 
gentle manner with competitive binding using various biotins. It has been 
shown that by using affinity based separation technique; human cells can be 
separated under physiological conditions. This was demonstrated with B and 
T cells from human continuous cell lines. 
Following the successful characterization and static studies on glass 
coverslips, the method was subsequently transferred to hollow capillary tubes 
for the qualitative verification. The study has demonstrated the considerable 
potential for application of developed technology to the affinity 
chromatography. Therefore, future work will concentrate on the transfer of the 
technology to the existing chromatography supports, i.e. packed bed columns.   
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3. PREPARATION, CHARACTERIZATION AND 
APPLICATION OF NON-POROUS GLASS BEADS 
FOR THE POSITIVE SELECTION OF HUMAN 
RED BLOOD CELLS 
Abstract 
Following the successful development and application of affinity selection 
technology on glass coverslips and hollow capillary tubes, the development 
and evaluation of a human cell affinity selection system based on high grade 
smooth monodisperse 98 μm non-porous glass beads is presented in this 
chapter. The beads were converted into materials for positive, and importantly 
reversible, affinity selection of human therapeutic cells, in a rigorously 
characterized multi-step ‘layer-by-layer’ deposition procedure culminating in 
dextran-coated supports bearing monomeric avidin, and subsequently 
employed in packed bed chromatography experiments with human red blood 
cells isolated from cord blood. Initial chromatography experiments offer 
promising results for further development.  
3.1 INTRODUCTION 
Glass beads packed into column were the first choice when the formidable 
task of the isolation of individual morphologic cell types appeared in early 
1970s. As the separation was based on the differences in the adherence on 
the glass it lacked selectivity. Various types of beads and experimental 
designs were tested, with a goal of achieving as purer cell type of interest as 
possible (Rabinowitz, 1964; Rabinowitz 1965).  
Affinity chromatography has been investigated for the positive and negative 
separation of mammalian cells from the late 1970s with an emphasis on the 
selective binding of cells on various chromatographic matrices (Plotz and 
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Talal, 1967; Wigzell and Andersson, 1969; Truffa-Bachi and Wofsy, 1970; 
Venter et al., 1976; Yui et al., 1985). Some attempts for the cell recovery of 
adherent cells were made, but researchers have experienced difficulties. 
Biotinylation and its affinity for immobilized avidin was at first exploited for the 
selective adsorption of thymocytes by Jasiewicz and his coworkers in 1976, 
but no cell retrieval was obtained. The first successful recovery of murine 
cells, in a viable form, using avidin-biotin technology was made by combining 
the affinity approach with rosetting. Unfortunately, this led target population 
coated with sheep erythrocytes used for rosetting and could potentially affect 
the function of cells (Wormmeester et al., 1984).  
First reports of positive selection of viable cell populations using avidin-biotin 
immunoadsorption are date back to 1986, when Berenson and his co-workers 
successfully enriched Leu-4 positive cells from the human bone marrow 
mononuclear cells with avidin-Sepharose 6MB and Biogel P-30 column. The 
selectivity of the method exploited high affinity constant between tetrameric 
avidin and D-biotin and elution was achieved by mechanical agitation with 
plastic Pasteur pipette. Although yields and purities where promising, the 
method had negative impact on cell viability and low repeatability, as well as 
limited scale-up (Berenson et al., 1986a; Berenson et al., 1986b).  
Although the discovery of monomeric avidin and its much lowered dissociation 
constant for avidin was first published in 1973 by Green and Toms, to date no 
reports of its use for the separation of human cells have been published. 
In this section various approaches are undertaken for the modification and 
functionalization of glass beads, its characterization and initial affinity 
chromatography method development for the separation of human therapeutic 
cells using red blood cells are explained.  
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3.2 MATERIALS AND METHODS 
3.2.1 MATERIALS 
Medical grade nonporous borosilicate glass spheres GL-0179B5 (90-106 µm 
in diameter with 2.2 g/cm3 density and 1.472 refractive index) were obtained 
from MO-SCI Specialty Products, L.L.C (Rolla, Missouri, USA).  
Liquinox® detergent, (3-aminopropyl)triethoxysilane (3-APTES; ≥98 % purity), 
biotin p-nitrophenyl ester (98 % purity), dextran from Leuconostoc spp. (Mr ≈ 
70000) and sodium borohydride (NaBH4, 98 % purity) were obtained from 
Sigma-Aldrich Company Ltd. (Gillingham, UK). PD-10 desalting column were 
purchased from GE Healthcare Life Sciences (Little Chalfont, UK). 
Quant*Tag™ Biotin kit was supplied by Vector Laboratories Ltd. 
(Peterborough, UK). Desiccated avidin, egg white (Molecular Probes®, 
Invitrogen; Mr ≈ 66000; biotin binding of 13.6 units/mg of protein), D(+)-biotin 
(Acros Organics; 98% purity), Ficoll-Paque™ Plus (GE Healthcare Life 
Sciences), BCA Protein assay kit (Thermo Scientific Pierce) and Alexa Fluor® 
488 tetrafluorophenyl (TFP) ester fluorescent dye (10 mg/mL solution in 
DMSO; Invitrogen) were purchased through Fischer Scientific UK Ltd. 
(Loughborough, UK). All other materials and reagents were supplied by 
Fischer Scientific UK Ltd. (Loughborough, UK).  
Acetone, toluene and ethanol were HPLC grade (Fisher Chemical brand). 
Guanidine hydrochloride (Gdm HCl) was purchased as 8 M water solution.  
Sodium azide (NaN3) and glycerol were supplied as 99 % pure and suitable 
for cell culture. Ammonium bicarbonate (NH4HCO3), 
ethylenediaminetetraacetic acid (EDTA; disodium salt dehydrate suitable for 
electrophoresis), glycine (C2H5NO2; Gly), hydrogen chloride (HCl), potassium 
chloride (KCl), sodium acetate (C2H3NaO2), sodium chloride (NaCl) sodium 
hydrogen carbonate (NaHCO3), sodium hydroxide (NaOH), sodium 
metaperiodate (NaIO4), sodium phosphate (Na3PO4) and 
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tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), salts used for 
preparation of buffer solutions, were analytical grade (99+ % purity) and 
suitable for use in cell culture. Phosphate buffered saline (PBS buffer) was 
supplied in a form of tablets. Each tablet prepares 100 mL of PBS buffer. 
Dimethyl sulfoxide (DMSO), trichloroacetic acid (TCA) and dithiothreitol (DTT) 
were 99 % pure and molecular biology grade. 
All solutions were prepared using water purified by a Millipore Elix Gulfstream 
Clinical 100 (Merck Millipore UK Ltd, Watford, UK) water purification system 
and analytical grade reagents. Buffer solutions were prepared by dissolving a 
known mass of buffering species into ca. 80 % of the desired final volume of 
deionized water, titrating with 1 M solution of HCl or NaOH and adding water 
to yield the final solution volume. 
Sterilization of solutions and suitable materials was performed either by 
autoclaving at 121 °C for 30 min using ASB 300T autoclave (Astell Scientific, 
Sidcup, UK) or by filtering through (Merck Millipore UK Ltd, Watford, UK). 
Anti-glycophorin A (anti Gly-A) monoclonal antibody in cell culture supernatant 
was a generous gift from Dr Oliver Goodyear (School of Immunity and 
Infection, College of Medicine, University of Birmingham, UK).  
Red blood cells were isolated by density gradient centrifugation from umbilical 
cord blood, which was obtained from anonymous donors through NHS Blood 
and Transplant (NHSBT).  
Tricorn 5/50 column and complementary Tricorn 5 coarse filter kit were 
supplied by GE Healthcare (Uppsala, Sweden). 
Disposable 35 mm plastic petri dishes with 10 mm glass bottom (MatTek, 
Ashland, Ohio, USA) for the confocal microscopy were a generous gift from 
Dr Nuno Reis (Chemical Engineering Department, School of Aeronautical, 
Automotive, Chemical and Materials Engineering, Loughborough University, 
UK). 
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3.2.2 METHODS 
3.2.2.1 Surface modification 
Surface modification of glass beads was performed following the protocol 
already described in Section 2.2.1.1, with a slight modification. Amination of 
surface was obtained according to Thermo Scientific Tech tip #5 (2008). 
Cleaned beads were immersed in 2 % solution of 3-APTES in acetone (v/v) 
for 1 min, followed by rinsing with acetone. Beads were dried overnight at 
room temperature in a laminar flow hood.  
3.2.2.2 Surface functionalization 
When applicable, modified glass beads were functionalized with biotinylated 
anti-glycophorin a monoclonal antibody as described in Section 2.2.2.4. The 
antibody was purified in advance following the method from the Section 
2.2.2.2 and biotinylated with D-biotin as described in Section 2.2.2.3. 
3.2.2.3 Isolation of red blood cells from the umbilical cord 
blood 
Red blood cells were isolated from umbilical cord blood by density gradient 
centrifugation as previously described in the Section 2.2.2.6. 
3.2.2.4 Labelling beads with biotinylated anti-glycopherin A 
antibody 
Functionalized glass beads were incubated for 12 h in the solution of 
biotinylated antibodies. To the 5 mL of bead slurry (1:1 ratio beads:water (v/v); 
in the average 1 mL of bead slurry contained 0.5845 g of dry beads) antibody 
was added up to the final antibody concentration of 50 µg/mL and incubated 
at 4 °C protected from the light. After incubation, the supernatant was 
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collected and beads gently rinsed once with 5 mL of PBS buffer. Absorbance 
of all supernatants at 280 nm was measured in order to calculate mass of 
bound antibody on the beads with equation 2.2 from the Section 2.2.2.4. 
3.2.2.5 Analytical methods 
The size distribution of the beads was measured by a particle size analyser, 
Mastersizer 2000 (Malvern Instruments, Malvern, UK), in the range 0.05 up to 
880 µm. The measurement was performed with beads in the air and with the 
reflection index of beads (1.472) taken into consideration. The measurement 
zone (a distance from the face of the range lens along the analyser beam) 
was set to 2.40 mm. Analysis of so obtained data was polydisperse. 
Surface area of non-modified and dry glass beads was measured by physical 
adsorption of krypton (Kr) at -169 °C using ASAP2020 Surface Area and 
Polarity Analyser (Micrometrics, Norcross, Georgia, USA). Data was 
evaluated according to the Brunauer, Emmet and Teller (BET) theory. For the 
analysis 11.0 ± 0.5 g beads were dried and gradually degassed under 
vacuum for 720 min. Before and after analysis sample tube was filled with 
liquid nitrogen (N2). Kr was dosed to sample gradually at 5 mm Hg, with a 
relative pressure tolerance of 5 %. At each step, the sample was equilibrated 
for 10 s. The amount of adsorbed gas is the difference of admitted gas and 
the gas filling the dead volume (free space in sample tube) and the adsorption 
isotherm is a plot of the adsorbed gas versus the relative pressure (Lowell et 
al., 2006). 
For X-ray photoelectron spectrometry (XPS analysis), dried beads were 
immobilized onto sample holder with double tape. The analysis was 
performed as described in the Section 2.2.2.10. 
Naked (non-modified) and fully functionalized glass beads were visualized 
with scanning electron microscopy (SEM), following the method from the 
Section 2.2.2.10. 
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Surface modification of beads was further assed with atomic force microscope 
Explorer (Vecco, Plainview, New York, USA). 10 µm x 10 µm sections of 
immobilized dried beads were analysed at frequency of 330 kHz and surface 
tension in the range 20 and 80 N/m. Analyses were performed in non-contact 
mode. 
Qualitative evaluation of functionalization with avidin and biotinlyated antibody 
was carried out with inverted confocal microscope Eclipse TE300 (Nikon, 
Tokyo, Japan) in the combination with LaserSharp 2000 software (Zeiss, 
BioRad, Hemel Hempstead, UK). To the 500 µL of beads, Alexa Fluor® 488 
tetrafluorophenyl (TFP) ester fluorescent dye was added to a final 
concentration of 0.2 ng/mL. Beads were incubated for 1 h at room 
temperature on 3-D rocking platform STR 9 (Stuart Scientific, Stone, UK) with 
shaking at 70 revs/min. Excess dye was then removed by triple rinsing of 
beads with 1 mL of PBS. Before 20 µL of beads were transferred into 35 mm 
disposable plastic petri dishes with 10 mm glass and topped with 1 mL of 
glycerol in order to enhance imaging. So prepared samples were immediately 
scanned using an objective lens with a magnification of 20 times and emission 
filter HQ500. The pinhole aperture varied. Fluorescence was excited by 
argon/krypton laser at 488 nm wavelength. Cross sections of beads were 
automatically scanned at varying depths using a 2 µm step. Kalman averaging 
of 3 steps was introduced to further reduce noise and consequently improve 
images. All images were in the size 512 x 512 pixels and the pixel size was 
0.41 µm. For the analysis, images were translated into fluorescence intensity 
profiles using ImageJ software (National Institutes of Health, Bethesda, 
Maryland, USA) as previously described by Ljunglöf and Hjorth (1996), 
Ljunglöf and Thömmes (1998) and Ljunglöf et al. (1999). The selected area 
along the particle in pixels was then plotted against the fluorescence in 
arbitrary units.  
The Pierce™ Bicinchoninic acid (BCA) Protein assay, the number of biotin 
binding sites and the content of free soluble D-biotin in the fractions collected 
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during the monomeric avidin immobilization were performed as described in 
Section 2.2.2.10. 
Mass of immobilized avidin on the beads was further indirectly evaluated by 
TCA precipitation of avidin from the slurries collected during monomeric avidin 
immobilization. Protein precipitation solution (20 % TCA, 0.2 % DTT in iced-
cold acetone) and wash solution (0.2 % DTT in iced-cold acetone) were 
prepared in advance and stored at – 20 °C until further use. The method was 
performed on ice and in a dark. To 3 parts of the slurry, 1 part of precipitation 
solution was added. Samples were incubated overnight in the fridge at 4 °C. 
The following day samples were centrifugated at 3400 gav and pellet was 
resuspended in 1 mL of ice-cold wash solution. Samples were centrifugated 
again and pellets resuspended in 1 mL of ice-cold acetone. Acetone above 
precipitated proteins was then carefully decanted and samples were dried 
overnight in a bell jar. The following day were tubes with precipitated proteins 
collected and immediately weighted.  
3.2.2.6 Affinity chromatography 
Beads were packed under gravity into Tricorn™ 5/50 Empty High 
Performance column (internal diameter: 5.0 mm; adjustable bed height: 35 - 
59 mm), equipped with coarse filters (porosity: ≥ 25 µm) and one adaptor unit 
(GE Healthcare, Uppsala, Sweden). The column was then connected to an 
Äkta Explorer 100 Air or Äkta Prime Plus lab-scale chromatography system 
(GE Healthcare, Uppsala, Sweden). All the experiments listed in this section 
were performed at room temperature. 
Column efficiency testing was done with pulse test and performed on the non-
modified beads packed into column (bed height: 55 mm). After the column 
was equilibrated with water, 0.5 mL of 1 % acetone in water (v/v) was injected 
onto column at flow rate 3000 cm/h. For the detection ultraviolet (UV) monitor 
was used at 280 nm wavelength. From the chromatogram were calculated the 
reduced plate height and the asymmetry of the peak.  
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Reduced plate height (h) was calculated from height equivalent to the 
theoretical plate (HETP) normalized for the diameter of particles (dp) packed 
in the column and it was calculated from the equation 3.1 below:  
ℎ = 𝐻𝐻𝐻𝐻
𝑑𝑝
                  (3.1) 
Height equivalent to the theoretical plate (HETP) was calculated from the 
equation 3.2 below: 
𝐻𝐻𝐻𝐻 = 𝐿
𝑁
                (3.2) 
where: L is the total length of the column and N is number of theoretical 
plates. To calculate the number of theoretical plates for a packed column, 
equation 3.3 has been introduced: 
𝑁 = 16 � 𝑠𝑎
𝑊𝑣
�
2
               (3.3) 
where: N is number of theoretical plates, tr is the retention time of the probe 
molecule and Wb is the width of the peak at the baseline.  
Asymmetry (As) of the peak was defined as (equation 3.4 below): 
𝐴𝑠 = 𝐴𝑡                (3.4) 
where: a is the distance from the leading edge to the midpoint and b is the 
distance from the midpoint to the tailing edge of the peak. The asymmetry 
factor was calculated from the peak width at 10 % of the peak height and 
describes the deviation of the peak from an ideal Gaussian peak shape 
(Hagel et al., 2008).   
Pressure drop on the column packed with non-modified glass beads was 
measured using differential manometer (Relative and differential pressure 
transmitter type 692 (pressure range from 0.1 to 25 bar); Huba Control, 
Würenlos, Switzerland) at various linear flow rates between 30 and 3000 cm/h 
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using water as a mobile phase. The column was packed under gravity with 
beads up to the height of 36 or 58 mm and then connected to the 
chromatographic system together with manometer using standard capillary 
tubing and tee bore PEEK fingertight union (0.020 inch thread ¼-28; Supelco, 
Bellefonte, Pennsylvania, USA). 
Experiments with red blood cells were performed in the following way. Mobile 
phase A (running buffer; PBS, pH 7.4) and mobile phase B (elution buffer; 2 
mM D-biotin in PBS, pH 7.4) were prepared in advance by filtering through a 
0.22 µm filter unit and degassing for 10 min in ultrasonic bath (Fisherbrand 
S15, Fisher Scientific Ltd., Loughborough, UK). The column was then 
equilibrated with mobile phase A until UV signal at 215 and 280 nm was 
stable for 1 min (acceptable UV fluctuation: 20 mAu). If UV signal was not 
stable after 10 min of equilibration, the column was removed from the system, 
beads decanted and column was then re-packed with fresh beads. After 
completed equilibration, 0.5 mL cell suspension was injected through injection 
valve onto the column from the top or the bottom or vice versa at linear flow 
rate of 30 cm/h (0.1 mL/min). To maximize recovery, the sample loop was 
overfilled, i.e. into 0.5 mL loop 1 mL of cell suspension was injected. Injection 
valve was then emptied with 2 mL of mobile phase A at linear velocity of 30 
cm/h. Washing (mobile phase A; 300 cm/h) and elution (mobile phase B; 30 
cm/h) were conducted under same and reversed flow conditions. During 
elution flow might be stopped for in between 30 and 120 minutes. Cells in all 
fractions were counted using a Neubauer Improved Bright-Line 
haemocytometer (Sigma Aldrich, Gillingham, UK) as previously described in 
Section 2.2.2.10. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 PREPARATION AND CHARACTERIZATION OF GLASS 
BEADS 
According to the manufacturer, the glass beads supplied were sieved in order 
to achieve size distribution between 90 and 106 µm in diameter (GL-0179 
Data Sheet, Appendix D). The size distribution of beads was additionally 
evaluated and results support manufacturer’s data, as the beads diameter 
was in the range 79.12 and 118.59 µm, with an average diameter of 98.43 µm 
(Appendix E).  
Used glass beads were relatively large in diameter and non-porous, therefore, 
the expected surface area was at the lower end of the detection limit of the 
analyser, which is 0.01 m2/g (Micromeritics, 2004-2010). The specific surface 
area was measured four times; each time with the different sample from the 
same container. In order to aid the analysis the samples were degassed and 
heated for 24 h in order to remove all impurities, which might have impact on 
the surface area. The average measured surface area was 0.02963 ± 
0.00158 m2/g (5.33 % RSD). 
Each step of surface modification (animation and deposition of aldehyde 
groups) of beads was evaluated by XPS. Table 3.1 below summarizes the 
atomic percentages (%) of detected elements in the overall scan of the 
supports.  
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Table 3.1: Elemental evaluation of surface modification of beads by XPS 
Element  
(atomic %) 
XPS analysis of 
glass beads 
Deposition of 3-
APTES (amination) 
Deposition of 
oxidized dextran 
(aldehyde groups) 
C  7.49 16.16 ▲ 22.13 ▲ 
N  N/D 4.15 ▲ 2.13 ▼ 
Na  52.49 48.00 ▼ 47.98 ▬ 
O 10.01 0.95 ▼ 1.54 ▲ 
Si  22.95 30.74 ▲ 25.78 ▼ 
B  7.06 N/D ▼ N/D ▬ 
I  N/D N/D ▬ 0.44 ▲ 
N/D: not detected; ▼decrease; ▲increase; ▬ no change 
 
XPS results were evaluated according to NIST X-ray Photoelectron 
Spectroscopy Database (National Institute of Standards and Technology, 
2012). Amination of non-modified beads resulted in increase of C, N and O 
and decrease of Na and O. This was expected due to the use of 3-APTES 
(molecular formula: C9H23NO3Si) as an amination reagent. Detailed scan of C 
and Si on the surface of unmodified and aminated glass beads revealed 
differences in the spectral line of both elements. In the case of non-modifed 
glass beads, detected spectral line indicates presence of only silica (glass), 
while in the case of aminated glass beads 67.3 % of measured Si represents 
spectral line distinctive for silanes, such as 3-APTES. The remaining Si is 
silica. For all other detected elements the differences between spectral lines 
were not significant. 
The deposition of oxidized dextran to the aminated beads achieved a further 
increase of C, while the N and Si decreased, simultaneously an increase in O 
was observed. This was all expected due to the structure of deposited dextran 
(Figure 2.1). By oxidation, the ring of dextran, which does not have any N or 
Si present in its structure, is opened, and therefore more C and O is exposed. 
Detected I was most likely due to the preparation of aldehyde glass beads, i.e. 
NaIO4 was used during the oxidation of dextran. This is additionally confirmed 
by the atomic percentage of the detected Na, which remained the same, 
although it was expected to drop slightly. The detailed scan of the C present 
on the sample revealed significant changes in the ratio between spectral lines 
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of C. While the spectral lines characteristic for C in the ring and C-O-C or C-
OH remained basically the same, the deposition of aldehyde groups resulted 
in increased spectral line for O-C-O formula by 18.2 %. O-C-O is present in 
the structural formula of immobilized oxidized dextran, which was used for the 
deposition of aldehyde groups on the surface (Figure 2.1). 
A high degree of reproducibility was achieved during the deposition of 
aldehyde groups and immobilization of monomeric avidin, which was 
confirmed by BCA assay, determination of the number of biotin binding sites 
and TCA precipitation of avidin from the experimental slurries. BCA assay 
revealed that after completed immobilization of tetrameric avidin, 4.2 mg 
remained bound per m2 (0.1244 mg/g of dried beads). Its dissociation resulted 
in the reduction of immobilized protein to 1.1 mg of avidin with reversible 
biotin binding sites per 1 m2 (0.0326 mg/g of dried beads). To confirm this, 
TCA assay was introduced. Protein contents in all the slurries collected during 
the immobilization of monomeric avidin were precipitated with a goal to close 
mass balances. Results revealed that initially 5.0 mg of tetrameric avidin was 
immobilized and after completed preparation of monomeric beads, 1.017 mg 
of avidin remained bound per m2 (0.0301 mg/g of dried support). Several 
methods were considered in order to determinate the state of remaining 
bound avidin, but no method was sensitive enough to detect differences 
between individual forms of bound avidin on the glass beads. Based on 
previous reports (Green and Toms, 1973; Sproβ and Sinz, 2012) it was 
concluded that, it was most likely that after the preparation of the glass beads, 
bound avidin is monomeric, dimeric, trimeric and tetrameric, but it has 
reduced dissociation constant for biotin.  
According to the manufacturer (Certificate of analysis; Appendix E), the 
tetrameric avidin from egg white had a specific activity of 13.6 units/mg (1 unit 
is equal to 1 µg of D-biotin bound per mg of avidin), which means that in 
theory, to the 1 g of immobilized tetrameric avidin on the beads, between 13.8 
(according to results obtained by TCA assay) and 15.0 µg of D-biotin (BCA 
assay results) could be bound, if ignoring steric hindrance. In the case that all 
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the tetrameric avidin was dissociated to 4 subunits of which 1 remained bound 
on the beads and 3 were successfully removed from the surface, between 3.5 
(TCA assay) and 3.75 µg of D-biotin (BCA assay) could be bound. This was 
evaluated experimentally by the determination of number of biotin binding 
sites. Before the dissociation of immobilized tetrameric avidin to its subunits, 
3.6 µg of D-biotin could be bound. After the immobilization and blocking 
procedure were completed, the D-biotin was further reduced to 3.2 µg per 1 g 
of dried beads (10.8 µg of D-biotin per m2 of the support). Reduction of the 
capacity of the support correlates with previous publications (Green and 
Toms, 1973; Sproβ and Sinz, 2012), which state that approximately 90 % of 
remaining avidin on the support has a dissociation constant for biotin of 10-7 
M, which allows gentle elution by displacement of bound biotin with free D-
biotin in elution buffer, i.e. the capacity for the D-biotin after immobilization 
and blocking of monomeric avidin is reduced by only 10 % (11.1 % based on 
research work described in this Chapter). 
SEM was used to visualize unmodified and fully modified and functionalized 
beads with biotinlyted antibody. Figure 3.1 shows that the selected beads are 
relatively uniform in the size and shape.  
 
Figure 3.1: Unmodified glass beads (300x magnification) 
 
After functionalization beads were kept as sterile bead-buffer slurry in dark at 
4 °C. Because SEM is performed in the vacuum, beads were dried overnight 
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at room temperature before the analysis (protected from the light), which 
resulted in the cracking of the grafted layers (Figure 3.2 below).  
 
Figure 3.2: Modified and functionalized bead under SEM microscope. (A) Surface of 
bead (550x magnification). Cracklings in the grafted layers can be observed. (B) 
Under 650x magnification is clearly visible deformation of the modified bead, most 
likely due to the vacuum in which analysis was performed. 
 
To confirm deformation of modified beads is due to the experimental SEM set-
up, immobilized proteins and peptides on the beads were fluorescently 
labelled with Alexa Flour® dye (Molecular Probes by Life Technologies, 2013), 
and visualized with confocal microscopy in wet conditions (Figure 3.3). 
 
Figure 3.3: Functionalized glass bead analysed by confocal microscopy. For the 
qualitative evaluation of functionalization with avidin and biotinlyated antibody 
confocal microscopy was used. Immobilized proteins were in advance labelled with 
Alexa Fluor® 488 tetrafluorophenyl (TFP) ester, followed by scan of cross-section of 
the bead (300 x magnification).  
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On the outside of each modified bead a green fluorescent ring is formed, 
which represents labelled immobilized proteins, i.e. monomeric avidin and 
biotinlyted antibody. The thickness of the fluorescently labelled grafted area 
was then determined from the fluorescent intensity profile below (Figure 3.4). 
 
Figure 3.4: Fluorescence intensity profile of analysed glass bead. (A) Cross-section 
of the fluorescently labelled bead. The area used for the evaluation is shown by 
rectangular box. (B) Fluorescence intensity profile is plotted as distance along the 
particle in pixels versus fluorescent intensity (arbitrary units). Thickness of the 
adsorption layer is indicated by arrow. 
 
In the presented example, the fluorescently labelled grafted layer on the left 
side of the bead is equivalent to 4.633 pixels (1.900 µm), while the thickness 
of the adsorbed layer on the right hand side is 4.637 pixels (1.901µm). This 
additionally confirms the uniformity of the grafting across the bead.  
The surface of beads was furthermore scanned after each step of modification 
and functionalization by AFM. Results are presented in Figure 3.5.  
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Figure 3.5: 3D AFM images of 10 µm x 10 µm sections of glass bead surfaces (A) 
The surface of unmodified non-porous glass bead is smooth. (B) After deposition of 
3-APTES the surface is even more uniform, which suggests successful modification. 
(C) Deposited oxidized dextran forms thin and uniform biocompatible film. (D) 
Binding of native, tetrameric, egg white avidin results in the change of the 
morphology and its depth. (E) Cleaveage of tetrameric avidin to its monomeric form 
results in the reduction of the depth for more than 40%. 
The AFM probe was oscillating across the surface of immobilized bead and 
imaging the topology of the surface. Unmodified beads are smooth and 
uniform. 3-APTES formed even smother monolayer on the surface. The 
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deposition of oxidized dextran, which forms thin, uniform and biocompatible 
films on the surface (Kühner and Sackmann, 1996; Massia et al., 2000), 
resulting in uniform grafting, with the difference in the depth across scanned 
section of only 3.19 nm. Cleavage of immobilized tetrameric avidin into its 
form with reversible biotin binding sites caused significant change in the 
topology of the analysed sample, i.e. the height of the peaks was reduced 
from 140.32 to 82.41 nm.  
3.3.2 APPLICATION OF PREPARED GASS BEADS IN AFFINITY 
CHROMATOGRAPHY 
Prepared beads were packed under gravity into Tricorn column and the 
quality of column packing was evaluated prior the experiments with cells. 
Calculated reduced plate height of 0.81 suggests efficient column packing and 
no interaction between glass beads and acetone, as the value is below 3 
(Rathore et al., 2003; GE Healthcare Application note). The asymmetry factor 
of the peak was between 0.8 and 1.8 (1.5 precisely), which indicates beads 
were not packed too tight or too loose, this confirms no air pockets were 
present and sample injection technique was appropriate (Rathore et al., 2003; 
GE Healthcare Application note; Hagel et al., 2008).  
The next step was to messure the pressure drop on the column in order to 
assess if selected chromatographic support is suitable for the application. 
Mehta and Hawley (1969) recommend that the ratio between the column and 
particle diameter is 50:1 or less to be able to accurately correlate pressure 
drop vs. flow rate through packed beds. This parameter was fulfilled. Besides 
velocity and the ratio between the particle and column diameter, pressure 
drop on the column also depends on the viscosity and density of mobile 
phase, porosity of the bed, orientation of the packing and the size, shape and 
surface of the particles (Ribero et al., 2010). Due to the nature of human cells, 
the experimental design was limited and all experiments were designed with a 
goal to retain the viability and function of target cells intact. For example, 
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during the selection of chromatographic support, porous glass beads were 
rejected – not only because the inaccessibility of the surface area inside pores 
to the cells due to their size, but also to the significantly increased pressure 
drops across the column, which was expected (Chhabra et al., 2001). In the 
study made by Gu and his co-workers back in the 2000, the sensitivity of 
white blood cells from donors when exposed to to the shear stress, pressure 
drop and various other parameters was measured using hollow capillary tubes 
and flat membranes. Although the characteristics of the selected devices for 
their study cannot be directly compared to the conditions in the column 
packed with nonporous glass beads, study gave a good indication of the 
sensitivity of cells and at the same time confirmed adequacy of selected 
chromatographic format. Their study suggests that even cells from unhealthy 
patients demonstrated  pressure drops between 99 ± 4 mmHg (0.13 ± 0.01 
bar) and 111 ± 9 mmHg (0.15 ± 0.01 bar). As shown in Figure 3.6, cells 
applied to the column at a flow rate of 305 cm/h (1 mL/min) were not exposed 
to the pressure drop above the suggested values (below 0.15 bar) and even 
when using flow rate of 3050 cm/h (10 mL/min), pressure drop on the column 
did not exceed 1.2 bar.  
Additionally, several reports have been published in which researchers were 
exposing mammalian cells to the hydrostatic pressure of 200 atm (283.71 bar) 
and higher, these reports show that the cells did not show any long term 
defects as long as pressure did not exceed their threshold, which differs 
between cell types. Cells can adapt to the high pressure for short period of 
time (up to 1 h) by ‘‘rounding up’’ and when pressure is released, cells spread 
out again (Bourns et al., 1988; Crenshaw et al., 1996). For example, human 
cell line HeLa is resistant to short exposure to the hydrostatic pressure up to 
200 atm (202.65 bar; Crenshaw et al., 1996).  
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Figure 3.6: Pressure drop on the packed column at various flow rates. Tricorn 5/50 
column was packed with non-modified beads up to the minimum bed height of 36 
mm (black circles) and maximum bed height of 58 mm (white circles). Pressure drop 
at various linear flow rates was measured with differential manometer and with 
deionized water as mobile phase. 
 
Following the successful characterization of modified beads and 
chromatographic support, initial chromatographic experiments were 
performed with red blood cells. Although they cannot be representative of 
other suspension cells due to their biconcave disk shape, size and structure, 
they allow visual observation of the separation process because of their 
colour and therefore do not require any labelling which might interfere with the 
experimental set-up. Not only it was possible to observe the state of the 
column during loading, wash (removal of non-specifically and weakly bound 
cells), elution and after the experiment, cells could also be observed in 
collected fractions during separation (Figure 3.7 below). More red blood cells 
were present on the column or in the fraction, red tones were observed.  
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Figure 3.7: Photographs of column and collected fractions during affinity based 
separation of red blood cells. Column at the beginning of the loading of cells (A), after 
red blood cells were loaded (B), during washing step in order to remove all non-
specifically bound cells (C) and after completed elution (D). Red blood cells can be 
observed as well in the collected fractions (E). An excess of cells applied onto the 
column is present in the fraction collected during loading (E-1), plenty of non-
specifically bound cells is rinsed from the support during wash step (E-2, E-3, E-4). 
Eluted cells are dying collected fractions during elution in red tones (E-5, E-6, E-7, E-
8). 
 
Besides “proof of principle” experiments, red blood cells were also used for 
the initial determination of the ideal separation conditions, i.e. flow rates, 
contact and incubation times, and the length of the load, wash and elution 
step. Red blood cells were chosen due to their clinical relevance in a 
treatment of anaemia patients as well as their colour, which allowed on-line 
Chapter 3: Preparation, characterization and application of non-porous glass beads 
for the positive selection of human red blood cells 
 
124 
 
observation of the separation process without the need for an additional 
labelling, which might interfere with the affinity based separation. They are 
unique in their size and shape (Bain, 1996), therefore cannot be 
representative for the other human therapeutic cells, e.g. white blood cells 
and stem cells. Initial design of the chromatography separation was based on 
the results obtained on glass coverslips, as described in Chapter 2.  
Two approaches for the loading and elution were evaluated, namely loading 
from the top of the column or from the bottom up to the top and then in the 
next step elution with the same or reversed flow path. In terms of loading, 
there were no significant differences between the number of specifically 
bound cells between approaches, therefore it was proceeded with the second 
option (loading from the bottom to the top of the column) to eliminate the 
effect of the gravity and consequently all the bound cells were concentrated at 
the bottom of the column, which was an advantage during the elution and 
wash step when reversed flow was applied (Figure 3.8 below). 
 
Figure 3.8: Chromatography of red blood cells elution flow path strategies. (A) When 
cells are loaded from the bottom to the top of the column (red arrow) and then eluted 
with reversed flow path (green arrow), cells are not passing the top part of the 
column, while when (B) cells are loaded (red arrow) and eluted (green arrow) with the 
same flow direction, therefore eluted cells are passing through the whole column and 
can re-bound to the affinity support. 
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By washing and eluting cells with reversed flow elution the efficiency was 
improved significantly (for 3.5*106 injected cells from 40.92 % up to 48.75 %). 
The difference, nearly 8 %, is most likely due to cells passing through the 
remaining part of the column during the washing and elution, these cells were 
potentially, specifically and non-superficially re-bound to the chromatographic 
support, which slowed down the elution process and as well reduced yields. 
Initially 3*106 cells were injected onto column at a linear flow rate of 30 cm/h 
(0.1 mL/min). Due to the low number of cells present in the elution fractions 
and the low detection limit of the selected method for the evaluation of cell 
number in samples, it was preceded with greater cell injections rather than 
combining individual fractions in order to be able to evaluate number of cells 
after completed separation. The bed height in the column was fixed to 5.5 cm, 
which was equal to 1 mL of bead slurry (1 column volume). The selected 
approach allowed for comparison between the experiments and closer 
tracking of cells throughout the whole separation process. The only limitation 
was the fraction size, which was set to 1 column volume (1 mL; 1 CV). Initial 
loading and elution of red blood cells at 30 cm/h did not have any impact on 
their viability, it was therefore retained, but the washing of any non-specifically 
bound cells was performed at 300 cm/h. This increase in the flow rate was 
introduced with a goal to remove all non-bound cells as well as to prevent any 
clogging and mechanical entrapment within the column. This precaution was 
made due to the “sticky” nature of red blood cells (Chasis and Mohandas, 
1992).  
Surprisingly the desorption kinetics between cells tagged with biotinylated 
antibody and immobilized avidin on the surface of the beads was slow and 
necessitated pausing the flow during the elution to allow sufficient time for D-
biotin present in the elution buffer to compete with biotinylated antibody and 
consequently release cells from the support. With red blood cells only partial 
optimization of stops during elution was made due to their characteristics 
(size, shape, “stickiness”), but the best elution efficiency was achieved when 
Chapter 3: Preparation, characterization and application of non-porous glass beads 
for the positive selection of human red blood cells 
 
126 
 
retained red blood cells were eluted by pausing the flow sequentially three 
times for 1.5 h. 
After optimization of the sample size, flow direction, linear flow rate and 
partially the elution step, a series of experiments were performed with the aim 
of testing the capacity and the elution efficiency of the prepared 
chromatographic support. The results are present in the Table 3.2.  
Table 3.2: Summary of representative data of affinity chromatography of human red 
blood cells on antibody labelled monoavidin/dextran coated glass beads. Red font 
colour is used for the experiment with the best elution efficiency (%). 
Number of viable red 
blood cells (*106) 3.5 4.5 15 23 53 64 82.5 
Cells in flow through 
and washout fractions 
(*106) 
1.7 2.4 9.9 6.0 19.3 10.7 15.8 
Retained cells on the 
column (*106) 1.8 2.1 5.1 17.0 33.7 63.9 66.7 
Eluted cells (*106) 0.9 1.8 0.7 0.3 0.71 0.6 0.2 
Elution efficiency (%) 48.8 85.0 14.3 1.9 0.02 0.01 0.003 
Number of elution steps 4 3 2 3 3 3 3 
Total elution time (h) 4.5 4.5 4 4.5 3.5 3.5 3.5 
Lost cells (*106) 0.9 0.3 4.4 16.7 33.0 63.3 66.5 
 
The beads packed in the column were challenged with 3.5*106 cells up to 
8.25*107 cells. Surprisingly, the elution efficiency depends on the number of 
loaded cells, it dropped exceptionally when more than 4.5*106 cells were 
applied. Preliminary experiments have shown that the number of elution steps 
has a little impact on the elution efficiency; more significant is the duration of a 
single pause. After 15 min flow pause no cells were detected in the elution 
fractions, while pausing the flow for 1.5 h had a positive impact on the number 
of eluted cells. It was concluded that the D-biotin mediated displacement of 
cells from the affinity support is slow, therefore the decision was made to limit 
the elution time to 4.5 h in order to retain the separation process within a 
reasonable time frame.   
Mechanical entrainment within the interstices was identified as the most 
significant problem, and the extent to which this occurred was correlated with 
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the cell concentration in the feed. This phenomenon could be explained by the 
interactions between red blood cells (Figure 3.9). So called rouleau formation 
is a physiological condition in vertebrates, is a result of a weak cell-cell 
interaction which temporary overcome the negative surface charge of cells. 
These interactions can be relatively easily dissociated. On the other hand, the 
aggregation of red blood cells is an outcome when associations between red 
blood cells are strong and regulated usually by antibodies. This type of 
interactions requires much greater forces for cell dissociation (Chasis and 
Mohandas, 1992). 
 
Figure 3.9: Interactions between red blood cells. (A) Rouleau formations are 
physiologically common weak cell-cell interactions and are readily dissociated, while 
(B) aggregation of red blood cells is induced by antibodies and requires greater 
forces for its dissociation. 
 
Rouleau formations should not have any significant impact on the elution of 
cells from the column except, but it might slow down the displacement of free 
D-biotin in elution buffer with biotinylated antibody. However, although anti 
Gly-A, antibody used for the positive selection, is immobilized on the support, 
it might induce aggregation of red blood cells in the column, especially after 
the elution buffer is applied on the column and free biotinylated antibody and 
cells labelled with biotinylated antibody are released from the surface. These 
cells and antibodies can interact with each other as well as with any uneluted 
cells and form large aggregates. The more cells that are applied to the 
column, the higher their concentration is during loading, washing and elution, 
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giving them more chance to interact, hence the elution efficiency drops 
drastically (Figure 3.10 below).  
 
Figure 3.10: Impact of cell loading on subsequent elution. The number of red blood 
cells applied onto affinity chromatographic support has a major impact on the number 
of eluted cells (left graph; black circles) and elution efficiency (right graph; white 
circles). Optimum elution efficiency was noted at cell load of 4.5*106 cells. 
 
The best elution efficiency (85.0 %) was achieved when the column was 
challenged with 4.5*106 cells. An upper limit for 1 mL of packed bead slurry 
was identified as less than 15*106 cells, beyond which the column elution 
efficiency dropped below 14.3 % and therefore the column does not function 
as an effective affinity chromatographic matrix.  
A closer look at the chromatogram of the run with 4.5*106 red blood cells 
(Figure 3.11) revealed that during loading no significant changes in the 
pressure on the system were recorded, suggesting no, or very little, cell 
entrapment and aggregation was present. The increase during washing step 
was due to the increased flow rate (from 30 cm/h to 300 cm/h). Only small 
changes were observed during experiments with greater cell numbers, but the 
change was below 7 % in all cases, and could be treated as an experimental 
mistake. Additionally, the pressure is measured on the whole Äkta system and 
it is not sensitive enough to define presence of cell entrapment and/or 
aggregation on the column. Unfortunately the system did not allowed 
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observation of the pressure drop on the column, which would give better 
indication of cell entrapment.  
Measuring absorbance at 215 nm was useful especially during the elution 
because it allowed the identification of the onset of the competitive D-biotin 
elution. Conductivity values remained constant throughout the whole 
experiment (within the difference of 17 mS/cm), indicating that no cell lysis 
occurred during the time spent on the column.  
 
Figure 3.11: Affinity chromatography of human red blood cells (4.5*106 cells injected) 
on antibody labelled monomeric avidin coated glass beads. Black line indicates 
pressure (mPa) on the system during the run, dark brown conductivity (mS/cm) and 
blue line represents absorbance at 215 nm (mAU). Dark red bars show cell counts of 
fractions. With black arrows are indicated points at which flow was paused for 1.5 
hours. 
 
The desorption kinetics of tightly adsorbed cells was surprisingly slow, which 
is the opposite from the results obtained with batch static set-up (Chapter 2), 
therefore it was essential to pause the flow twice for 1.5 h and once for 1 h 
after 3 mL of elution buffer passed the column. This proved an effective 
elution as the majority of the cells were eluted immediately after flow was 
paused. To confirm cells were not eluted due to the mechanical force after 
flow was set-up, the same experimental procedure was repeated with 
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tetrameric avidin, a form with higher dissociation constant for D-biotin, 
immobilized on the beads. This time red blood cells were present only in the 
fractions collected during the load and wash steps.  
Additionally, the specificity of the cell binding to the immobilized antibody on 
the chromatographic matrix was assessed. An experiment was conducted 
with naked, amino-derived and dextran coated beads packed into column 
(bed height: 5.5 cm). In all three cases, 3*106 cells were injected through 500 
µL loop on the column and all the injected red blood cells were detected in 
flow through and wash fractions. When non-modified beads were challenged 
with red blood cells, 98.2 % of applied cells were detected in flow through 
fraction, remaining were present in rinsing fraction. 93.5 % of cells applied to 
the amino-derived beads were present in flow through fraction, additionally 
5.7 % of applied cells were detected in rinsing fraction. Furthermore, dextran 
coated beads do not promote non-specific cell binding as 98.6 % of applied 
cells were present in flow through fraction, remaining 0.9 % was detected in 
rinsing fraction. This additionally confirmed that the selected chemistry was 
appropriate as it did not promote nonspecific cell binding.  
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3.4 CONCLUDING REMARKS 
The adsorption and desorption kinetic rate are the two most important factors 
in the affinity separation of human cells. Especially as slow desorption kinetics 
have proven to be the most challenging part of process.  
The findings presented in this study have shown the adequacy of the 
developed monomeric avidin–biotin technology for the use in packed bed 
chromatography for the positive selection of human therapeutic cells. The use 
of red blood cells in the experiments might have impacted on the yields and 
elution efficiency, as well as on the duration of the separation process. 
Therefore, it is necessary to further optimize the separation conditions, 
preferably using a different feedstock. Possible candidates are white blood 
cells (B and T lymphocytes).  Additionally, there is a need to assess cell 
viability with another, more precise, method and to measure the cell function 
before and after the experiments. For example, the functionality of red blood 
cells can be visually assessed under microscope since the main role of red 
blood cells in the human body is to transport oxygen bound to hemoglobin, 
iron-rich protein. Cells which have lost their main functionality look smaller 
and paler (Cook, 2005).  
  
Chapter 3: Preparation, characterization and application of non-porous glass beads 
for the positive selection of human red blood cells 
 
132 
 
3.5 REFERENCES 
Bain B.J. 1996. A beginner’s guide to blood cells. Oxford: Blackwell Science. 
Berenson R.J., Bensinger W.I., Kalamasz D. and Martin P. 1986a. Elimination of 
Daudi lymphoblasts from human bone marrow using avidin- biotin 
immunoadsorption. Blood, vol. 67, no. 2, pp. 509-515. 
Berenson R.J., Bensinger W.I. and Kalamasz D. 1986b. Positive selection of viable 
cell populations using avidin-biotin immunoadsorption. Journal of immunological 
methods, vol. 91, no. 1, pp. 11-19. 
Bourns B., Franklin S., Cassimeris L. and Salmon E.D. 1988. High hydrostatic 
pressure effects in vivo: Changes in cell morphology, microtubule assembly, and 
actin organization. Cell motility and the cytoskeleton, vol. 10, no. 3, pp. 380-390.  
Chasis J.A. and Mohandas N. 1992. Red blood cell glycophorins. Blood, vol. 80, no. 
8, pp. 1869-1879.  
Chhabra R.P., Comiti J. and Machač I. 2001. Flow of non-Newtonian fluids in fixed 
and fluidised beds. Chemical engineering science, vol. 56, no. 1, pp. 1-27. 
Cook J.D. 2005. Diagnosis and management of iron-deficiency anaemia. Best 
Practice & Research Clinical Haematology, vol. 18, no. 2, pp. 319–332. 
Crenshaw H.C., Allen J.A., Skeen V., Harris A. and Salmon E.D. 1996. Hydrostatic 
pressure has different effects on the assembly of tubulin, actin, myosin II, vinculin, 
talin, vimentin, and cytokeratin in mammalian tissue cells. Experimental cell 
research, vol. 227, no. 2, pp. 285-297. 
GE Healthcare Application note 28-9372-07 AA. Column efficiency testing. [online]. 
[viewed 07/01/2014]. GE Healthcare, Uppsala, Sweden, pp. 1-6. 
Available from: 
https://www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/1
352880951136/litdoc28937207_20141127221416.pdf 
Green N. M. and Toms E. J. 1973. The properties of subunits of avidin coupled to 
Sepharose. Biochemical Journal, vol. 133, no. 4, pp. 687-698. 
Chapter 3: Preparation, characterization and application of non-porous glass beads 
for the positive selection of human red blood cells 
 
133 
 
Gu Y.J., Boonstra P.W., Graaff R., Rijnsburger A.A., Mungroop H. and van Oeveren 
W. 2000. Pressure drop, shear stress, and activation of leukocytes during 
cardiopulmonary bypass: A comparison between hollow fiber and flat sheet 
membrane oxygenators. Artificial organs, vol. 24, no. 1, pp. 43-48. 
Hagel L., Jagschies G. and Sofer G. 2008. Handbook of Process Chromatography: 
Development, Manufacturing, Validation and Economics. 2nd ed. London: 
Academic Press, pp. 1-330. 
Jasiewicz M.L., Schoenberg D.R. and Mueller G.C. 1976. Selective retrieval of biotin-
labelled cells using immobilized avidin. Experimental cell research, vol. 100, no. 1, 
pp. 213-217.   
Kühner M. and Sackmann E. 1996. Ultrathin hydrated dextran films grafted on glass: 
Preparation and Characterization of structural, viscous and elastic properties by 
quantitative microinterferometry. Langmuir, vol. 12, no. 20, pp. 4866-4876. 
Ljunglöf A., Bergvall P., Bhikhabhai R. and Hjorth R. 1999. Direct visualisation of 
plasmid DNA in individual chromatography adsorbent particles by confocal 
scanning laser microscopy. Journal of Chromatography A, vol. 844, no. 1-2, pp. 
129-135. 
Ljunglöf A. and Hjorth R. 1996. Confocal microscopy as a tool for studying protein 
adsorption to chromatographic matrices. Journal of Chromatography A, vol. 743, 
no. 1, pp. 75-83. 
Ljunglöf A. and Thömmes J. 1998. Visualising intraparticle protein transport in porous 
adsorbents by confocal microscopy. Journal of Chromatography A, vol. 813, no. 2, 
pp. 387-395. 
Lowell S., Shields J.E., Thomas M.A. and Thommes M. 2006. Characterization of 
Porous Solids and Powders: Surface Area, Pore Size and Density. 2nd ed. 
Dordrecht: Springer, pp. 1-93. 
Massia S.P., Stark J. and Letbetter D.S. 2000. Surface-immobilized dextran limits cell 
adhesion and spreading. Biomaterials, vol. 21, no. 22, pp. 2253-2261. 
Chapter 3: Preparation, characterization and application of non-porous glass beads 
for the positive selection of human red blood cells 
 
134 
 
Mehta D. and Hawley M.C. 1969. Wall effect in packed columns. Industrial and 
engineering chemistry process design and development, vol. 8, no. 2, pp. 280-
282. 
Micromeritics. ASAP 2020. Accelerated surface area and porosimetry system. User’s 
manual V3.04. 2004-2010. Micromeritics Instrument Corporation. 462 pp.   
Molecular Probes by Life Technologies. Amine-reactive probes. 2013. [online]. 
[viewed 28/05/2013]. Thermo Fisher Scientific, Carlsbad, USA, pp. 1-11. Available 
from: 
https://tools.lifetechnologies.com/content/sfs/manuals/mp00143.pdf 
NIST X-ray Photoelectron Spectroscopy Database. Version 4.1. 2012. [online]. 
[viewed 13/07/2014]. National Institute of Standards and Technology, 
Gaithersburg, USA. Available from: http://srdata.nist.gov/xps/ 
Plotz P.H. and Talal N. 1967. Fractionation of splenic antibody-forming cells on glass 
bead columns. The journal of immunology, vol. 99, no. 6, pp. 1236-1242. 
Rabinowitz Y. 1964. Separation of lymphocytes, polymorphonuclear leukocytes and 
monocytes on glass columns, including tissue culture observations. Blood, vol. 23, 
no. 6, pp. 811-828. 
Rabinowitz Y. 1965. Brief report: Adherence and separation of leukemic cells on 
glass bead columns. Blood, vol. 26, no. 1, pp. 100-103. 
Rathore A.S., Kennedy R.M., O’Donnell J.K., Bemberis I. and Kaltenbrunner O. 
2003. Qualification of a chromatographic column. Why and how to do it. BioPharm 
International, vol. 16, no. 3, pp. 30-40. 
Ribeiro A.M., Neto P. and Pinho C. 2010. Mean porosity and pressure drop 
measurements in packed beds of monosized spheres: Side wall effects. 
International review of chemical engineering, vol. 2, no. 1, pp. 40-46. 
Sproβ J. and Sinz A. 2012. Monolithic columns with immobilized monomeric avidin: 
preparation and application for affinity chromatography. Analytical and 
Bioanalytical Chemistry, vol. 402, no. 7, pp. 2395-2405. 
Chapter 3: Preparation, characterization and application of non-porous glass beads 
for the positive selection of human red blood cells 
 
135 
 
Thermo Scientific Tech tip #5. Attach an antibody onto glass, silica or quartz surface. 
2008. [online]. [viewed 14/05/2012]. Pierce Biotechnology, Rockford, USA, pp. 1-
4. Available from: 
https://www.piercenet.com/instructions/2160905.pdf 
Truffa-Bachi P. and Wofsy L. 1970. Specific separation of cells on affinity columns. 
Proceedings of the National academy of sciences, vol. 66, no. 3, pp. 685-692. 
Venter B.R., Venter J.C. and Kaplan N.O. 1976. Affinity isolation of cultured tumor 
cells by means of drugs and hormones covalently bound to glass and Sepharose 
beads. Proceedings of the National academy of sciences, vol. 73, no. 6, pp. 2013-
2017. 
Wigzell H. and Andersson B. 1969. Cell separation on antigen-coated columns. 
Elimination of high rate antibody-forming cells and immunological memory cells. 
The journal of experimental medicine, vol. 129, no. 1, pp. 23-36. 
Wormmeester J., Stiekema F. and De Groot K. 1984. A simple method for 
immunoselective cell separation with the avidin-biotin system. Journal of 
immunological methods, vol. 67, no. 2, pp. 389-394. 
Yui N., Sanui K., Ogata N., Kataoka K., Okano T. and Sakurai Y. 1985. Reversibility 
of granulocyte adhesion using polyamine-grafted nylon-6 as a new column 
substrate for granulocyte separation. Biomaterials, vol. 6, no. 6, pp. 409-415. 
Chapter 4: Application of glass bead chromatography for the positive selection of 
human white blood cells 
 
136 
 
4. APPLICATION OF GLASS BEAD 
CHROMATOGRAPHY FOR THE POSITIVE 
SELECTION OF HUMAN WHITE BLOOD CELLS 
Abstract 
A developed monomeric avidin packed bed column is implemented for the 
positive selection of white blood cells, namely B lymphocytes, by biotin 
mediated displacement. Evaluated are two approaches: (i) binding of the 
selected biotinylated antibody to the chromatographic support; and (ii) 
labelling cells in advance with biotinylated antibody. The effects of cell 
concentration, number of applied cells, loading, wash and elution linear flow 
rates and flow pause on the binding efficiency, elution efficiency and yield are 
evaluated in order to develop an effective, highly selective and fast affinity 
based separation.  
4.1 INTRODUCTION 
The avidin/biotin system has been widely used for an affinity separation of 
mammalian cells (Berenson et al., 1986a; Berenson et al., 1986b). Early 
studies exploited the high affinity between protein avidin and vitamin biotin to 
achieve specific cell attachment, but, as the adhesion strength of a bond is 
not dependent on the affinities, it allows mechanical disruption of the bond 
and consequently release of a cell (Kuo and Lauffenburger, 1993). Besides 
mechanical release, various other approaches could be utilized, for example 
non-specific elution by change of pH, temperature or salt concentration, or 
shear forces to physically dislodge cells from the support, but the most 
elegant approach is the competitive displacement, although it might not work 
when the number of interactions is more than ten, as it is unlikely that a 
monovalent competitor could be used at sufficient high concentration to be an 
Chapter 4: Application of glass bead chromatography for the positive selection of 
human white blood cells 
 
137 
 
effective displacer (Cao et al., 2002). For example, 6 M guanidine 
hydrochloride at pH 1.5 is commonly used to elute biotinylated molecules, 
however it is a harsh condition not always suitable for biomolecules 
(Magdeldin and Moser, 2012), therefore it is not a surprise it has not 
beenwidely used in commercial separations (Lightfoot and Moscariello, 2004).  
The monomeric form of avidin has a much lower affinity constant towards 
biotin, as each subunit consists only of one biotin binding site (Qureshi and 
Wong, 2002). The preparation of affinity support is a multistep procedure, 
which consists of the immobilization of native, tetrameric, avidin, followed by 
its denaturation and renaturation of the monomeric avidin support with a 
dissociation constant of 1.8*10-7 M (Kohanski and Lane, 1990). First report for 
the preparation of monomeric avidin affinity column is dated back to the 1979, 
used for the specific isolation of biotin-containing enzymes, namely propionyl-
CoA carboxylase and methylmalonyl-CoA pyruvate transcarboxylase, both 
originate from bacteria (Henrikson et al., 1979). Just a year later, purification 
of a human liver propionyl-CoA carboxylase was reported (Gravel et al., 
1980). Since then it has been used for the purification of biotinylated proteins 
(Qureshi and Wong, 2002), but has never been applied so far for the positive 
selection of human or mammalian cells.  
Besides gentle elution, monomeric avidin-biotin approach allows as well site-
specific attachment of antibody, which minimalize steric hindrance and 
consequently improves binding, since immobilized avidin has a role as a linker 
and therefore improves accessibility of biotinylated antibodies for surface 
antigens on the cells (Magdeldin and Moser, 2012). 
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4.2 MATERIALS AND METHODS 
4.2.1 MATERIALS 
Medical grade nonporous borosilicate glass spheres GL-0179B5 (90-106 µm 
in diameter with 2.2 g/cm3 density and 1.472 refractive index) were obtained 
from MO-SCI Specialty Products, L.L.C (Rolla, Missouri, USA). 
Ethylenediaminetetraacetic acid, disodium salt dehydrate for electrophoresis 
(EDTA; Acros Organics), bovine serum albumin (BSA; cell culture grade, pH 
7.0, lyophilised powder; Thermo Scientific HyClone), D(+)-biotin (Acros 
Organics; 98 % purity), 7-aminoactinomycin D (Molecular Probes®, Invitrogen; 
7-AAD), streptavidin R-Phycoerythrin conjugate (Molecular Probes®, 
Invitrogen; SAPE; 1 mg/mL solution), RPMI-1640 liquid medium with 2.05 mM 
L-glutamine (Thermo Scientific HyClone; RPMI), foetal bovine serum (Thermo 
Scientific HyClone; FBS; standard filtered through three sequential 100 nm 
(0.1 μm) pore size rated filter) and Trypan blue (Molecular Probes®, 
Invitrogen; 0.4 % solution) were purchased through Fischer Scientific UK Ltd. 
(Loughborough, UK), as well as phosphate buffered saline (PBS buffer) in a 
tablet form. Each tablet prepares 100 mL of PBS buffer.  
Analytical grade (99+ % purity) hydrogen chloride (HCl) and sodium hydroxide 
(NaOH) supplied by Fischer Scientific UK Ltd. (Loughborough, UK) were used 
for preparation of buffer solutions and were and suitable for cell culture. 
All solutions were prepared using water purified by a Millipore Elix Gulfstream 
Clinical 100 (Merck Millipore UK Ltd, Watford, UK) water purification system. 
Buffer solutions were prepared by dissolving a known mass of buffering 
species into ca. 80% of the desired final volume of deionized water, titrating 
with 1 M solution of HCl or NaOH and adding water to yield the final solution 
volume. 
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Sterilization of solutions and suitable materials was performed either by 
autoclaving at 121 °C for 30 min using ASB 300T autoclave (Astell Scientific, 
Sidcup, UK) or by filtering through through a 0.22 µm syringe filter (Merck 
Millipore UK Ltd, Watford, UK). 
Rituximab (anti-CD20 monoclonal antibody) was purchased from Roche 
(Basel, Switzerland). Toledo ATCC® CRL2631™ continuous cell line (CD20 
positive cell line (Gabay et al., 1999) was purchased from LGC Standards 
(Teddington, UK) and CCRF-HSB-2 cell line was purchased from the Health 
Protection Agency, Culture Collection (Salisbury, UK). 
Tricorn 5/50 column and complementary Tricorn 5 coarse filter kit were 
supplied by GE Healthcare (Uppsala, Sweden). 
4.2.2 METHODS 
4.2.2.1 Preparation of antibodies and cells 
Rituximab antibody was biotinylated in advance following the procedure from 
the Section 2.2.2.3.  
Toledo cell line was cultured as described in the Section 2.2.2.5. Prior the use 
was cell suspension collected, cells counted and their viability checked by 
Trypan blue exclusion method. Cells were then centrifuged at room 
temperature at 200 gav for 5 min in a Heraeus Labofuge 400R centrifuge 
(Thermo Scientific, Fisher Scientific, Loughborough, UK). After completed 
centrifugation supernatant was decanted and pellet resuspended in 1 mL of 
PBS buffer. Just before the use was suspension gently mixed by pipette and 
diluted with RPMI medium without supplements to the required concentration. 
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4.2.2.2 Preparation of affinity support 
Beads were prepared and characterized as previously described in the 
section 3.2.2 and stored at 4 °C, protected from the light, until use. 
On the day of experiment were beads packed into Tricorn column under 
gravity to the height of 5.5 cm. Column was then connected to the Äkta Pure 
chromatographic system (GE Healthcare, Uppsala, Sweden) and ready for 
the use. 
4.2.2.3 Coupling of biotinylated antibody to the beads 
To the 5 mL of bead slurry (1:1 ratio beads:buffer) the antibody suspension 
was added to a final concentration of 50 µg/mL and incubated overnight at 4 
°C, protected from the light. Before the use, beads were centrifugated (200 gav 
for 2 min, without a brake) and gently rinsed with 2.5 mL of PBS buffer. All the 
suspensions were collected to measure absorbance at 280 nm (UV mini 1240 
UV/VIS Spectrophotometer, Shimadzu, Milton Keynes, UK) and mass of 
antibody in the suspension was calculated using equation 2.1. 
4.2.2.4 Binding of biotinylated antibody to cells 
When required, cell suspensions were incubated with biotinylated. To the 5 
mL of cell suspension (4*107 cells/mL; 2*108 cells in total) in PBS buffer 
supplemented with 2 mM EDTA and 0.5 % BSA, antibody solution was added 
to a final concentration of between 0.5 and 50 µg/mL. The suspension was 
then incubated on the 3-D rocking platform STR 9 (Stuart Scientific, Stone, 
UK) with shaking at 70 revs/min for 1 h at room temperature, followed by 
centrifugation at 200 gav at room temperature for 5 min. Supernatant was 
decanted and pellet resuspended in 10 mL of RPMI medium without 
supplements. 
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4.2.2.5 Affinity chromatography  
The development of the affinity method for the positive selection of human 
cells was performed in a following way. Mobile phase A (running buffer; PBS, 
pH 7.4) and mobile phase B (elution buffer; 2 mM D-biotin in PBS, pH 7.4) 
were filtered through a 0.22 µm filter unit, to sterilise, and degassed for 10 min 
in ultrasonic bath (Fisherbrand S15, Fisher Scientific Ltd., Loughborough, 
UK). The column was at first equilibrated with mobile phase A until UV signal 
at 280 nm remained stable for 1 min (acceptable UV fluctuation: 20 mAu). If 
the UV signal was not stable after 10 min of equilibration, column was 
removed from the system, beads decanted and column was re-packed with 
fresh beads. After equilibrium was achieved, 0.5, 2 or 5 mL of cell suspension 
was injected onto the column from the top or the bottom at linear flow rate of 
30 cm/h (0.1 mL/min) or 60 cm/h (0.2 mL/min). To maximize recovery, sample 
loop was overfilled, i.e. into 0.5 mL loop, 1 mL of cell suspension was injected. 
The injection valve was then emptied using the mobile phase at a volume of 
twice that of the sample loop. Washing to remove non-specifically and weakly 
bound cells were conducted under the same or reversed flow conditions with 
10 mL (10 column volumes, i.e. 10 CV) of mobile phase A at flow rate from 30 
cm/h up to 600 cm/h. Elution (mobile phase B) varried from 30 cm/h to 600 
cm/h and both, the same or reversed flow, were evaluated. During elution the 
flow was stopped for in between 15 and 120 minutes to allow competitive 
displacement of biotinylated antibody and cells with D-biotin. Cells in all 
fractions were counted using a Neubauer Improved Bright-Line 
haemocytometer (Sigma Aldrich, Gillingham, UK) as previously described in 
Section 2.2.2.10. Elution was stopped after the viability of cells, assessed by 
Trypan blue exclusion method, dropped below 60 %. 
4.2.2.6 Immunophenotypic analysis of cells 
Immunophenotypic analysis of cells was determined by flow cytometry using 
Guava easyCyte 8HT flow cytometer (Merck Millipore UK Ltd, Watford, UK) 
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and the data was analysed with InCyte software (Merck Millipore UK Ltd, 
Watford, UK) following the procedure from the Section 2.2.2.10. 
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4.3 RESULTS AND DISCUSSION 
Following the successful modification, functionalization and characterization of 
the beads with immobilized avidin with the revisable biotin binding sites and 
initial development of the affinity method for the positive selection of human 
therapeutic cells with red blood cells, the positive selection method described 
in Chapter 3 was further optimized with Toledo cell line, i.e. B lymphocytes, 
which were introduced together with T lymphocytes from various human cell 
lines, as they are more similar to the CD34+ progenitor cells, the most popular 
target population in the positive cell selection, which can be sourced from 
bone marrow and peripheral blood (Hipp and Atala, 2008). 
The first part of experiments was performed with antibody immobilized on 
beads and injection of 3*106 cells onto column.  
Cells were initially loaded, eluted and non-specific and weakly bound cells 
removed at linear flow rate of 30 cm/h from the bottom to the top of the 
column. But no cells were eluted, the majority (>90 %) of cells present in 
fractions collected during load and wash step were not in a viable form. This 
indicated that cells were being starved of nutrients and were exposed for too 
long to shear stress, even with a relatively short loading time of 10 min and 
washing step of 100 min. This is in agreement with Gu et al. (2000) who found 
that human cells might be resistant to the high shear stress, but for only 
limited time. In the comparison, Kumar and his group (2003) were applying 
cells to their affinity monolithic cryogel columns at flow rate 1.5 mL/min (linear 
flow rate not available). Although the structure of monolithic columns cannot 
be directly comparable with packed bed column, and consequently the mass 
transfer in packed bed differs from the mass transfer in monoliths (Jungbauer 
and Hahn, 2004), it was agreed that this is a good indication of cell resistance 
and therefore it is worth to try and proceed with increased flow rates. 
Initially cells were injected in PBS buffer; however, to improve their viability 
and to be able to indirectly track them during loading and partially wash, 
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samples were prepared in the basic cell culture medium RPMI 1640 without 
supplements, which absorbs at 280 nm. 
Simultaneously with the injection of cell suspension in RPMI medium and the 
increase of flow rates, sequential stops during elution were introduced. The 
increase of the loading flow rate from 30 cm/h to 60 cm/h still allowed enough 
of contact time between immobilized antibodies and antigens on the surface 
of cells in order for cells to specifically bound, and also resulted in an 
increased viability of cells collected in flow-through fractions (at least 75 % 
viability assessed by Trypan blue assay). The washing flow rate was gradually 
increased to 600 cm/h (2 mL/min), which was high enough to remove all non-
specifically bound cells, as well as weakly bound cells and did not have any 
negative impact on the viability of eluted cells. Subsequently it was discovered 
that the washing step does not only remove non-specifically bound cells, but 
also dead CD20 positive cells. The elution flow rate was also increased to 600 
cm/h, with a goal to reduce elution time and, potentially improve cell viability. 
The time intervals, during which the flow was paused in order to allow D-biotin 
to competitive displace immobilized biotinlyted antibody and cells were 
gradually decreased from 120 min to 15 min. Pausing the flow was an efficient 
way to elute cells, but long stops increased the duration of a single 
experiment and consequently the viability of the cells was poor (below 50 %, 
assessed with Trypan blue exclusion method) when stops lasted for 45 min or 
more. Stopping the flow for 30 min or less resulted not only in significantly 
increased viability of cells (above 80 %), but also in a greater number of 
eluted cells. A pause in the flow for 15 min was long enough for D-biotin to 
remove cells from the surface and it allowed at least 6 stops to elute more 
cells in a viable condition (above 70 %) in less than 2 h. Over the time, the 
viability of cells dropped as expected based on previous findings (Gu et al., 
2000), for example after the first stop the average viability was 94 % but after 
6th stop was only 71%.  
To confirm that elution was due to the displacement of D-biotin and not to the 
instant increase of flow rate from 0 to 600 cm/h, the experiment was 
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conducted with beads with immobilized tetrameric form of avidin. As no cells 
were eluted it was concluded that elution is based on competitive basis rather 
than mechanical one. 
Reversed flow during the washing and elution proved an efficient way to elute 
more red blood cells (see Section 3.3.2), this approach was also tested with 
white blood cells, but without success. Not only were fewer cells eluted, all 
were dead and simultaneously a change in the conductivity was observed, 
which suggests the conditions were suboptimal and the cells underwent lysis. 
Therefore it was switched back to the same flow path during all three 
separation steps, i.e. from the bottom of the column to the top. 
The selectivity of the developed method was tested by challenging naked 
(non-modified) beads, amino derived and dextran coated beads with B 
lymphocytes. In all three cases, the majority of injected cells (more than 95 %) 
were detected in flow through fractions and remaining ones in washing 
fractions. This confirms the adequacy of the selected chemistry. In the next 
step monomeric avidin beads with immobilized biotinylated anti-CD20 
antibody were challenged with CD20 negative cells (CCRF-HSB-2 cell line) to 
evaluate the selectivity of the developed method. Once again, the majority of 
cells (87 %) were present in flow through fractions, while the remaining ones 
were washed through by mobile phase A.  
After conditions were optimized, various numbers of cells were applied onto a 
column with a goal to determinate its capacity for B lymphocytes. Results are 
presented in the Table 4.1 below. 
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Table 4.1: Overview of results obtained by challenging the monomeric avidin 
immobilized in a packed bed column with various number of cells.  
Number of 
injected B 
lymphocytes 
(Toledo cell line) 
(*106) 
3.0 6.6 23.0 35.0 40.0 75.2 100.0 120.0 270.0 
Cell 
concentration 
(*106 cells/mL) 
6.0 13.3 46.0 70.0 20.0 15.0 20.0 48.0 108.0 
Loop size (mL) 0.5 0.5 0.5 0.5 2 5 5 5 5 
Cells in flow 
through and 
washout 
fractions (*106) 
0.05 0.1 13.0 13.2 9.5 7.8 23.2 24.3 140.0 
Retained cells on 
the column (*106) 2.95 6.53 10.2 22.0 30.5 67.4 76.8 95.7 130.0 
Eluted cells 
(*106) 0.13 0.15 3.3 8.4 13.6 28.8 37.3 48.5 55.2 
Elution 
efficiency (%) 4.3 2.3 32.10 38.72 44.64 42.78 48.52 50.71 42.39 
Number of 
elution steps 6 6 7 9 8 8 7 7 7 
Total elution 
time (h) 1.75 1.75 2 2.5 2.25 2.25 2 2 2 
Lost cells (*106) 2.82 6.38 6.9 13.6 16.9 38.6 39.5 47.2 74.8 
 
It is important to stress that all presented separations of B lymphocytes did 
not take more than 3 h. 
Initially it was observed that the cell concentration of loaded cell suspension 
has the impact on the binding efficiency and the viability of eluted cells (Figure 
4.1 below). The results demonstrated that the number of bound cell was 
inversely proportional to the initial concentration of cells, moreover, poorer cell 
viability was observed with a high initial concentration. The breakthrough point 
was determinated as 4*107 cells/mL.  
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Figure 4.1: The impact of concentration of injected cell suspension on the binding 
efficiency (%) on the monomeric avidin packed bed column. 
 
To reduce the impact of the concentration of cell suspension on the cell 
binding and viability the loop size was increased proportionately from 0.5 to 5 
mL.  
The number of specifically bound cells has an influence on the elution 
efficiency (Figure 4.2 below). The best elution efficiency (50.71 %) was 
achieved when 9.57*107 cells were specifically bound to the support.  
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Figure 4.2: The impact of the number of specifically bound cells onto elution 
efficiency (%) from the monomeric avidin affinity support.  
 
The elution efficiency decreases dramatically when less than 2.3*107 cells are 
injected onto column. This might be due to the fact that on the column was an 
excess of immobilized antibodies. According to the absorbance 
measurements of supernatants after antibody immobilization, between 34.2 
and 38.5 µg of the antibody was immobilized per mL of bead slurry 
(approximately 1:1 ratio between beads and buffer). In a single packed bed 
column there was between 36.9 and 41.5 µg immobilized antibody, which is 
equal to in between 0.84 and 0.94 mg of antibody per m2. Based on the 
experiments with red blood cells (Section 3.3.2), D-biotin is gradually 
replacing biotinylated antibody. Although there might be a lot of cells released 
from the matrix surface after the first pause of the flow, an excess of 
immobilized antibody gives them a chance to re-bind. When more cells are 
initially bound to the surface; fewer antibodies are accessible for cells to 
rebound. Additionally is important not to neglect steric hindrance, as more 
cells are bound, steric hindrance has a greater impact on the binding. To 
confirm this, 3*106 cells were loaded under various linear flow rates (Figure 
4.3). 
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Figure 4.3: The impact of linear flow rate (cm/h; left graph; black circles) and  contact 
time (min; right graph; white circles) on the specifically bound cells (%). 
 
Although the number of specifically bound cells correlates with the loading 
flow rate, linear flow rate of 600 cm/h is still slow enough to allow specific 
binding of 94 % loaded cells, even though the contact time (the time a single 
cell is retained on the column) is only 1.25 min. Having in mind that each cell 
expresses at least 1.23*105 CD20 antigens on the surface (Ginaldi et al., 
1998), this is likely to happen.  
In order to have more control over re-binding of cells during the elution, cells 
were incubated in advance with the biotinylated antibody before being 
separated on the affinity packed bed column, aiming to reduce the level of 
rebinding during the elution step. After an initial test run it was evident that the 
loading flow rate of 60 cm/h was no longer appropriate. It was too high and 
had the negative impact on the binding efficiency, which dropped below 45 %. 
Therefore, the loading linear flow rate was reduced to 30 cm/h (volumetric 
flow rate of 0.1 mL/min) before proceeding with a series of experiments which 
varied the concentrations of antibody in the cell suspension.  
Based on the results of experiments with antibodies immobilized on beads 
were for the evaluation of the impact of antibody concentration in cell 
suspension used 2*107 cells/mL (1*108 cells in total), which were injected on 
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the column using 5 mL loop. The concentration of the antibody was gradually 
decreased from 50 µg/mL down to 0.5 µg/mL.  
Unfortunately the detection of free antibodies in the supernatants after 
completed incubation was not doable due to the presence of cell metabolites, 
therefore, the amount of antibody needed was calculated based on the data 
published by Ginaldi and his coworkers (1998). For the calculations, the 
assumption that 1 µg of IgG antibody (CD20, for an example) consists of 
3.6*1012 molecules, was made. As each antibody has 2 antigen binding sites, 
in theory 1 µg of IgG can bind to 7.2*1012 antigen molecules. As a typical 
antigen may be present in 104 or 105 copies per cell, 1 µg should be enough 
for between 7.2*107 and 7.2*108 cells. If in the cell suspension only, for 
example, 20 % of cells are positive for the selected marker; this number of 
cells should be multiplied by a factor of 20, as the total number of antigens is 
20 times lower. From the antibody concentration the number of antibody 
molecules needed for a single B lymphocyte from a human peripheral blood 
was calculated. Usually B lymphocytes from a healthy donor has 9.4*104 
copies of CD20 antigen per cell (Ginaldi et al., 1998). Calculations are 
summarized in the Table 4.2. 
Table 4.2: Theoretical percentage of the occupancy of surface CD20 antigens on the 
single B lymphocyte from a peripheral blood of a healthy donor by various antibody 
concentrations. Red font is used for the cases when antibody is in excess.   
Antibody concentration 
(µg/mL) 
Percentage of antigens occupied per cell (%) 
1 antibody per 1 antigen 1 antibody per 2 antigens 
50.0 191.49 765.96 
10.0 38.30 153.19 
1.0 3.83 15.32 
0.5 1.91 7.66 
0.1 0.38 1.53 
 
In theory, when the concentration of antibody is 50 µg/mL, the antibody is in 
abundance, while in 0.1 µg/mL might not be enough of antibody present to 
label each CD20 positive cell which would have negative impact on the yield; 
therefore experiments were carried out only with antibody concentration 
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between 50 and 0.5 µg/mL. Results of affinity chromatography are presented 
in the Table 4.3.  
Table 4.3: The summary of the positive selection of B lymphocytes from Toledo cell 
line labelled with biotinylated antibody on the immobilized monomeric avidin in the 
packed bed column. 
Antibody concentration (µg/mL) 50.0 10.0 1.0 0.5 
Number of injected B lymphocytes (*106) 100 100 100 100 
Cells in flow-through and washout fractions (*106) 11.5 14.9 15.3 16.5 
Retained cells on the column (*106) 88.5 85.1 84.7 83.5 
Eluted cells (*106) 30.6 37.5 41.4 45.2 
Elution efficiency (%) 34.58 44.12 48.80 54.21 
Number of elution steps 5 7 7 7 
Total elution time (h) 1.5 2 2 2 
Lost cells (*106) 57.9 47.6 43.3 38.3 
 
As it can be seen in the Figure 4.4 below, the antibody concentration has an 
impact on the binding and elution efficiency. The number of specifically bound 
cells and consequently the binding efficiency depends on the antibody 
concentration - the higher it is the more cells are bound. On the other hand 
the elution efficiency is increasing by titrating down the antibody.  
 
Figure 4.4: The impact of antibody concentration on the binding (left graph) and 
elution efficiency (right graph) of white blood cells to and from the affinity packed bed 
with immobilized monomeric avidin. Black and white dots represent experiments with 
1*108 cells (2*107 cells/mL) injected, red dots represent loaded 1*107 cells (2*107 
cells/mL) on the column and yellow dots are results from the experiments with loaded 
3*106 cells (6*106 cells/ml). 
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Comparing the results when the same number of cells (1*108 cells) was 
applied to the immobilized antibody on the column, the binding efficiency is 
higher in all cases (76.82 % was when antibody was immobilized on the 
beads), most likely due to the decreased loading flow rate, as cells labelled 
with antibody are retained on the column for twice as long (Figure 4.3; right 
part of the figure). In terms of elution efficiency, results from the experiment 
with antibody on the beads were comparable with the ones when cells were 
incubated in the presence of 1 µg of antibody per mL of suspension and better 
in comparison with 50 and 10 µg/mL. Elution efficiency correlates with 
antibody concentration, as by reducing concentration of antibody and cell 
suspension from 50 µg/mL to 0.5 µg/mL, elution efficiency was increased from 
34.6 to 54.2 %. Overall the best elution efficiency (54.21 %) was achieved 
after cells were incubated in 0.5 µg of antibody per mL.  
Cell viability assessed by Trypan blue was reduced by an average of 4 %, but 
after 6 stops cell viability was still at least 65 %. The reason for this might be 
in the length on the separation method, as the loading took twice as long, but 
together with the incubation of cells in the presence of antibodies, the 
experiment did not take more than 3.5 h. 
Following this, the number of cells labelled in 0.5 µg/mL antibody solution, 
was decreased from 1*108 to 1*107 cells, while the concentration of injected 
samples remained the same. It was observed that the binding efficiency 
remained basically the same (from 83.45 % dropped slightly to 82.95 %), 
while the impact on the elution efficiency was greater. By decreasing the 
number of specifically bound cells for the factor ≈10, elution efficiency 
dropped from 54.21 % to 45.05 %. But the elution efficiency for injected 1*107 
cells is still for nearly 12 % greater when antibody is bound on the cells in 
comparison to the case, when the same number of cells was applied to the 
column with immobilized biotinylated antibody.  
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Cells may be lost during the centrifugation during the preparation of sample 
for injection and cell counting after collected fractions, as each centrifugation 
step can result to the losses of 20-30 % (Lemarie et al., 2005). 
The chromatogram from one of the runs injected with 1*107 cells after 
incubation in 0.5 µg/mL antibody solution is presented in the Figure 4.5 below.  
 
Figure 4.5: Affinity chromatography of human CD20 positive cells (challenge = 1x107 
cells) labelled in advance with biotinlyated monoclonal antibody. Black line indicates 
pressure (mPa) on the system during the run, dark brown conductivity (mS/cm) and 
blue line represents absorbance at 280 nm (mAU). Dark red bars show cell counts of 
fractions during load, wash and D-biotin mediated elution. Change in the pressure to 
0 mPa indicates where flow was stopped for 15 min. 
 
In the case of white blood cells, in contrast to red blood cells, conductivity 
slowly and linearly dropped during the elution. The final conductivity had 
dropped from 16 to 8 mS/cm. This explains gradual decrease in cell viability 
over time. Additionally, cells were eluted by D-biotin throughout the elution 
step of the separation, while in the case of red blood cells (Figure 3.11), the 
majority of cells were eluted in the first of three fractions after stopped flow. 
The reason for this might be in the differences in the cell structures and 
characteristics (for example, B lymphocytes are round, while red blood cells 
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are biconcave shape), as well as in the interactions between red blood cells 
(see Section 3.3.2, Figure 3.9). 
The pressure drop on the system changed during the run for the 0.02 mPa, 
which indicates that very little or no cell entrapment was present on the 
column during the experiment. Each time pressure dropped to zero was due 
to the flow being stopped.  
Cell fractions collected during the same separation step were then combined 
and analysed by flow cytometry to compare the cellular function of cells 
before and after the assay and additionally assess cell viability as Trypan blue 
exclusion method could be ambiguities in the identification of stained, 
nonviable cells (Altman et al., 1993).   
The goal of the analysis of the samples after performed affinity separation 
with the developed monomeric avidin-biotin technology was to confirm the 
presence of CD20 marker on cells from the selected cell line and to assess 
the impact of the separation on the viability and immunophenotype of cells. 
Results are summarized in the Table 4.4.  
Table 4.4: The overview of the flow cytometry results of injected sample and 
fractions collected during positive separation of CD20 positive cells on monomeric 
avidin packed bed column. 
Sample source Injected cell suspension Loading Wash Elution 
CD20 positive and 
viable cells (%) 95.62 80.84 18.16 92.64 
CD20 positive and 
viable cells (*104 cells) 956.2 10.7 7.0 385.4 
CD20 positive and 
dead cells (%) 1.86 4.31 5.42 3.97 
CD20 positive and 
dead cells (*104 cells) 18.6 0.6 2.1 16.5 
CD20 negative cells 
(%) 2.52 14.84 76.42 3.38 
CD20 negative cells 
(*104 cells) 25.2 2.0 29.3 14.1 
Total cell number in 
fraction (*104 cells) 1000 13.3 38.4 416.0 
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As predicted, more than 95 % of cells in the suspension were CD20 positive 
and in a viable state (95.62 %), an additional 1.86 % was positive for the 
selected marker, but not viable. Collected fractions during load contained 
80.84 % positive and viable cells which indicate there is a scope for the 
optimization of the loading conditions although only 1.33*105 cells were 
present in this fraction (1.33 % of the applied cells). Options are further 
decreasing the linear flow rate or by pausing the flow when cell suspension 
reaches the top of the column in order to increase contact time of cells on the 
column.  The increase of the flow rate for the removal of the weakly and non-
specifically bound cells has a positive effect on the separation as it does not 
mechanically disturb the monomeric avidin – biotinylated antibody interaction, 
i.e. only 18.16 % of cells collected during the wash were detected as CD20 
positive, which is equal to 0.7 % of all loaded CD20 positive cells. This 
indicates the developed technology is highly selective and could be applied 
for the negative selection of cells, i.e. the removal of not wanted cells from the 
suspension. In this case no elution step would be implemented. 
The cells of choice were successfully eluted by the displacement of 
biotinylated antibody attached to the cells with free D-biotin present in the 
elution buffer, as 92.64 % were positive for the CD20 antigen and alive. A 
further 3.97 % of cells were CD20 positive but not in a viable condition. Eluted 
CD20 positive and viable cells represent 40.10 % of the injected CD20 
positive cells or 39.60 % of specifically bound CD20 cells. 
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4.4 CONCLUDING REMARKS 
The positive selection method using immobilized monomeric avidin packed 
bed was implemented for the selection of human B lymphocytes (CD20 
positive cells). Two approaches were evaluated, namely binding biotinylated 
antibodies to the chromatographic support and a priori binding of antibodies to 
the cells. Not only the binding of biotinlyted antibody to cells rather to the 
chromatographic support proved to have positive impact on elution efficiency, 
binding of antibodies to the cells is the preferred way in the selection of cells 
using magnetic beads (Grützkau and Radbruch, 2010). Additionally it is more 
suitable for a user, as it is not limited to the products currently on the market 
and can use its own antibodies, antibody fragments or even aptamers. 
In order to further improve elution efficiency and yields it might be worth 
reconsidering further decreasing the antibody concentration in the cell 
suspension to 0.1 µg/mL and/or loading linear flow rate, although it might 
have negative impact on the yields, binding and elution efficiency. 
The immunophenotypic analysis of cells collected during the separation 
process indicated the developed affinity matrix is highly selective and could be 
therefore be applied for the removal of non-wanted cells (negative selection). 
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5. GLASS BEAD CHROMATOGRAPHY VERSUS 
MACS® MICROBEADS: A FIRST PRINCIPLE 
COMPARISON 
Abstract 
Since the first applications of magnetic beads for cell separation they have 
been a popular choice and are now the first choice in the clinical applications 
and research. The goal of the experimental work presented in this chapter 
was to directly compare the developed affinity separation technology based 
on the immobilized monomeric avidin and MACS® Microbeads, the gold 
standard in the separation of human therapeutic cells. Results suggest that 
the developed chromatography method is a competitive and could be used for 
the purposes of regenerative medicine, as the achieved yields, purities and 
cell viabilities are comparable.  
5.1 INTRODUCTION 
Initial attempts to develop affinity chromatography separation for the selection 
of mammalian cells cover the magnetic separation of red blood cells and 
antibody-coated cells with iron-containing polymeric microspheres conjugated 
to lectines (Molday et al., 1977). A year later, separation of C-1300 
neuroblastoma cells, 10 % of which expressed target ganglioside GM1 in their 
membranes, was published. The results were already promising, with 
researchers achieving a 99 % purity in only 6 minutes (Kronick et al., 1978), 
therefore, it is not surprising that by the 1985 it was already being frequently 
used for medical applications, such as tumour cell removal from bone marrow 
and cell sorting and screening for malarial parasites in blood. For these 
purposes heteroantisera or monoclonal antibodies as targeting agents were 
immobilized on magnetic beads of various size ranges and materials 
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(Kemsheadl and Ugelstad, 1985). The real breakthrough occurred in 1987, 
when Stefan Miltenyi invented cell sorting, shortly MACS®, few years later 
being granted with a patent and founding Miltenyi Biotec (Miltenyi et al., 1990; 
Miltenyi et al., 1991). 
First magnetic particles were less than 0.5 µm in a diameter and with a 
particle surface modified by dextran. The selectivity of the separation was 
achieved by an avidin-biotin system, as to was considered to be the most 
versatile immunological detection system. Cells were at first labelled with 
biotinylated antibody, followed by staining with fluorescent avidin conjugate 
and completed with incubation with biotinylated microbeads. A steelwool 
column was inserted into the external magnetic field and cells were then 
applied onto column and eluted by removal of the column from the magnetic 
field (Miltenyi et al., 1990). Since then several improvements have been made 
and nowadays beads are suspension of colloids, ten times smaller than first 
beads (50 nm in the diameter) and the antibody is usually directly coupled 
onto the beads (Šafařik and Šafařiková, 1999). A column matrix is made up of 
spheres, which are between 250 and 500 µm in the diameter (Miltenyi Biotec 
MACS® Technology). Besides Miltenyi Biotec other magnetic beads are 
available, which can be roughly divided into micro- and nonobeads, for 
example Invitrogen (Carlsbad, USA) offers Dynal® microbeads, BD 
Biosciences (San Jose, USA) advertise nanobeads named IMAG® and 
EasySep®, nanobeads are manufactured by Stem Cell Technologies 
(Vancouver, Canada). All beads come with specially designed column and a 
separator (Grützkau and Radbruch, 2010).  
No matter what beads are used, the separation process is usually performed 
in a batch mode and consists of three separation steps: (i) cells of interest are 
labelled with magnetic beads and applied on the column with the appropriate 
magnetic separator; (ii) column is washed several times in order to remove 
non-target cell population; and (iii) column is removed from the separator and 
cells are eluted by, for example, a plunger (Šafařik and Šafařiková, 1999). 
Miltenyi Biotech has also launched flow-through semi-automated, fully 
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automated and robotic integrated magnetic separators, where magnetically 
labelled cells are pumped through the column and retained on it. After the 
removal of the magnetic field, cells are retrieved by the combination of flow 
and gentle vibration of the column (Šafařik and Šafařiková, 1999; Miltenyi 
Biotec MACS® Technology).   
During the past 30 years magnetic particles have been established and 
accepted, with a plethora of applications in biology and biomedicine (Grützkau 
and Radbruch, 2010), stem cell separation is a bottleneck in stem cell 
therapy, as MACS® technology cannot meet purification needs for the 
purposes of cell therapy as it cannot provide highly pure and viable cells 
(Schriebl et al., 2010), even with optimized multistep protocols (Gonzáles-
Gonzáles et al., 2011). The demand is enormous, as it was estimated that in 
2009, in the USA alone, more than 100 million patients were treated by cell-
based therapies and in the 2014 annual revenue in cell-based therapies 
(excluding cord blood banking) was predicated to be around 5 billion US 
dollars (Mason et al., 2011). Between 2007 and 2009, the average cost for the 
collection and processing of autologous peripheral blood stem cells together 
with a hospital treatment for a 100-day treatment in the USA was 99899 US 
dollars per patient (Majhail et al., 2013), because the isolation of CD34 
positive cells includes apheresis, negative selection (depletion of non-target 
cells), followed by positive selection of cells of interest, which are present in 
small numbers (Riley et al., 2009). 
In the past, magnetic separations have been as well combined with 
chromatographic approach. For the determination of which subclass of mice 
splenocytes able to metabolite benzo[a]pyrene (B(a)P), cells were initially 
separated by the density gradient centrifugation and immunomagnetic 
negative selection and then the metabolites were detected by high-pressure 
liquid chromatography (Ladics et al., 1992). Besides that, the enrichment of 
CD34 positive cells by magnetic beads were directly compared with 
chromatography separation. Magnetic separation was performed with Isolex 
300i® magnetic separator in conjunction with Dynabeads® (Baxter Biotech) 
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and for chromatography based separation CellPro® Ceprate SC system (Cell 
Pro Incorporation) (Stella et al., 1995; Johnsen et al., 1999). Initially was 
CellPro® developed for the depletion of T lymphocytes exploiting avidin-biotin 
approach. Native, tetrameric, avidin is conjugated to polyacrylamide beads 
packed into column and cells are passed through the column after the 
incubation in biotinylated monoclonal antibody solution (20 µg/mL) (Colter et 
al., 1996). Later on a positive selection was developed where elution is 
achieved by the agitation of the column (Johnsen et al., 1999). Both, magnetic 
beads or chromatography device did not perform to the required standard. 
While the purity achieved with magnetic beads was on average 86 % (for 
comparison only 49 % with affinity chromatography), the yield was poor using 
the both devices (40 % magnetic beads, 30 % chromatography). Additionally 
more than 50 % of depleted cells were positive for CD34. Authors suggested 
improvements of both devices in order to have a safe and sufficient product in 
clinical practice (Stella et al., 1995; Johnsen et al., 1999). 
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5.2 MATERIALS AND METHODS 
5.2.1 MATERIALS 
Medical grade nonporous borosilicate glass spheres GL-0179B5 (90-106 µm 
in diameter with 2.2 g/cm3 density and 1.472 refractive index) were obtained 
from MO-SCI Specialty Products, L.L.C (Rolla, Missouri, USA). 
Ethylenediaminetetraacetic acid, disodium salt dehydrate for electrophoresis 
(EDTA; Acros Organics), bovine serum albumin (BSA; cell culture grade, pH 
7.0, lyophilised powder; Thermo Scientific HyClone), D(+)-biotin (Acros 
Organics; 98 % purity), 7-aminoactinomycin D (Molecular Probes®, 
Invitrogen; 7-AAD), streptavidin R-Phycoerythrin conjugate (Molecular 
Probes®, Invitrogen; SAPE; 1 mg/mL solution), RPMI-1640 liquid medium 
with 2.05 mM L-glutamine (Thermo Scientific HyClone; RPMI), foetal bovine 
serum (Thermo Scientific HyClone; FBS; standard filtered through three 
sequential 100 nm (0.1 μm) pore size rated filter) and Trypan blue (Molecular 
Probes®, Invitrogen; 0.4 % solution) were purchased through Fischer 
Scientific UK Ltd. (Loughborough, UK), as well as phosphate buffered saline 
(PBS buffer) in a tablet form. Each tablet prepares 100 mL of PBS buffer.  
All solutions were prepared using water purified by a Millipore Elix Gulfstream 
Clinical 100 (Merck Millipore UK Ltd, Watford, UK) water purification system.  
Sterilization of solutions and suitable materials was performed either by 
autoclaving at 121 °C for 30 min using ASB 300T autoclave (Astell Scientific, 
Sidcup, UK) or by filtering through through a 0.22 µm syringe filter (Merck 
Millipore UK Ltd, Watford, UK). 
Rituximab (anti-CD20 monoclonal antibody) was purchased from Roche 
(Basel, Switzerland). Toledo ATCC® CRL2631™ continuous cell line (CD20 
positive cell line (Gabay et al., 1999)) was purchased from LGC Standards 
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(Teddington, UK) and cell lines Jurkat E6.1, Bristol-8 and CCRF-HSB-2 were 
purchased from Health Protection Agency, Culture Collection (Salisbury, UK). 
Tricorn 5/50 column and complementary Tricorn 5 coarse filter kit were 
supplied by GE Healthcare (Uppsala, Sweden). 
CD20 MicroBeads (human) and LS columns for magnetic cell sorting were 
purchased from Miltenyi Biotec (Bergisch Gladbach, Germany), as well as 
CD20-PE (human, clone LT20) staining antibody for flow cytometry. 
MidiMACS separator, consisting of magnet and a stand, was generously lent 
for the use by Miltenyi Biotec UK Division.  
5.2.2 METHODS 
5.2.2.1 Preparation of affinity matrix 
Glass beads were prepared, characterized and packed into Tricorn column to 
the bed height of 5.5 cm as described in Chapter 3 (Sections 3.2.2.1, 3.2.2.2, 
3.2.2.5 and 3.2.2.6).   
5.2.2.2 Chromatography-based cell enrichments 
Chromatography-based separations were performed using the method 
detailed in this section. Rituximab antibody was biotinylated in advance and 
stored at 4 °C following the procedure from the Section 2.2.2.3.  
Cell lines were cultured as described in the Section 2.2.2.5. Prior the use cell 
suspensions were collected, cells counted and their viability checked by 
Trypan blue exclusion method. Cells were then centrifuged at room 
temperature at 200 gav for 5 min in a Heraeus Labofuge 400R centrifuge 
(Thermo Scientific, Fisher Scientific, Loughborough, UK). After completed 
centrifugation supernatant was decanted and pellet resuspended in 1 mL of 
PBS buffer. Just before the use suspensions were gently mixed by pipette 
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and cell lines were combined if required. To the 5 mL of cell suspension 
(4*107 cells/mL; 2*108 cells in total) in PBS buffer supplemented with 2 mM 
EDTA and 0.5 % BSA, required volume of antibody solution was added to the 
final concentration of 0.5 µg/mL. The suspension was then incubated on the 
3-D rocking platform STR 9 (Stuart Scientific, Stone, UK) with shaking at 70 
revs/min for 1 h at room temperature, followed by centrifugation at 200 gav at 
room temperature for 5 min. Supernatant was decanted and the pellet 
resuspended in 10 mL of RPMI medium without supplements. 
On the equilibrated column with PBS buffer as a running buffer, were injected 
1*107 cells through the 0.5 mL loop from the bottom to the top of the column 
at a loading flow rate of 30 cm/h for 10 min, followed by washing at 600 cm/h 
for 10 column volumes (CV; 10 mL) and elution with 2 mM D-biotin in PBS 
buffer at flow rate 600 cm/h. After 3 CV of elution buffer passed the column, 
the pump was stopped for 15 min. This was repeated at least 6 more times. 
Throughout the separation process fractions of 1 mL were collected. For the 
flow cytometry evaluation, fractions of each separation step were combined in 
order to have enough big samples for the analysis. 
5.2.2.3 Immunophenotypic analysis of cell suspensions 
Immunophenotypic analysis of cells was determined by flow cytometry using 
Guava easyCyte 8HT flow cytometer (Merck Millipore UK Ltd, Watford, UK) 
and data was analysed with InCyte software (Merck Millipore UK Ltd, Watford, 
UK) following the procedure from the Section 2.2.2.10. 
5.2.2.4 MACS® enrichment of selected cell populations 
MACS® experiments were performed in ice-cold PBS buffer supplemented 
with 0.5 % BSA and 2 mM EDTA. Each time 1*107 cells were used for the 
separations. Cell suspensions were collected and centrifuged at room 
temperature at 200 gav for 5 min and pellet resuspended in 80 µL of buffer, to 
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which 20 µL of CD20 MicroBeads were added and incubated for 15 min at 4 
°C in the dark. Then 10 µL of CD20-PE staining antibody was added and 
further incubated for 5 min. Wash was performed by addition of 2 mL of buffer 
and centrifuged at room temperature at 200 gav for 5 min. Supernatant was 
decanted and pellet resuspended in 500 µL of buffer.  
In the meantime, a LS column was mounted on the stand with a magnet and 
equilibrated by passing through 3 mL of buffer. Separations started by 
application of cells onto the column, labelled cells were retained on the 
column and passed cells were collected for further analysis. Then column was 
washed three times by 3 mL of buffer, each time column reservoir was 
emptied. Eluent was kept for flow cytometry analysis. The column was then 
removed from the stand and consequently magnetic field. In the reservoir 5 
mL of buffer was pipetted and cells were eluted by the plunger supplied. 
All the suspensions were then centrifuged at room temperature at 200 gav for 
5 min and pellet resuspended in 200 µL of buffer and 10 µL of 7-AAD viability 
dye was added. Cells were then analysed by flow cytometry following the 
same procedure as for the fluorescently labelled cells separated with affinity 
matrix.  
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5.3 RESULTS AND DISCUSSION 
As MACS® technology cannot be directly comparable with the developed 
affinity approach, the experiments were performed by challenging both 
columns with the same number of cells – 1*107 cells, as this is a 
recommended number of cells for the positive selection of CD20 cells with LS 
MACS® column by manufacturer (MACS Magnetic cell sorting).  
Columns for the chromatography and magnetic cell separations are similar in 
size (Figure 5.1). The height of a packed bed column was fixed to 5.5 cm, 
while the height of the bead matrix in the LS column is 4 cm. The average 
glass bead is 98.43 µm in diameter, while beads packed in the LS column are 
in between 250 and 500 µm in diameter. 
 
Figure 5.1: Comparison of chromatography and MACS® column. (A) Tricorn 5/50 
column with adjustable adapter on the top packed with modified and functionalized 
glass beads. (B) MACS® LS column with the inserted plunger for the mechanical 
elution of cells of interest. 
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The performance of separation techniques was compared based on three 
separation challenges, using various feedstocks, namely (i) CD20 positive 
cell; (ii) 95 % of cells CD20 positive, remaining CD20 negative (CCRF-HSB-2 
cell line); and (iii) mixture of cell with only 5 % CD20 positive cells. In all three 
cases the separation process (e.g. flow rates for chromatography and 
incubation times for the separation with magnetic beads) was the same. To 
reduce the impact of biological viability on the positive selection of CD20 cells, 
cells were synchronously taken from the same cell stock. Results are 
presented in the Table 5.1 below. 
Table 5.1: Comparison of glass bead chromatography and MACS® system for the 
separation of human B lymphocytes 
Challenge Performance MACS® Chromatography 
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 Elution efficiency (%) 20.14 40.37 
Cell purity (%) 99.5 96.7 
Cell viability (%) 99.6 95.7 
Yield (%) 15.25 39.50 
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 Elution efficiency (%) 16.51 37.00 
Cell purity (%) 98.4 93.7 
Cell viability (%) 92.1 94.5 
Yield (%) 5.38 35.09 
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 Elution efficiency (%) 32.39 38.82 
Cell purity (%) 28.8 (74.4*) 78.5 
Cell viability (%) 46.7 (90.8*) 95.5 
Yield (%) 32.29 30.93 
 *after 2nd separation step 
The initial set of experiments with only CD20 positive cells, proved that the 
developed affinity separation method based on the monomeric avidin-biotin 
system could be used as an alternative to MACS®. Cell purity and viability in 
the elution fraction were slightly weaker, but the difference is less than 5 % 
which could be due to experimental error. On the other hand, when using a 
chromatographic approach, the elution efficiency was twice that observed with 
MACS®, additionally, the overall yield was better. This suggests affinity 
chromatography is a more efficient approach to positive cell separation. 
Following this, CD20 positive cell lines were combined with 5 % of cells 
without CD20 antigens on the surface to further investigate the selectivity of 
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both processes, although great differences were not expected as both 
approaches are based on the antibody interactions with the cell surface 
antigens. In terms of cell purity, MACS® performed slightly better, but this time 
the affinity beads used had a positive impact on the cell viability. Again, the 
differences in these two parameters are below 5 %. A new chromatographic 
approach was performed over magnetic beads. This time the elution efficiency 
was more than 2 times better, while the yield was 6.5 times better, suggesting 
that although to the avidin modified beads packed into column was nearly 
1*106 less cells specifically bound (9.59*106 vs. 8.61*106 cells), almost 2 
times more specifically bound cells are eluted (1.67*106 vs. 3.19*106 cells).  
To really challenge both matrices, the target CD20 population in the initial 
feedstock was further reduced to 5 %. It was expected that this would show 
the true value of the developed chromatographic system as the number of 
target cells, suitable for the therapeutic applications, in the cell suspensions is 
low, usually below the selected 5 % (Schriebl et al., 2010).  Based on results, 
developed chromatography based separation has been ratified to be a step in 
the right direction. First of all, it was performed as a single step separation, 
while magnetic bead separation required a 2 step purification process, which 
was performed by reapplying the collected flow through and washing fractions 
to the new, fresh, LS column. Resulting in the overall, elution efficiency and 
yield of affinity based separations are being comparable to the results 
obtained with MACS®, but cell purity and viability were still slightly better even 
after the second MACS® purification. Finally 1.22*105 CD20 positive cells 
(95.5 % viability) were collected in the elution fraction by chromatography and 
1.20*105 CD20 cells (90.8 % viability) in the second MACS® elution fraction. 
The difference between the both methods was only 2000 cells (1.6 %). 
Unsurprisingly MACS® does not provide with a highly pure and viable cell 
suspensions isolated from feedstocks with initial low percentage of target cells 
after only one separation step. In one of the studies, performed with low cell 
target percentage cell sources, between 68.4 and 78.4 % purity was achieved 
(de Wynter et al., 1999). Significant improvement can be made by introducing 
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a multi-stage process (Schriebl et al., 2010), as it was demonstrated above.  
Results presented in this chapter confirm chromatography requires less 
separation steps, especially when the initial cell population is complex and the 
starting percentage of cells is low.  
The results from the monomeric avidin affinity separations are promising due 
to the fact that, based on the FDA recommendations, a safe CD34 positive 
cell dose in cell therapy should have a purity of at least 80 % and it is cost 
effective only when the process yield is at least 40 % (Johnsen et al., 1999).  
In terms of costs, the estimate for each separation approach was made based 
on the online retail prices on 24th July 2014. The cost was calculated based 
on the material needed for a single purification of CD20 cells, sufficient for a 
single cell based treatment, from the heterogeneous cell population (5 % of 
the target population). The assumption was made that there are no 
differences between the required time for the separation, as chromatography 
based separation takes approximately 1.5 h less, but it requires preparation of 
beads and biotinylation of antibody. Comparing with MACS® technology, 
where beads and column are sold as ready to use kit, if beads for the affinity 
chromatography would be available on the market they would probably be 
already packed in the single use column, which would mean an advantage for 
the chromatography based separation. Additionally nowadays the most 
common antibodies against cell surface markers can be purchased 
biotinylated, which would spare the user approximately 30 minutes. 
The initial cost of the required equipment was used for the cost evaluation, 
unless it is possible to rent it. In this case hourly rate is complied. 
Consumables (e.g. pipette tips and centrifuge tubes) and buffers were 
overlooked as similar amount is required for both separation processes. 
Additionally the cost of the use of flow cytometer for the evaluation of 
separated cells is left out as both approaches require it, with the only 
difference being the use of a fluorescently labelled marker. 
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Table 5.2: Evaluation of costs associated with affinity based chromatography and 
MACS® for the purification of 5 % target cells from the cell population, sufficient for a  
single dose of cell based treatment 
Affinity based separation MACS® 
Preparation of glass beads Separation 
Glass beads £1.50 Stand £130.00 
Avidin from egg white £12.30 Separator £427.00 
D-Biotin £0.06 LS column (2 pieces) £21.20 
Antibody biotinylation CD20 MicroBeads £4.11 
Rituximab  £0.95 Flow cytometry  
D-biotin £0.03 CD20-PE £6.40 
PD-10 columns (2 pieces) £13.07 7-AAD viability dye £0.53 
Separation   
Äkta Pure (4 hour rental*) £20.49   
Tricorn 5/50 column £337.00   
Coarse 5/50 filter kit £62.78   
D-biotin £0.12   
Flow cytometry   
Streptavidin-PE £3.18   
7-AAD viability dye £0.53   
TOTAL COST £452.10  £589.24 
*based on the cost of 1 year lease 
 
The simplified economical evaluation (Table 5.2) additionally confirms the 
adequacy of the newly developed monomeric avidin chromatographic 
separation technique, as it is the cost associated with the preparation of glass 
coverslips, the separation itself and evaluation performance, is comparable 
with the current leading technology for the cell separation for the purpose of 
cell therapy. Overall, the total cost for the affinity based separation is slightly 
lower. 
The initial cost for the columns is greater for the affinity separation, but Tricorn 
columns are reusable and can be sterilized, while LS columns are single use. 
Additionally the coarse filters for the Tricorn column can be reused up to 10 
times and one kit consists of 5 sets of bottom and top filters. 
In terms of the cost of the antibody, which is the most crucial part for the 
success of the separation, as the selectivity is based on its reactivity with the 
surface antigens on the cells of interest, are expectedly antibodies conjugated 
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with magnetic beads 4 times more expensive than biotinylated antibody for 
the developed packed bed chromatography. Flow cytometry of cells 
separated by MACS® requires as well an secondary antibody, which needs to 
bind to a different region on a cell in order to get a signal from the flow 
cytometric analysis. This additionally adds to the total cost of the separation 
technique.   
In terms of equipment needed, for the liquid chromatography is required a 
chromatographic system, such as Äkta Pure, which was used for the 
experiments presented in this chapter. To reduce the cost, simpler liquid 
separation system can be used, as long as it allows set up described above. 
The biggest costs for MACS® technology are stand and magnetic separator. 
Both are reusable but especially magnetic separator cannot be substituted 
with less costly alternative as it is specially designed for LS columns.  
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5.4 CONCLUDING REMARKS 
The direct comparison of the developed monomeric avidin based affinity 
system for the positive separation of human cells with MACS®, magnetic 
affinity cell separation, currently the leading technology for the cell separation, 
has confirmed the adequacy of the newly developed system. 
Throughout the evaluation glass bead chromatography outperformed 
magnetic beads in terms of the elution efficiency and yields and produced 
comparable results in the purity and the viability of purified cells. Challenging 
both columns with more heterogeneous cell population and with only 5 % 
target cells in it, resulted in promising results as for the similar purity and cell 
viability, MACS® system required 2 step purification, while the selectivity of 
affinity matrix requires only one. Additionally the simplified economic 
evaluation of both separation techniques was made and it can be concluded 
that the associated costs are similar. 
It would be sensible to test both systems with different feedstocks, e.g. 
isolation of stem cells from the bone marrow or adipose tissue, and to perform 
the scale-up study in order to gain more purified cells of interest.  
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6. CONCLUSIONS AND FUTURE WORK 
RECOMMENDATIONS 
6.1 CONCLUSIONS 
Research of adult stem cells has been slow, largely because challenges 
associated with the maintenance of pure stem cell culture over long period of 
time, especially as these cells are low in the number in their original sources. 
It is believed that although the use of adult stem and progenitor cells is 
currently limited, their future utilization in tissue specific regenerative therapies 
shows a great potential, especially as they can be used in autologous 
therapies, thus avoiding any immune rejections (Hipp and Atala, 2008). 
The goal of the work presented in this thesis was to develop a new affinity 
matrix for the separation of human (therapeutic) cells. The feasibility of the 
developed separation technology has been proven in this work by successful 
transfer from static tests on glass coverslips, through initial studies under flow 
with glass hollow capillary tubes, to the application on non-porous glass 
coverslips. The positive cell selection method was successful developed and 
optimized. Based on the results, the affinity method is comparable with 
MACS™ technology, currently the number one choice in the research, as well 
as in the clinical applications.  
The development and optimization of the biocompatible surface chemistry 
was performed on glass coverslips. Consistent manufacture of affinity 
supports was achieved by layer-by-layer deposition of (3-
aminopropyl)triethoxysilane and oxidized dextran, followed by the cleavage of 
native avidin from egg white into its subunits under controlled conditions. The 
selectivity of so modified glass coverslips was obtained by the use of 
biotinylated monoclonal antibodies specific for the cell surface antigens. Cells 
were recovered from the support by the competitive elution with 2 mM D-
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biotin. This approach proved to be highly selective on a small scale and has 
the additional advantage of not promoting non-specific cell attachment. 
The first attempts of the chromatographic separation of cells were performed 
with human red blood cells. Although they might not be representative model 
for the majority of human cells due to their size and shape, they are visible to 
the naked eye; therefore there was no need for the additional labelling, which 
might interfere with the selection assay, in order to track them online 
throughout the experiment. 
After the partial optimization of the chromatographic method, white blood 
cells, i.e. B and T lymphocytes from human cell lines, were introduced as they 
are more similar to the CD34+ progenitor cells, the most popular target 
population in the positive cell selection (Tomlinson et al., 2012). 
The ideal separation conditions were set as loading at 30 cm/h or 60 cm/h 
(depending on the location of the biotinylated antibody – on the cell or 
immobilized on the support), washing non-specific cells and elution was 
performed at 600 cm/h. The elution efficiency was significantly improved once 
sequential pause of the flow during the elution was introduced and allowed D-
biotin to displace biotinylated antibody and consequently elute cells. 
The goal of the final study was the direct comparison between the developed 
technology on the packed bed affinity column and MACS®. Both devices were 
synchronously challenged with the same number and origin of cells. Although 
there is still a scope for the improvement of the developed affinity approach to 
the positive selection, the packed bed chromatography was a competitive 
product and it even performed better than magnetic beads in terms of elution 
efficiency and yields.  
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6.2 FUTURE WORK RECOMMENDATIONS 
Clinical devices for cell separation exist, but there is still room for the 
improvement of the technology before the procedure results in a sufficient and 
safe product in clinical practice (Johnsen et al., 1999). Due to the current 
techniques, FACS, MACS® and density gradient centrifugation, having 
limitations such us low selectivity, low scalability and contaminations risks 
(Diogo et al., 2012). As the low-cost alternative selection method we propose 
the developed affinity chromatography method. 
There are many areas highlighted in this work that would be interesting for 
further study. The most promising are listed and shortly described below.  
6.2.1 THE SELECTION OF THE CHROMATOGRAPHIC 
SUPPORT 
The selected format of packed bed of spherical particles is not the ideal 
affinity chromatographic support format, but it is preferred choice in the 
separations as it can currently be made with the highest degree of uniformity 
(Billen and Desmet, 2007). As the transport in packed bed columns is based 
on the diffusivity, it would be interesting to test convective media, such as 
cryogels and polymeric monoliths. The separation should be faster and the 
productivity higher (Jungbauer and Hahn, 2004) which should result in a 
positive impact on cell viability. This is important as one of the biggest issues 
during the method development was the duration of the separation process 
and its negative impact on cell viability. Another alternative chromatographic 
support suitable for the positive selection of cells with the developed 
monomeric avidin-biotin system are membranes.  
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6.2.2 OPTIMIZATION OF THE SURFACE MODIFICATION AND 
FUNCTIONALIZATION 
In order to reduce the cost of the chromatographic support manufacturing, it 
would be interesting to attempt to collect and recycle avidin from the 
immobilization procedure with, e.g. size exclusion chromatography. 
Furthermore it might be worth reconsidering the production on a larger scale 
and, if possible, under flow conditions, especially if the chromatographic 
support of choice are monolithic columns. 
6.2.3 SCALE-UP 
Currently, single dose for cells for the therapy consists in between of 1*107 
and 4*107 cells (Perin et al., 2003), therefore, for the transfer of the 
technology into clinics, there is a need to investigate the scale-up of the 
developed technology. This can be done either by the scale up of the existing 
chromatographic matrix using Tricorn™ columns or by using a different 
support. In both cases the characteristics of the affinity matrix need to be 
carefully chosen in order to allow efficient mass transport and to not expose 
cells to a large pressure drop in the column and consequently a too big shear 
stress. 
6.2.4 THE SELECTION OF AFFINITY LIGANDS 
In this study purely monoclonal antibodies were used as selection markers, 
but there are limitations connected with its use as the specific marker for the 
cells of interest might not be known, although new markers are being 
described rapidly (Hipp and Atala, 2008; Diogo et al., 2012). But both, FACS 
and MACS® are based on monoclonal antibodies as the selection tool for the 
efficient separation. Aptamers, in laboratory engineered ligands, could be 
used as an alternative, although they are not yet widely accepted in the 
connection with FACS and MACS®. As the developed chromatographic 
support allows both, use of the immobilized ligands on the separation matrix, 
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and labelling cells with them, this is an additional bonus. Any ligand of choice 
can be used, as long as it is in advance biotinylated, which is a simple and 
fast procedure and usually does not interfere with the function of the 
biotinylated molecule (Cole et al., 1987; Cronan et al., 2000; Elia, 2008). 
6.2.5 THE EVALUATION OF THE SELECTIVITY AND 
EFFICIENCY OF THE DEVELOPED AFFINITY METHOD 
WITH VARIOUS FEEDSTOCKS 
Due to the limited resources, the method development was performed with 
red blood cells from cord blood and B and T lymphocytes from the continuous 
cell lines. To further evaluate the adequacy of the positive selection the 
method should be tested with various feedstocks, e.g. peripheral blood, bone 
marrow, cord blood and adipose tissue. These samples are more complex in 
terms of the cell diversity and in addition, cells of interest (e.g. CD34+ cells) 
are present in low numbers (Hipp and Atala, 2008).  This will really challenge 
the developed support and consequently show the true value of this approach 
for the cell separation. 
6.2.6 ADDITIONAL ASSESSMENT OF CELLS AFTER 
COMPLETED SEPARATION 
The additional evaluation of the function (e.g. white blood cells take part in the 
immune response) and origin of cells after completed separation process can 
be done by their transplant in vivo into immunodeficient mice models. Using 
this approach additional data would be generated to demonstrate if the 
developed selection method does not have negative impact on cells and 
subsequently confirm its adequacy for the use in the clinical and medical 
research applications. 
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6.2.7 CLOSED SYSTEM SEPARATION 
For the translation of stem cells and stem cell-derived products to the clinics 
and drug discovery it is necessary to retain sterility of cells during separation 
(Diogo et al., 2012). Developed chemistry is resistant to the sterilization with 
antibiotics, but not to the autoclave sterilization. In order to avoid 
contamination of cells during the processing, is essential the use of sterile 
techniques in sterile closed environment. This can be achieved either by 
placing the chromatographic system in the biological safety cabinet or, even 
better, the direct integration of separation technique with stem cell bioreactor 
culture. 
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7. APPENDICES 
APPENDIX A: STANDARD CURVE FOR TNBS 
(PICRYLSULFONIC ACID) ASSAY 
 
Figure App. A: An example of standard curve for TNBS assay. The absorbance of 
standard, picric acid in 1 M NaOH (mmol/L), was measured at 410 nm wavelength. 
Black circles represent measured data and a line statistical evaluation of the data 
using a nonlinear regression. 
 
The data analysis was performed with SigmaPlot 12.0 software (Systat 
Software, Inc., San Jose, California, USA) and the report is summarized 
below. As the R2 is above 0.95 and P value for a is below 0.05, are results 
statistically significant, therefore the model can be used for the determination 
of picric acid in the slurries. 
Nonlinear Regression    
Equation: Polynomial, Linear 
f = y0+a*x 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9982 0.9964 0.9956  0.0015  
  Coefficient Std. Error t  P  
y0 -0.0022  0.0007  -2.9818  0.0307  
a 0.0016  4.2557E-005 36.9521  <0.0001 
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APPENDIX B: STANDARD CURVE FOR BCA 
(BICINCHONINIC ACID) PROTEIN ASSAY 
 
Figure App. B: An example of standard curve for BCA assay. Concentration of 
standard albumin (µg/mL) is plotted on the x-axis and absorbance at 562 nm on the 
y-axis. Black circles represent measured data and a line statistical evaluation of the 
data using a nonlinear regression. 
 
The model is statistically significant (R2 is above 95 % and P value for the 
coefficient a is below 0.05), as it can be seen from the software report section 
below. 
Nonlinear Regression    
Equation: Polynomial, Linear 
f = y0+a*x 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9990 0.9979 0.9976  0.0131  
  Coefficient Std. Error t  P  
y0 -7.5849E-005 0.0063  -0.0121  0.9907  
a 0.0004  6.5931E-006 57.8992  <0.0001 
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APPENDIX C: STANDARD CURVE FOR THE 
DETERMINATION OF FREE BIOTIN 
 
Figure App. C: An example of standard curve for the determination of free biotin in 
the experimental slurries. Concentration of standard biotin (nmol) is plotted on the x-
axis and absorbance at 535 nm on the y-axis. Black circles represent measured data 
and a line statistical evaluation of the data using a nonlinear regression. 
 
The statistical model used for the determination of free biotin in the samples is 
statistically significant , as R2 is aboce 0.95 and P value for the coefficient a in 
the used equation is less than 0.05. 
Nonlinear Regression    
Equation: Polynomial, Linear 
f = y0+a*x 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9910 0.9821 0.9776  0.0141  
  Coefficient Std. Error t  P  
y0 0.0149  0.0078  1.9086  0.1290  
a 0.0246  0.0017  14.8072  0.0001 
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APPENDIX D: MEDICAL GRADE BOROSILICATE GLASS 
SPHERES “GL-0179” DATA SHEET  
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APPENDIX E: GLASS BEADS SIZE DISTRIBUTION – 
ANALYSIS REPORT 
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APPENDIX F: CERTIFICATE OF ANALYSIS FOR AVIDIN, 
EGG WHITE 
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The following two papers are in the preparation and will be submitted to the 
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